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ABSTRACT
Non-Hodgkin's lymphoma (NHL) represents the second most common cancer
affecting individuals infected with Human Immunodeficiency virus (HIV). NHL is
60 to 100 times more likely to develop in AIDS patients than in the general
population. The great majority (90-95%) of these are aggressive high-grade B cell
lymphomas that respond poorly to chemotherapy, and are associated with a median
survival, after diagnosis, of only 4-6 months. Approximately one-third of HIV-
infected individuals present early in infection with a syndrome called Persistent
generalised lymphadenopathy (PGL). The enlarged lymph nodes of this condition
may represent pre-malignant lesions.
The aim of this study was to investigate genetic and virological variables in PGL and
to identify early genetic lesions that might be predictive of future lymphoma
development in these individuals. Lymph node biopsies from 23 individuals with
PGL together with appropriate controls from HIV-uninfected individuals were
analysed for alterations in the structure and expression of selected genes.
The results of the study were as follows: i) Mutations in p53 were detected in 26% of
HIV-infected individuals, ii) A distinct pattern of p73 and p63 gene expression was
observed in the HIV-PGL samples compared to the controls, iii) Structural
modifications of the genes on the INK4 locus were absent, iv) Epigenetic silencing of
the INK4a, INK4b, and p73 genes was not observed, v) Mutations in bcl-6 were
detected in 48% of HIV-infected individuals and in 12.5% of healthy individuals,
along with polymorphic substitutions at nucleotides, +753 and +875. vi)
Rearrangements of c-myc t(8:14) and bcl-2 t( 14:18) were not observed in either the
study or control groups except for a single t(8:14) in the lymph node of a healthy
individual, vii) EBV DNA was detected in 100% of HIV-infected individuals and in
86% of healthy individuals. KSHV DNA was detected in 8.7% of HIV-infected
individuals and in none of the healthy controls. Based on the findings in this study, a
speculative model for the molecular pathogenesis of AIDS-NHL is proposed. This
model hypothesises that p53 and bcl-6 mutations occur early in lymphomagenesis,
whereas activation/deregulation of oncogenes such as c-myc and bcl-2, and/or
inactivation of the tumour suppressor genes of the INK4 family constitute later
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1.1 Human Immunodeficiency virus (HIV)
The World Health Organisation (WHO) and the Joint United Nations Programme on
HIV/Acquired Immunodeficiency Syndrome (UNAIDS) estimated that at the end of
2000 over 36.1 million people were living with the Human Immunodeficiency virus
(HIV), with 5.3 million new infections occurring world-wide in that year alone
(UNAIDS/WHO, 2000). HIV belongs to the family Retroviridae and subfamily
Lentivirinae. Since its discovery, (Barre-Sinoussi et al., 1983; Gallo et al., 1984) this
retrovirus, recognised because of its association with AIDS, has claimed more than
21 million lives (UNAIDS/WHO, 2000). However, with the inception of highly
active antiretroviral therapy (HAART), or triple "cocktail" therapy in 1995, deaths
from AIDS in the United States have declined by 44%, along with the frequency of
hospitalisations and the incidence of major AIDS-related opportunistic infections
(Palella et al., 1998). However, in developing countries the full impact of HAART
has not been realised due to cost implications, and hence HIV continues to be a
major cause of infectious death in these countries.
1.1.1 Structure and genome organisation of the virus
The structure of the virus is depicted in Figure 1 and reviewed in (Levy, 1993;
Luciw, 1996; see figure 1). The HIV genome is about 9.8kb in length and is
comprised of nine genes that are flanked by long terminal repeat (LTR) elements
(figure 2). These include the gag, pol and env genes that are common to all
replication-competent retroviruses as well as the regulatory genes Tat and Rev and
the accessory genes Nef, Vif, Vpr and Vpu. The protein products of these genes are
translated from different RNAs produced through the use of ribosomal frame-shifting
and alternative splice sites (reviewed in Luciw, 1996; see figure 2).
1.1.2 Tropism and spread
HIV primarily infects activated CD4+ cells (T-cell tropic) through binding of viral
gpl20 to the CD4 molecule, and terminally differentiated cells of the macrophage
lineage (M-tropic). The virus however, has a diverse cellular host range (reviewed in
Levy, 1993). Sequence variation within a region of the gpl20 molecule, called the
2













The HIV virion is spherical with a diameter of approximately 110nm. A lipid bilayer
envelope encapsulates a cone-shaped core. Projecting from the envelope surface
are 72 knob-like structures, which are heterodimers of the envelope glycoproteins,
gp120 and gp41. The core contains two identical molecules of single-stranded
RNA, with which the virally encoded enzymes, RNA-dependent DNA polymerase
or reverse transciptase (RT), integrase (IN) and protease (PR), are associated.
The protein products of the gag polyprotein gene provide the structure and
integrity of the virion. They include the matrix protein (MA), located between the
nucleocapsid and the envelope, the capsid protein (CA), and the nucleocapsid
protein (NC) that is closely coupled with the RNA genome.
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V3 loop plays an important role in influencing biological properties of the virus such
as cell tropism, syncytium formation, infectivity and cytopathicity (Stamatatos and
Cheng-Mayer 1993; Willey etal., 1994)
HIV can be transmitted both vertically (mother to child) and horizontally through
sexual exposure, contaminated blood and blood products, or sharing of needles by
intravenous drug users (IVDUs) (reviewed in Levy, 1993).
1.1.3 Clinical course of HIV infection
Primary infection provokes an acute mononucleosis-like illness with fever, sore
throat, headache, rash, lymphadenopathy and malaise, which lasts between 1-3
weeks. This phase is characterised by high-level virus replication in the activated
lymphocytes in the lymph nodes, simultaneous with a transient decrease in CD4+ cell
counts and increase in CD8+ cell numbers.
A marked reduction in viremia due to a highly active cytotoxic T cell (CTL) immune
response and a rise in CD4+ T cell numbers coincide with the clinically latent or
asymptomatic period, which averages around 10 years (Bacchetti and Moss, 1989).
Neutralising antibodies, particularly against the V3 loop of gpl20 are detectable after
seroconversion, although they are not as effective as the cellular response in the
control of viral infection. During this period equilibrium is established between the
virus and host immunity, and the set point of this steady state predicts clinical
outcome. Thus, low viral load correlates with long clinical latency whereas a high
viral burden predicts a short latent period (Mellors et al., 1996). Viral replication,
however, continues over the entire course of infection (Ho et al., 1995) with proviral
load in the lymphoid tissues being 5-10 times greater than in peripheral blood,
suggesting that the lymphoid germinal centres serve as important reservoirs of viral
RNA (Pantaleo et al., 1993).
The terminal phase of HIV infection, characterised by the onset of AIDS, is marked
by a sudden increase in viremia due to decline in host CTL immune responses.
Progressive depletion of CD4+ T cells is the defining feature of immunodeficiency
(Lang et al., 1989). At this stage opportunistic infections and/or malignancies occur
and death ensues in an average of 15 months.
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1.1.4 HIV-associated Persistent Generalised Lymphadenopathy (PGL)
PGL is a frequent finding of early HIV infection, and is present in more than one-
third of infected patients in some studies (Gerstoft et al., 1987; Metroka et al., 1983).
PGL is defined by the Centers for Disease Control (CDC) as "unexplained
lymphadenopathy of longer than 3 months duration, in two or more extrainguinal
sites, in the absence of any intercurrent illnesses known to cause adenopathy".
1.1.4.1 Morphology of lymph nodes in PGL
Morphologically the abnormal lymph nodes exhibit a characteristic B cell
hyperplasia and dysplasia (Meyer et al., 1984). Distinct histological stages (I to III)
have been described, although the change may be gradual, with lack of clear markers
of transition from one stage to the next.
Stage I is characterised by florid follicular hyperplasia, with mantle zone depletion
and lymphocyte infdtration, particularly CD8+ T cells, which frequently invade and
fragment the follicular centres. The lymph node sinuses frequently contain clusters of
monocytoid B cells, which represent reactive B lymphocytes derived from the
marginal zone. Stage II is characterised by a decrease in the number of follicles with
the remainder showing involution. This is accompanied by a decrease in
lymphocytes and an increase in plasma cells in the interfollicular areas. In Stage III
there is complete destruction of lymph node architecture with remnants of the
dendritic reticulum cells. The "burned-out" lymph nodes are usually small and
depleted of both T and B lymphocytes.
Follicular hyperplasia, with follicular fragmentation and disruption are non-specific
changes commonly seen in a number of benign conditions and immunodeficiencies.
However, thinning of the mantle zone and marked depletion of the lymphocytes is
pathognomonic of HIV lymphadenitis, and may be used in the differential diagnosis
of this syndrome (Chadburn et al., 1989; Jaffe et al., 1985; Pallesen et al., 1987). A
further distinguishing feature of lymphadenopathy in HIV-infected individuals is the
increased production of interferon y (IFN-y) by the CD8+ cells of these lymph nodes,
which is believed to promote B cell proliferation (Boyle et al., 1993).
The clinical and immunological status at the time of biopsy in HIV-infected PGL
individuals correlates significantly with histological lymph node changes. In the
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study by Gerstoft et al., all patients with opportunistic infections and AIDS-related
complex were found to have Stage III histology. Furthermore, they also had
significantly fewer CD4+ cells and inverted CD4+: CD8+ ratios compared to Stage I
individuals. Consistent with the polyclonal hypergammaglobulinemia observed in
these patients, serum IgA and IgM levels were significantly higher in Stage III
individuals compared with Stage I individuals, perhaps reflecting secondary infection
with opportunistic pathogens (Gerstoft et al., 1987).
1.1.4.2 Role of viruses in the pathogenesis of PGL
Only limited studies have been carried out to investigate the role of B cell tropic
viruses such as Epstein-Barr virus (EBV) in the germinal centre B cell activation and
hyperproliferation that is characteristic of PGL. Using molecular and in situ
techniques, some investigators have suggested that the B cells of these abnormal
nodes are very rarely infected with EBV or HIV (Boyle et al., 1992; Uccini et al.,
1989). These findings however, were contradicted by the detection of EBV and HIV
in PGL lymph nodes using sensitive PCR techniques (Ometto et al., 1997; Shibata et
al., 1991; Armstrong and Home 1984; Tenner-Racz et al., 1986). Despite detection
of these viruses in the lymph nodes of individuals with PGL, there is no direct
evidence suggesting that they contribute to the B cell proliferation observed.
1.1.5 AIDS-related lymphomas (ARJL)
1.1.5.1 Incidence
Lymphoma was incorporated into the CDC case definition of AIDS in 1985, and is
now recognised as the second most common malignancy affecting HIV-positive
women and homosexual men (second only to Kaposi's sarcoma [KS]), and the most
frequently diagnosed cancer in other HIV transmission groups (CDC, 1985; Beral
and Newton 1998).
The National Cancer Institute (NCI) estimates that between 8% and 27% of the
approximately 50,000 cases of Non-Hodgkin's lymphomas (NHL) diagnosed yearly
in the United States are HIV-related (Gail et al., 1991). HIV-infected individuals are
60 times more likely to develop NHL (Beral, 1991), and 10 times more likely to
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to develop Hodgkin's disease (HD) than the general population (Beral, 1991; see
Table 1). Although the advent of HAART has been associated with a significant
decline in common HIV-1 associated opportunistic infections and KS, the effect of
HAART on AIDS-related NHL (AIDS-NHL) is still unclear (Palella et al., 1998).
Table 1
Relative risk of AIDS-related lymphoma compared with the general population
Lymphoma type Relative risk





Primary central nervous system 1000
Hodgkin's disease 10
Adapted from Beral and Newton (1998) and Levine (2000).
1.1.5.2 Histopathological classification of AIDS-NHL
90-95% of AIDS lymphomas are of B cell origin, and comprise a spectrum of lesions
ranging from polyclonal lymphoid hyperplasia to high-grade malignancies most
frequently of the diffuse large-cell type (Levine et al., 1985). The two most common
histological types of AIDS-NHL are diffuse large-cell lymphomas (AIDS-DLCL)
and small non-cleaved cell lymphomas (AIDS-SNCCL) that differ in regard to the
time of onset, EBV positivity, molecular genetic features, and histogenetic
derivation. Anaplastic CD30+ large-cell lymphomas (Nosari et al., 1996), as well as
primary effusion lymphomas containing KSHV (Cesarman et al., 1995) have also
been described in the spectrum ofAIDS-NHL, but are less frequently observed.
1.1.5.3 Clinical classification of AIDS-NHL
In addition to the histological classification described above, AIDS-NHL may also
be broadly classified on the primary site of presentation as systemic lymphoma,
constituting 80% of all AIDS-NHL, and central nervous system (CNS) lymphoma
comprising the remaining 20%. Clinically, disease presentation is that of an
aggressive tumour with frequent extranodal involvement and poor response to
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chemotherapy. Prognosis of patients with AIDS-NHL has been associated with
extent of disease and extranodal involvement, severity of underlying
immunodeficiency (measured by CD4+ lymphocyte count in the peripheral blood)
and prior AIDS diagnosis (history of opportunistic infection or KS). Individuals with
CNS lymphoma have more severe underlying disease than those with systemic
lymphomas as shown by higher incidence of prior AIDS diagnoses (73% vs. 37%),
lower median CD4+ cell count (30/dL versus 189/dL), and a worse median survival
time (2.5 months vs. 6.0 months) (Levine et al., 1991).
1.1.5.3.1 AIDS-related systemic NHL
Systemic NHLs arise in patients with a wide range of immune function. 70% of cases
occur in persons with a CD4+ lymphocyte count higher than 50xl06/L and
approximately 30% in persons with a CD4+ count in excess of 200x106/L (Levine et
al., 1991). Extranodal presentation commonly occurs (87-95% of individuals) at a
variety of sites. The CNS, bone marrow, gastrointestinal tract and liver are involved
in 42%, 33% 27% and 12% of cases respectively. The vast majority of patients
present with systemic 'B' symptoms, which include unexplained fever, drenching
night sweats and/or weight loss in excess of 10% of normal body weight (Kaplan et
al., 1989). Prognostic criteria predicting shorter survival in patients with AIDS-NHL
constitute age greater than 35 years, CD4+ count less than 100xl06/L, elevated serum
LDH levels and history of intravenous drug use (Straus et al., 1998). Treatment of
systemic disease is problematic, although recently, combination chemotherapy in
conjunction with HAART has been found to improve prognosis (Ratner et al., 2001).
(i) AIDS-related small non-cleaved cell lymphoma (AIDS-SNCCL)
These lymphomas represent 20-30% of AIDS-NHL, and develop in the presence of
relatively high CD4+ counts (>200xl 06/L) (Boyle et al., 1990). According to the
Revised European American Lymphoma (REAL) classification, SNCCL is further
categorised into Burkitt's lymphoma (BL) or high-grade Burkitt's-like lymphoma
(BLL) (Chan et al., 1994). AIDS-BLL is a distinct histological entity and
morphologically intermediate between typical BL and DLCL, with immunoblastic
features (Carbone et al., 1995).
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(ii) AIDS-related diffuse large cell lymphoma (AIDS-DLCL)
AIDS-DLCL is sub-divided into AIDS-related large non-cleaved cell lymphoma
(LNCCL) and AIDS-related immunoblastic lymphoma (IBL), and constitutes
approximately 70% of AIDS-NHL (Gaidano and Dalla-Favera 1995). These
lymphomas arise in the setting of severe immunosuppression and are more
heterogeneous than AIDS-SNCCL (Boyle et al., 1990).
1.1.5.3.2 AIDS-related primary central nervous system lymphoma (AIDS-
PCNSL)
These tumours predominantly have a large-cell histology (Camilleri-Broet et al.,
1997) and arise in the advanced stages of HIV infection when CD4+ T lymphocyte
counts fall below 50x106/L. Up to 75% of these individuals exhibit a previous AIDS-
defming diagnosis, in contrast to those with systemic lymphoma (37%) (Levine et
al., 1991).
PCNSL lesions usually occur as solitary or multiple parenchymal lesions in a
perivascular cuffing pattern (Camilleri-Broet et al., 1997). About half of the patients
diagnosed with PCNSL present with focal neurological problems such as seizures,
headache, memory loss, as well as systemic symptoms of diarrhoea, weight loss and
fatigue (Rosenblum et al., 1988). Symptoms are often indistinguishable from those
of an opportunistic infection, central nervous system toxoplasmosis. Traditional
treatment involves corticosteroids, followed by whole-brain radiation, but a key
aspect of control is immune restoration in these patients through HAART (McGowan
and Shah, 1998).
1.1.5.4 HIV-associated Hodgkin's disease (HIV-HD)
Unlike NHL and KS in the setting of HIV-associated immunodeficiency, Hodgkin's
disease is not considered an AIDS-defining diagnosis by the CDC (CDC, 1993).
Although most patients have not had an AIDS-defming diagnosis prior to the onset
of HD, between 36-83% have had a history of PGL (Andrieu et al., 1993). HIV-HD
is usually aggressive, with widely disseminated disease and bone marrow
involvement in up to 50% of cases (Rubio, 1994). Most patients present with mixed
cellularity or lymphocyte-depleted Hodgkin's disease, systemic 'B' symptoms, and a
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median CD4+ count of 300x106/L or less. Median survival time is between 8 and 18
months. Death in these patients is not due to Hodgkin's disease (most patients
respond to chemotherapy regimens and granulocyte colony stimulating factor), but
rather to opportunistic infections or other HIV-related malignancies (Levine, 1998).
1.1.5.5 Human herpes virus-6 (HHV-6) and AIDS-NHL
A causative role for HHV-6 in AIDS-NHL has been suggested (Corbellino et ai,
1993; Lusso and Gallo, 1994). Although low copy numbers of HHV-6 DNA have
been found in lymphadenopathies associated with HIV infection, the prevalence of
HHV-6 DNA in B cell AIDS-NHL was found to be lower or similar to that observed
in lymphoproliferative disorders from HIV-uninfected individuals (Dolcetti et ai,
1996; Fillet et al., 1995). These studies therefore argue against a strong association
between HHV-6 infection and pathogenesis of AIDS-NHL.
1.2 The Cell Cycle
The cell cycle is typically characterised by four stages: G1-S-G2-M; G1 and G2
signify the gap phases of the cycle, S the phase of DNA synthesis and M the mitotic
phase. In addition to these 4 phases there are two major control points: one towards
the end of Gl, known as the restriction point, and the other at the initiation of
mitosis. G2 cells deprived of growth factors before the restriction point exit the cell
cycle and enter GO.
Homeostasis in an organism is maintained by a fine balance between cell
proliferation and cell death, both of which are controlled by the sequential assembly
and activation/inactivation of crucial cell cycle regulators. Some of the genes
encoding these growth regulators are directly involved in tumourigenesis and
constitute the cancer-related genes such as the oncogenes, tumour suppressor genes,
apoptosis regulators and DNA repair genes.
Tumour suppressor genes, refers to a group of growth regulators that are capable of
suppressing tumour formation. Knudson's two-hit hypothesis for tumour suppressors
requires inactivation of both alleles by deletion or mutation, before loss of function
can occur (Knudson, 1971). A mutated tumour suppressor gene comprises one of
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many selected genetic events found in cancer progression, and may serve either as an
initiator (in the case of germline mutation) or a progressor in tumour progression.
Sections 1.3 to 1.5 will focus on the tumour suppressor genes, p53, the INK4 family
(INK4a, INK4b and ARF), and the newly discovered p53 family members, p63 and
p73, some of which are believed to contribute to the pathogenesis of AIDS-NHL.
p53 and ARF function both at the restriction point and at the mitotic checkpoint,
whereas the INK4a and INK4b genes and their protein products pl6INK4a and pl5INIC4b
have a key role in regulating Gl/S transition (see sections 1.3 to 1.5 and figure 3).
1.3 p53
TP53 is the most intensively studied gene in cancer biology. Its protein product, p53,
was first identified (in 1979), as a cellular protein tightly complexed to simian virus
40 large T antigen (SV40T) (Lane and Crawford, 1979). p53 is now known to be a
pivotal regulatory protein, a potent tumour suppressor and a multifunctional
homotetrameric transcription factor (reviewed in Levine, 1997).
1.3.1 Structure of p53
TP53, found on chromosome 17p 13 is 20kb in length and has 11 exons, the 1st of
which is non-coding. The gene gives rise to a 2.8kb mRNA transcript, which encodes
a 53 kilodalton (kDa) nuclear phosphoprotein, of 393 amino acids (aa) (Lamb and
Crawford, 1986). Sequence analysis has revealed the existence of five evolutionarily
conserved domains in exons 1,4,5,7 and 8 (Soussi et al., 1990 and see figure 4).
The protein is divided structurally and functionally into three domains: the
transactivation domain, the sequence-specific DNA-binding domain and the
oligomerisation domain. The first 42aa constitute the acidic N-terminal
transcriptional activation domain that allows p53 to recruit basic transcriptional
machinery and subsequently activate expression of target genes. This region is also
critical for regulating the stability and activity of p53 via interactions with proteins
such as the human form (hMDM2) of the mouse double-minute (MDM2) protein and
viral oncoproteins (Lin et al., 1995; Lohrum and Vousden, 1999). The core domain
localised between aa residues 102 and 292 is principally involved in the sequence
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Schematic representation of the cell cycle indicating the points of action of p53 and
its family members, p63 and p73, as well as members of the INK4 gene family,
p16INK4a, pl4ARFand p15INK4b.
The 4 stages of the cell cycle are depicted as G1 (Gap phase 1), S (DNA synthesis),
G2 (Gap phase 2) and M (mitosis). GO represents point of exit of the cell from the
cell cycle. The green triangles represent the direction of the cell cycle. The p53 and
p14ARF tumour suppressor proteins function both at the G1/S and G2/M checkpoints.
p53 acts to arrest the cell cycle at both these checkpoints by inducing either growth
arrest or apoptosis, whereas p14ARF can arrest the cell cycle via p53-dependent and
independent pathways. The INK4 proteins (p16INK4a and p15INK4b) specifically bind to
and inhibit the kinase activities of CDK4/6 and their association with the D-type
cyclins. This interaction prevents the phosphorylation of pRb (and release of E2F),
the primary substrate of the cyclin/CDK4 complex, with subsequent growth arrest at
G1. Similar to p53, p73 can arrest cells at G1. The role of p63 in the progression of
the cell through the cell cycle is presently unknown.
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specific DNA binding function of p53. The minimal p53 binding site consists of 2
copies of the consensus sequence 5'-PuPuPuC(A/T) (T/A)GPyPyPy-3', separated by
0-13 base pairs (el Deiry et al., 1992). A region of proline repeats that allows
interactions with signal transduction molecules containing a src-homology binding
region, separates this domain from the N-terminus (Gorina and Pavletich, 1996; see
figure 4).
Sequence-specific binding by the core domain is negatively regulated by the C-
terminus, which can bind DNA non-specifically (Wang et al., 1993). Such inhibitory
activity is relieved upon exposure to stress, which results in increased DNA binding
(Hupp and Lane, 1995). The C-terminus is further sub-divided into three regions; a
flexible linker connecting the DNA binding domain to the oligomerisation domain,
the oligomerisation domain (aa residues 320 to 360) and a regulatory region (30aa)
composed predominantly of basic residues. The basic region can allosterically
regulate conversion of p53 from the latent form (with respect to DNA binding) to
one that is active for sequence-specific DNA binding (Hupp and Lane, 1994). This
region also serves to recognise DNA damage and promote DNA strand re-annealing
(Gottlieb and Oren, 1996).
1.3.2 Physiological role of p53
In unstressed cells, p53 is expressed at low levels and has a short half-life due to
rapid turnover mediated by ubiquitination and proteolysis. The protein is stabilised
following various cellular stresses, including ionising and ultraviolet radiation, DNA
damage, hypoxia, ribonucleotide depletion, binding of viral proteins (SV40T,
Adenovirus E1B) and deregulated expression of oncogenes (e.g ras, c-myc and E2F)
(Lohrum and Vousden, 1999). The activation of p53 allows it to carry out its growth
regulatory function(s) such as cell-cycle arrest, apoptosis, DNA repair, inhibition of
DNA replication, senescence, differentiation, and anti-angiogenesis (Levine, 1997).
A major regulator of p53 levels in normal cells is hMDM2, which functions as an E3
ubiquitin ligase (Kubbutat et al., 1997) and negatively regulates p53 in an
autoregulatory feedback loop (Wu et al., 1993). This protein mediates shuttling of
p53 from the nucleus to the cytoplasm where it is degraded by ubiquitin-mediated
proteolysis (Haupt et al., 1997; Kubbutat et al., 1997), and this requires the
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interaction of hMDM2 with a transcriptional co-activator p300 (Grossman et al.,
1998). Proteolysis of p53 by this mechanism can be rescued by an alternative protein
product of the INK4a locus, pl4ARF (ARF), which binds and represses hMDM2
(Pomerantz et al., 1998; Ko and Prives, 1996; see below).
1.3.3 The p53 signalling pathway
p53 functions to integrate cellular responses to stress and effects growth arrest and
apoptosis through transactivation of target genes (see below and figure 5).
(i) Upstream events that signal to p53
There is now accumulating evidence that DNA damage and stress stimuli lead to the
phosphorylation of p53 at both the N- and C-termini. Such modifications both
stabilise the wild-type protein and increase its activity. These phosphorylation events
are effected by serine and threonine kinases, including ATM, ATR, and CHK2
(Canman et al., 1998; Tibbetts et al., 1999; Hirao et al., 2000). N-terminal
phosphorylation is believed to induce conformational changes that affect the
interaction of p53 with other proteins, including hMDM2 (Shieh et al., 1997). In
addition, covalent modification at regulatory sites within the C-terminus, such as
phosphorylation, O-glycosylation and acetylation, is known to stimulate DNA
binding by the central core region (Jayaraman and Prives, 1999). Furthermore, p53
appears to be connected to DNA repair processes through non-covalent modification
of the C-terminus by components of the DNA repair machinery such as Rad51 and
Refl (Jayaraman and Prives, 1999; Prives and Hall, 1999).
(ii) Downstream effectors of p53 function
p53 functions primarily as a transcriptional regulator (Crook et al., 1994) and its
activity is profoundly influenced by several co-activator and co-repressor proteins.
Considerable complexity and cell-type differences exist in the spectrum of genes that
are regulated by p53. The diverse biological functions of p53 (Levine, 1997; Ko and
Prives, 1996 and see above) are beyond the scope of this thesis and this section will
focus primarily on the growth arrest and apoptotic functions of this protein.
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Figure 5. Signalling to and from p53
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Figure 5. Signalling to and from p53. Events that signal to p53 and those that act
downstream of the protein to effect growth arrest and apoptosis are shown in the yellow and
green boxes, respectively.
The protein is activated in response to DNA damage that is induced by stress signals (e.g
radiation, hypoxia and reduction in triphosphate levels). This leads to the stabilisation of the
protein through modification by phosphorylation at the N- and C-termini by kinases, ATM,
ATR, CHK2, or by non-covalent modification of the C-terminus by components of the DNA
repair machinery (e.g. Rad51). Furthermore, stabilisation is also effected by expression of
viral proteins such as SV40 Large T and Adenovirus E1B.
The hMDM2 and p14ARF proteins function in negative and positive feedback loops with p53
respectively. The expression of these proteins is regulated by p53, and they in turn control
the stability of p53. p14ARF can induce p53 accumulation by inhibiting hMDM2-mediated
degradation of p53. In addition, the transcription factor E2F-1, the retinoblastoma protein
(pRb), and viral and cellular oncogenes (e.g. adenoviral E1A c-myc and ras) can stabilise
p53 through the upregulation of p14ARF.
Events occurring downstream of p53 to effect growth arrest and apoptosis include
transcriptional activation of the p21waf1, which induces growth arrest either by inhibiting the
function of the CDK4/cyclin D complex, or by binding to the proliferating cell nuclear antigen
(PCNA). Other genes that mediate G1 and G2 growth arrest include growth arrest and DNA-
damage inducible gene #45 (GADD45), 14-3-3<r, and cyclin G.
Apoptosis is induced via the upregulation of a number of pro-apoptotic proteins. These
include Bax (bcl-2 gene family), death receptors such as CD95/Fas and DR5/Killer, the
insulin growth factor-binding protein 3 (IGF-BP3) gene and the p53-inducible genes (P/Gs).
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The choice between effecting cell-cycle arrest or apoptosis by p53, upon sensing
DNA damage, is dependent on the cell-type, intensity of the DNA damage inducer,
efficiency of DNA repair mechanisms, growth and survival factors, and the levels of
p53 protein itself (Gottlieb and Oren, 1998). p53 mediates arrest of cells at the Gl/S
boundary mainly by transactivating the wild-type p53-activated fragment-1 (WAF1)
gene or p21 which inhibits the function of the CDK4-cyclin D complex. p21 also
binds to the proliferating cell nuclear antigen (PCNA) and can inhibit the
processivity of DNA replication. Other genes, including the growth arrest and DNA-
damage inducible gene #45 (gadd45), 14-3-3 a, and cyclin G, have emerged as
potential mediators of p53-dependent G1 and G2 arrest (reviewed in el Deiry, 1998;
see figure 5).
Overexpression of wild-type p53 causes apoptosis in a wide variety of cell types, and
this occurs both by sequence-specific, transactivation-dependent (SST) and
independent mechanisms (Caelles et al., 1994). Bax, a pro-apoptotic protein, was
first identified as a candidate effector of p53-mediated apoptosis, although its
induction is cell-type specific (Miyashita and Reed, 1995). Subsequently, death
receptors such as CD95/Fas and DR5/Killer and genes containing p53-binding sites
such as the insulin growth factor-binding protein 3 (IGF-BP3) gene, p53-inducible
genes (PIGs), and the c-fos gene have been identified as mediators of p53-dependent
apoptosis (reviewed in Gottlieb and Oren, 1998; Bates and Vousden, 1999; see figure
5). Viral proteins such as SV40T, adenovirus E1B and HPV E6 can antagonise the
apoptotic function of p53 by targeting it for degradation or repressing its
transcriptional ability (Mietz et al., 1992; reviewed in Gottlieb and Oren, 1996).
1.3.4 The role of p53 in carcinogenesis
Mutations involving p53 are the most common genetic alteration yet described in
human cancer, occurring in approximately 50% of all human cancers (Hollstein et
al., 1991). More than 90% of mutations occur in the DNA-binding domain of p53.
Such mutations either alter critical residues involved in DNA contact or modify the
structural conformation of the protein, with subsequent loss of ability to function as a
transcription factor. More than 40% of all mutations in p53 occur in residues R175,
G245, R248, R249, R273, and R282 ('hot-spots'), which play a critical role in the
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structural integrity of this domain (Hollstein et al., 1991, 1994).
The contribution of wild-type p53 to tumour suppression has been clearly
demonstrated in p53 null mice which develop normally but are highly prone to
spontaneous tumours later in life (Donehower et al., 1992). A similar propensity for
spontaneous tumours has also been observed in an inherited cancer syndrome, Li-
Fraumeni syndrome, wherein affected individuals carry a mutated p53 allele in their
germline in addition to a wild-type allele (Srivastava et al., 1990).
p53 commonly conforms to Knudson's two-hit hypothesis (Knudson, 1971), wherein
heterozygous loss of the short arm of chromosome 17 (LOH) containing p53 is often
accompanied by point mutations in the remaining allele and vice-versa (Vogelstein et
al., 1988; Takahashi et al., 1989). The spectrum of mutations is strongly biased in
favour of missense point mutations, which produce a stable protein lacking the
transactivating function of the wild-type protein (el Deiry et al., 1992; Kern et al.,
1992). 3 classes ofmutant p53 exist, which have distinct biological activities (Halevy
et al., 1990), according to the site of mutation and the relative levels of wild-type
(wt) and mutant p53 in the cell:
(i) Dominant mutants: protein from the single mutant allele can form hetero-
tetramers with wild-type p53, resulting in complexes that are defective for DNA
binding (Kern et al., 1992; Milner and Medcalf, 1991).
(ii) Recessive mutants: mutant p53 is unable to inactivate the function of wild-type
p53.
(iii) Gain-of-function mutants: mutant protein is capable of conferring increased
tumourigenicity or metastatic potential. Although the mechanism is uncertain it may
involve stimulation of the transcription of cellular genes with oncogenic or
angiogenic functions (Kern et al., 1992), or, alternatively abrogation of the function
of the p53 family member, p73 (Di Como et al., 1999; Marin et al., 2000 and see
below).
1.4 The p53 gene family: Recent additions - p73 and p63
In 1997, the widely held belief that p53 was indeed part of a family of proteins was
finally vindicated, when the structural homologue p73 was identified by Caput and
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co-workers (Kaghad et al., 1997). Shortly thereafter, several groups identified a third
member of the family, variously termed p63, Ket, p40, p51, p73L (Osada et al.,
1998; Schmale and Bamberger 1997; Trink et al., 1998; Yang et al., 1998).
Phylogenetic analysis of these proteins suggests that p63 is the evolutionary ancestor
of the p53 gene family (Yang et al., 1998).
1.4.1 Structural organisation of p73 and p63
The exon/intron organisation of the p53 family members is similar. Exon 1 is
invariably non-coding and each gene is characterised by the presence of very large
introns (Schmale and Bamberger 1997). The p73 gene is approximately 65kb with 14
exons (Kaghad et al., 1997), whereas the p63 gene contains 15 exons (Yang et al.,
1998). The sequences of p73 and p63 are more similar to each other than either is to
p53, with the highest degree of homology in the central DNA-binding domain, and
least homology in the N-terminal transactivation domain (Kaghad et al., 1997; Osada
et al., 1998; see figure 6). Akin to p53, both p73 and p63 can bind to canonical p53
binding sites, and activate transcription from a range of p53-responsive promoters
(Kato et al., 1999; Zhu et al., 1998). Although bax and several redox-related genes
(PIGs 2, 3, 6 and 11) induced by p53, are not significantly induced by p73, in vitro
studies in human keratinocytes indicate that both p63 and p73 can transactivate the
expression of markers of epidermal differentiation, namely loricrin, involucrin and
transglutaminase (De Laurenzi et al., 2000). Each can also induce apoptosis when
overproduced in cells (Jost et al., 1997; Osada et al., 1998) and recently it has been
shown that E2F1 can induce cell death in the absence of p53, through the activation
of p73 (Irwin et al., 2000).
The diversity in biological activity among p53 family members stems, at least in part,
from differences in mRNA processing. In striking contrast to p53, both p63 and p73
undergo complex alternative splicing at the C-termini to generate multiple mRNA
transcripts. To date, recognised variants of p63 include the (TA p63) a, (3, and y
isoforms that retain the coding sequence for the N-terminal transactivation domain
(TA) with additional N-terminal truncated transcripts being generated through the
utilisation of a cryptic promoter located in intron 3, (AN p63) a, p, and y. The AN
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TA p63 and wild-type p53 (Yang et al., 1998). Splicing of p73 generates at least 6
isoforms at the C-terminus, a, p, y, 8, s and C, (De Laurenzi et al., 1998, 1999; see
figure 7). Similar to the an variants of p63, investigators have recently reported the
expression of p73 variants lacking exon 2 (a2 p73) in neuroblastomas and ovarian
cancers (Casciano et al., 1999; Ng et al., 2000). Moreover, Pozniak and colleagues
have recently ascribed an anti-apoptotic role for an p73 in developing mouse
neurons (Pozniak et al., 2000), and suggest that this variant might act in a dominant
negative fashion, analogous to an p63.
p63 and p73 diverge from p53 predominantly in the C-terminus. In addition to the
multiple splice variants generated at this terminus, a second transactivation domain
between residues 382 and 491, not found in p53, has been described in p73 (Takada
et al., 1999). Furthermore, both p73a and p63a contain potential SAM (sterile alpha
motif) domains (protein-protein interaction domains found in proteins involved in
developmental regulation), underscoring the importance of these genes in
differentiation (Bork et al., 1999; see figure 7). The presence of a SAM structure
suggests the existence of binding proteins that modulate p63 and p73 activities. In
addition, a post-SAM domain, namely the last 70 amino acids, is necessary for
inhibiting the transactivation function of TA p63a and TA p73a (Ozaki et al., 1999;
see figure 7).
1.4.2 Homo- and hetero-oligomerisation of the p53 family
p53 binds DNA as a homo-tetramer. The oligomerisation domains (OD) of p63 and
p73 can bind weakly to each other but they are unable to form stable hetero-
oligomers with wild-type p53 (Davison et al., 1999). Moreover, the different C-
termini of the various isoforms of p63 and p73 directly or indirectly influence the
ability of these molecules to form productive oligomers, and may also influence their
ability to activate p53-responsive promoters (De Laurenzi et al., 1998; Kaghad et al.,
1997). There is evidence that certain p53 mutants can bind p73 and p63 and reduce
its transcriptional activation function, with subsequent decrease in its ability to
induce apoptosis (Di Como et al., 1999; Gaiddon et al., 2001). The existence of
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1.4.3 Activation of p63 and p73 by cellular stress signals
p73 is activated only by specific forms of DNA damage such as y-irradiation and
cisplatin. Treatment with these agents results in activation of c-abl tyrosine kinase
activity, which in turn leads to increased p73 protein levels and subsequent apoptosis
(Agami et al., 1999; Gong et al., 1999). More recently, it has been demonstrated that
p73 can be induced by E2F-1, c-Myc and El A, and activate apoptosis in the absence
of functional p53 (Irwin et al., 2000; Zaika et al., 2000). The upstream events that
activate p63 are not known.
1.4.4 Role of the p53 family members in development and cancer
(i) Role in differentiation and development
Although p53 is not indispensable for survival and growth, p63 and p73 have been
shown to be essential for development and differentiation. p73 null mice have severe
neurological, pheromonal and inflammatory defects but do not develop spontaneous
tumours (Yang et al., 2000), whereas p63_/" mice have major defects in limb,
cranofacial and epithelial development (Yang et al., 1999).
(ii) Role in carcinogenesis
The p73 gene maps to chromosome lp36, a region frequently deleted in human
cancers including neuroblastomas (Kaghad et al., 1997). To concur with Knudson's
two-hit hypothesis for tumour suppressor genes (Knudson, 1971), the remaining p73
allele is expected to be mutated in such cases. However, mutations in p73 are
exceedingly rare in human cancers (Ichimiya et al., 1999). A possible explanation for
this is the monoallelic expression of p73 (due to genomic imprinting) in these
tumours, such that loss of the transcribed allele would be sufficient to promote
tumourigenesis (Kaghad et al., 1997). This however does not account for the absence
of mutations in those tumours where both alleles are expressed. Conflicting reports
exist as to the biallelic and monoallelic expression of this gene, which varies with the
tissue type as well as between different individuals. Perhaps surprisingly, p73 mRNA
levels are frequently increased rather than decreased in tumour tissue relative to
surrounding normal tissue (Kovalev et al., 1998).
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Recently, transcriptional silencing of p73 has been observed in specific
haematological malignancies by aberrant hypermethylation of the promoter region
(Corn et al., 1999; Kawano et al., 1999). Interestingly, a methylation-independent
silencing mechanism of this gene has been proposed in neuroblastomas (Banelli et
al., 2000). Despite the above evidence, confirmation of p73's role as a tumour
suppressor requires further investigation.
The role of p63 as a tumour suppressor presently remains unclear. This gene located
on chromosome 3q27-29 is very similar to p73 in that it is rarely mutated in human
cancers (Osada et al., 1998). Recently, Sidransky and co-workers have shown that
this gene is over-amplified in lung and head and neck squamous cell carcinomas and
thereby behaves as an oncogene rather than a tumour suppressor (Yamaguchi et al.,
2000). Evidence in support of its oncogenic role also comes from studies that
demonstrate the ability of AN isoforms of p63 (see above) to act as oncoproteins, by
virtue of their ability to antagonise p53 function (Crook et al., 2000; Yang et al.,
1998). More recent evidence indicates that wild-type p53 can regulate the stability of
certain AN isoforms of p63 through caspase-mediated degradation, thus possibly
counterbalancing the ability of these isoforms to precipitate tumourigenesis or induce
epithelial proliferation (Ratovitski et al., 2001). Further studies however, are needed
to clarify the exact role of this gene in human neoplasia.
1.5 The INK4 locus
Orderly execution of the various stages of the cell-cycle is governed by the
expression and interaction of three types of molecule; a family of enzymes called the
cyclin-dependent kinases (CDKs), which are activated by a group of positive
regulators, the cyclins, and inhibited by the CDK inhibitors (CKls). The CKIs include
two distinct families; the INK4 (Inhibitors of cyclin dependent kinase 4) family
whose four members (pl6'NK4a, pl5INK4b, pl8INK4c and pl9INK4d) exclusively bind to and
inhibit CDK4 and CDK6, and the CIP/K1P family whose three members (p21CIP1/WAFI5
p27KIP1, p57KIP2) are able to inhibit the activity of all CDKs (Sherr and Roberts 1995).
The remainder of this section will focus on the INK4a and INK4b genes and their
protein products, pl6INK4a and pl5INK4b, and a second protein product of the INK4a
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locus, pl4ARF [alternative reading frame (ARF)].
1.5.1 Discovery and structure of pl6INK4a and pl5INK4b
Serrano and co-workers were the first to isolate the cDNA encoding pl61NK4ain 1993
(Serrano et al., 1993). Soon after, low stringency screening of a cDNA library from
transforming growth factor (3 (TGF-(3)-arrested human keratinocytes using a pl6INK4a
probe, led to the isolation of pl5INK4b (Hannon and Beach, 1994).
The INK4a and INK4b genes are tandemly linked on chromosome 9p21 within 30kb
of one another in the same transcriptional orientation. The pl5INK4b and the pl6INK4a
proteins are encoded by 2 and 3 exons respectively, with greater than 95% amino
acid sequence identity in exon 2. All the INK4 proteins are characterised by the
presence of anykrin repeat motifs that are used as structural scaffolds to facilitate
protein-protein interactions. Both pl6'NK4a and pl5INK4b contain 4 anykrin-like repeats,
and studies suggest that the third anykrin repeat is crucial for interaction of the INK4
proteins with CDK4 and CDK6 (Roussel 1999; Ruas and Peters, 1998).
The principal function of the INK4 proteins is to specifically bind to and inhibit the
kinase activities of CDK4 and CDK6 and their association with the D-type cyclins.
This interaction prevents the phosphorylation of pRb, which is the primary substrate
of the cyclin/CDK4 complex (Ewen, 1994). Hypophosphorylated pRb then forms
DNA complexes with members of the E2F and DP transcription factor families,
genes that are necessary for DNA synthesis, with subsequent growth arrest at G1
(Sherr and Roberts, 1995).
1.5.2 Alternative product of the INK4a locus: pl4ARF/pl9ARF (ARF)
The INK4 locus in mouse and man contains two independent but overlapping genes,
INK4a and ARF, which encode functionally distinct proteins (Quelle et al., 1995; see
figure 8). The initiator codon in exon 1 p is not in frame with sequences encoding
pl6INK4a in exon 2, and thus a novel 14 kDa polypeptide (19 kDa in the mouse, hence
P19ARF) is translated from an alternative reading frame in exon 2 (Quelle et al., 1995;
see figure 8).
Unlike pl6'NK4a and the other INK4 proteins, ARF does not bind the CDKs. It
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through the stabilisation of p53 (Pomerantz et al., 1998), but does not seem to be
required for p53's response to DNA damage (Kamijo et al., 1997, 1998).
Stabilisation of p53 by ARF can occur by several mechanisms, namely re-localising
hMDM2 to the nucleolus, preventing hMDM2-p53 shuttling and accumulation of
ARF-hMDM2-p53 'nuclear bodies' in the nucleoplasm, although the precise
mechanism/s are yet to be established (Weber et al., 1999; reviewed in Sherr and
Weber, 2000). ARF is also believed to negatively regulate the cell cycle in a p53-
independent manner (Carnero et al., 2000; Weber et al., 2000).
1.5.3 Expression and regulation of the INK4 proteins and ARF
INK4 and ARF transcripts are differentially expressed during murine embryogenesis
and adulthood, suggesting that they have tissue-specific functions (Roussel, 1999).
Regulation of pl6INK4a levels is primarily at the transcriptional level. In most tissues
pl6'NK4a mRNA is very low, although it is extremely stable (half-life >24 hours)
(Hara et al., 1996). Accumulation of pl6'NK4a mRNA and proteins occurs in response
to cellular senescence, expression of oncogenic ras, and inactivation of pRb (Hara et
al., 1996; Okamoto et al., 1995; Li et al., 1994a).
p 15INK4b is more abundantly and ubiquitously expressed than pl6INK4a. Its transcription
is induced in most cells, and in particular epithelial cells, by TGF-(3 (Hannon and
Beach, 1994), and there is evidence to indicate its upregulation by interferon-a in
lymphoid cell lines (Sangfelt et al., 1997). Its expression is not affected by pRb
status and is generally constant throughout the cell cycle (Stone et al., 1995).
Not only does ARF directly interfere with the p53-hMDM2 feedback loop but it is
also subjected to negative regulation by p53 (Stott et al., 1998). Furthermore, ARF is
known to link two important tumour suppressor pathways in cancer- namely the p53
and the pRb pathways, through direct induction by E2F-1 (Bates et al., 1998; see
figure 9). Furthermore, ARF is believed to be a link between viral (ElA) and cellular
(c-myc, ras) oncogene signalling and p53 accumulation, through its interaction with
hMDM2 (de Stanchina et al., 1998; Zindy et al., 1998; Palmero et al., 1998; see
figure 5, page 17).
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Figure 9. Regulatory mechanisms involving p14ARF and p16INK4a
p16'NK4a prevents the phosphorylation and inactivation of pRb by CDK4/6, whereas,
p14ARF prevents the hMDM2-mediated degradation of p53. Both p16INK4a and p14ARF are
themselves negatively regulated by pRB and p53 respectively. The release of E2F by
the phosphorylation and ablation of pRb leads to the upregulation of p14ARF, providing a
direct connection between the pRb and p53 pathways.
Adapted from James and Peters, 2000.
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1.5.4 Involvement of pl6INK4a, pl5INK4b and ARF in cancer
The evidence to validate INK4a as a tumour suppressor came from research in two
different fields, cancer genetics and cell cycle regulation. Search for a melanoma
susceptibility gene resulted in the discovery that the region on chromosome 9p21
containing the p 16INK4a gene is homozygously deleted in approximately 75% of
melanoma cell lines (Kamb et al., 1994). Its role in familial melanoma is now firmly
established and is defined by the presence of germline mutations, typically point
mutations or small intragenic deletions within the first or second exon (Hussussian et
al, 1994).
The ability of pl6INK4a and p 15INK4b to induce growth arrest by inhibiting
phosphorylation of pRb suggests that loss of function could contribute to
tumourigenesis, further endorsing their role as tumour suppressors. The importance
of this cell cycle regulatory pathway has been underscored by alterations in other
components of this pathway, such as inactivation of pRb, overexpression of D-type
cyclins and CDKs, or CDK4 mutations that abrogates binding of pl6INK4a. These
genetic lesions often appear to be mutually exclusive within tumours, suggesting that
they have functionally equivalent consequences (Sherr, 1996). In contrast, an inverse
correlation is not strictly observed between INK4a/ARF and p53 genetic alterations at
least in some human cancers, further denoting a p53-independent function for ARF
(Iida et al., 2000; Sanchez-Cespedes et al., 1999).
Inactivation of the INK4 locus has been shown in a range of cancers (Kamb et al.,
1994; Ruas and Peters, 1998). Essentially three modes of inactivation have been
observed: i) homozygous deletion, ii) intragenic mutation and iii) promoter silencing
by methylation.
(i) Homozygous deletion
Deletion of 9p21 is the most common method of inactivation, which generally
involves the entire INK4a/ARF locus and frequently, but not always, INK4b. It
affects up to 14% of all tumours analysed to date including gliomas, melanomas,
leukaemias, head and neck tumours and carcinomas of the bladder, lung, kidney,
pancreas and ovary (Ruas and Peters, 1998). Deletions of INK4a and INK4b have
been consistently observed in children with acute lymphoblastic leukaemia (ALL)
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(>30%), especially in leukaemias of the T-cell lineage (>50%) (Siebert et al., 1996).
In contrast, incidence of INK4a deletions is low in other haematological
malignancies such as NHL, chronic and acute myeloid leukaemia (CML and AML,
respectively) and primary breast cancers (<3%). Furthermore, deletions are
consistently absent in cancers of the colon, cervix and liver (Kamb, 1995; Ruas and
Peters, 1998).
Deletion of exon 1(3 in mice is associated with the development of lymphomas,
sarcomas, carcinomas and gliomas, similar to that observed in INK4a/ARF-null mice,
suggesting that ARF on its own is an important regulator of cell growth. The
sensitivity of ^RF-null mouse embryonic fibroblasts to oncogenic transformation
further establishes a vital tumour suppressor function for this protein (Kamijo et al.,
1997).
(ii) Intragenic mutations
Mutations in the INK4a/ARF locus is much higher in permanently growing cell lines
than in the primary tumours from which they are derived (Spruck et al., 1994; Zhang
et al., 1994). Most point missense mutations occur in exon 2, common to both INK4a
and ARF, and usually affect the amino acid sequence of both proteins (Quelle et al.,
1997; Kubo et al., 1997; Sanchez-Cespedes et al., 1999). Mutations occurring in
INK4a affects residues that are crucial for interactions between p 16INK4a and CDK4 or
CDK6 leading to phosphorylation of pRb, E2F release and Gl/S progression
(Lilischkis et al., 1996). Exon 2 mutations do not seem to affect the ability of ARF to
induce cell cycle arrest, although they might affect nucleolar localisation of the
protein (Quelle et al., 1997). A fraction of mutations have been found to exclusively
target exon la of INK4a, while mutations in INK4b are rare (Okamoto et al., 1995).
Mutations in exon lp ofARF are rare (Burri et al., 2001; Poi et al., 2001; Tanaka et
al., 1997). Overall, point mutations in the INK4a/ARF coding regions have been
detected in 5% of all human tumours analysed (Ruas and Peters, 1998).
(iii) Promoter silencing by methylation
Methylation of the INK4 genes, in particular exon la of the pl6INK4a gene, has been
observed in a significant fraction of human tumours, which results in a complete loss
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of its transcriptional activity. Hypermethylation has been proposed as an alternative
to intragenic mutation in silencing the residual allele of tumours showing LOH at
9p21, although this has not yet been proven in primary tumours (Merlo et al., 1995).
Silencing of the INK4a promoter has been found in 19% of all human tumours
studied (Ruas and Peters, 1998). Interestingly, methylation-induced silencing of the
pl6INK4a gene has been found in cancers of the breast and colon that do not show
homozygous deletions of the gene, and might represent an alternative to deletion as a
mode of inactivating pl6INK4a.
In murine T-cell lymphomas, loss of pl5INK4b expression by methylation is more
common than inactivation of the INK4a/ARF locus (Malumbres et al., 1997), and
recent studies by the same group reveal that in addition to promoter region
hypermethylation, the 3' untranslated region of pl5INK4b is also sensitive to
methylation (Malumbres et al., 1999). Furthermore, the INK4b gene is
hypermethylated without silencing of the INK4a promoter in certain haematological
malignancies (AML, T cell NHL and ALL) and gliomas. Hence, this suggests an
independent contribution and a tumour suppressor role for pl5INK4b, at least in some
human cancers (Herman et al., 1997). Methylation of both INK4a and INK4b is a
common occurrence in Burkitt's lymphomas, multiple myeloma and B cell NHL
(Herman et al., 1997).
Aberrant methylation of the ARF promoter has been recently reported in human
colorectal and gastric cancers (25-45%) independently of INK4a promoter
methylation (Esteller et al., 2000; lida et al., 2000). However, the promoter is
infrequently methylated in murine primary T-cell lymphomas (Melendez et al.,
2000).
1.6 Oncogenes
By definition, an oncogene typically refers to any gene that produces a malignant
phenotype when introduced into a normal cell (Bishop, 1991; Weinberg, 1994).
Oncogenes are derived from proto-oncogenes, cellular genes that function in various
aspects of cell cycle regulation, including growth, proliferation, differentiation and
apoptosis. Changes in the structure of the proto-oncogene, attributed to translocation,
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mutation, and/or amplification resulting in the synthesis of an abnormal gene product
(oncoprotein), or changes in the regulation of gene expression resulting in enhanced
or inappropriate production of the normal protein, contributes to tumourigenesis.
Table 2 highlights selected oncogenes and their mode of activation in associated
human tumours.
Table 2
Mode of activation of selected oncogenes in human cancer
Proto-oncogene Mechanism Associated human tumour
ras Point mutation Variety of cancers, including lung, colon,
pancreas, leukaemias, some AIDS-BL
c-myc Translocation BL, some DLCL
Amplification breast, lung, colon, prostate cancer and MM, ML
N-myc Amplification Neuroblastoma, small cell lung carcinoma
L-myc Amplification Small cell lung carcinoma
bcl-1 Translocation Mantle zone lymphomas
Amplification Breast, liver and oesophageal cancers
bcl-2 Translocation FL, DLCL
bcl-6 Translocation/ point DLCL, FL
mutations
bcl-10 Translocation/ point MALT lymphomas/ FL
mutation
BL, Burkitt's lymphoma; FL, Follicular lymphoma; DLCL, diffuse large cell lymphoma; MM,
multiple myeloma; ML, myeloid leukaemia
The following sections describe three genes, c-myc, bcl-2 and bcl-6, each of which
have a distinct function in growth and proliferation (c-myc), apoptosis regulation
(bcl-2) and differentiation (bcl-6). These genes have been investigated in the present
study due to their implied role in the pathogenesis of certain AIDS-NHL (Dalla-
Favera et al., 1982b; Tsujimoto et al., 1984; Ye et al., 1993).
1.7 c-Myc
1.7.1 Discovery of c-myc
In 1979, an oncogene which caused carcinomas, sarcomas, endotheliomas and the
leukaemic disorder myelocvtomatosis (hence the acronym, myc), was identified from
the MC29 avian leukaemia retrovirus (ALV) (Sheiness and Bishop, 1979). In 1982,
the human c-myc gene was isolated as the cellular homologue of the chicken
retroviral w-myc gene (Dalla-Favera et al., 1982a). Subsequently, its potent
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oncogenicity was realised by the presence of chromosomal translocations involving
the myc gene in animal and human tumours, such as murine plasmacytomas and
Burkitt's lymphomas (Shen-Ong et ah, 1982; Dalla-Favera et al., 1982b).
c-myc belongs to a family of genes including B-myc, L-myc, N-myc and s-myc.
Besides c-myc, only N-rayc and L-myc are involved in neoplastic transformation
(Schwab et al., 1985).
1.7.2 Structure of the c-myc gene and protein
The c-myc locus maps to chromosome 8q24 and consists of 3 exons. Exon 1 is
untranslated, while exons 2 and 3 providing the major coding regions. The 2.4kb and
2.2kb transcripts initiated from promoters Pi and P2, account for 10-25% and 75-90%
of steady-state c-myc RNAs in normal cells respectively, and contain the open
reading frame (ORF) for the two major c-myc polypeptides, p67 and p64 (Taub et al.,
1984; Hann et al., 1988; Bentley and Groudine, 1986). It has been suggested that
p67 may act as a negative regulator of p64 activity (Hann, et al., 1988). Minor
promoters Po (5' to Pi) and P3 give rise to less than 5% of c-myc mRNAs (3.1kb and
2.3kb respectively) (Bentley and Groudine, 1986).
The structure of the c-Myc protein is illustrated in Figure 10. The C-terminal DNA-
binding domain and N-terminal transactivation domain of c-Myc are required for its
biological activities (Kato et al., 1990). In addition, the conserved Myc box II (MBII)
is critical for the biological activity of c-Myc and for oncogenic transformation (Li et
ah, 1994b; Ingvarsson, 1990; Henriksson and Luscher, 1996).
1.7.3 c-Myc as a transcription factor
c-Myc is a nuclear phosphoprotein that functions primarily as a transcription factor.
The ability of c-Myc to interact with the transcriptional machinery is modulated by
its interaction with other transcription factors through both its C- and N-termini. In
addition, the protein can activate and repress transcription of a number of target
genes involved in cellular processes such as proliferation, differentiation and
apoptosis and these functions of c-Myc are summarised in Figure 11. The c-Myc
target genes are beyond the scope of this thesis and are reviewed in Dang (1999).
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Figure 10. Structural and functional domains of c-Myc














c-Myc harbors a transactivation domain (TAD; amino acids 1-143) at its N-terminus; a
nuclear localisation signal (NLS; amino acids 320-328), a basic region (b; amino acids
355-368), a helix-loop-helix motif (HLH; amino acids 368-410) and a leucine zipper
domain (ZIP; amino acids 411-439). The HLH/ZIP domains mediate protein-protein
interaction while the basic region specifies DNA binding. Yellow boxes within the TAD
represent Myc Box I (amino acids 45-63) and II (amino acids 129-141), two conserved
regions found in all Myc family members. P indicates the localisation of the major in vivo
phosphorylation sites. p67 contains an additional 14 amino acid residues at its N
terminus, due to an initiation codon in exon 1, compared to p64 which initiates at the
first AUG in exon 2. The functional and protein-protein interaction domains of Myc,
along with a few examples of proteins (purple text) that interact with the C- and N-
terminal domains are indicated.
Adapted from Henriksson and Luscher, 1996.
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Figure 11. Functions of c-Myc
> Cell cycle regulation








c-Myc has a number of biological functions. It positively affects cell cycle regulation,
apoptosis and metabolism. c-Myc is absent is quiescent cells but is rapidly induced
upon addition of growth factors. Ectopic c-Myc expression in quiescent cells
promotes entry into S-phase and is growth factor-independent (Evan and Littiewood,
1993). c-Myc can also activate cellular apoptosis, which requires both the N-terminal
transactivation domain and the b/HLH/Z domain (Evan et al., 1992). The proliferative
and apoptotic activities of c-Myc are thought to be coupled, safeguarding against
expansion of potentially malignant cells (Harrington et al., 1994). The protein
sensitises the cell to apoptotic stimuli and death receptor signals from the CD95/Fas
family in response to a variety of apoptotic stimuli such as hypoxia, DNA damage
and glucose deprivation (Hueber et al., 1997; Evan and Littiewood, 1993).
c-Myc represses genes involved in cellular differentiation and cell adhesion through
initiator or Inr elements. Transcriptional repression requires aa 106-143 within the
TAD as well as the HLH domain (Li et al., 1994b; Lee et al., 1996). c-Myc mediated
transformation thus requires both transactivation of growth-related genes and Inr-
driven transcriptional repression of differentiation and cell adhesion genes.
Adapted from Dang eta!., 1999.
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The CTD mediates c-Myc binding to physiological target genes that are involved in
transcriptional regulation. Max, a b/HLH/Z protein, was first identified as a binding
partner for c-Myc, which controls the access of c-Myc to physiological target sites
(Blackwood and Eisenman, 1991). Hetero-dimerisation with Max is necessary for c-
Myc to mediate proliferation, transformation and apoptosis (Amati et al., 1993). Max
in turn interacts with another b/HLH/Z protein family, Mad, which are implicated in
transcriptional repression, cell growth inhibition and differentiation (Amati and
Land, 1994).
1.7.4 Role of c-Myc in human neoplasia
c-myc is activated by a variety of genetic alterations such as chromosomal
translocations, gene amplification, and somatic mutations. Beside its characteristic
involvement in chromosomal translocations in BL (see below), the gene is also
amplified in various cancers (Nesbit et al., 1999, see Table 2). A common underlying
feature of tumours with c-myc alterations is the deregulated or elevated expression of
the gene (Cole, 1986; Spencer and Groudine, 1991).
1.7.4.1 c-myc alterations in BL
The juxtaposition of the c-myc gene on chromosome 8 with regulatory elements of
the immunoglobulin (Ig) heavy chain (IgH), or light chains X and k on chromosomes
14, 22 or 2 respectively, is a characteristic feature ofBL (Dalla-Favera et al., 1982b).
The most common translocation is t(8:14) (80% of cases) which involves a
breakpoint on chromosome 14 in the switch region of p (Sp) in the majority of
sporadic BL (sBL), and the IgH joining region in endemic BL. The site of
chromosomal breakpoint observed in the different BL-types, is believed to reflect the
stage of differentiation of the affected cell (Pelicci et al., 1986a). On chromosome 8,
the breakpoint is located at an undefined distance 5' to the c-myc locus in most eBL,
whereas in sBL and AIDS-BL the break is usually within intron 1 or the immediate 5'
non-transcribed region of the c-myc gene (Pelicci et al., 1986a). These translocations
place c-myc and the IgH gene in a head-to-head transcriptional configuration. In most
sBL with t(8:14), the first exon of c-myc is removed from the coding portion of the
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In the less common 'variant' t(2:8) (15% of cases) and t(8:22) (5% of cases)
translocations, the breakpoints on chromosome 8 occur up to 140kb downstream of
the transcribed region of c-myc, and 5' of the variable region on the Ig light chains.
The two loci are fused in the same transcriptional orientation (Cory, 1986).
Somatic mutation within the translocated c-myc allele, is another frequent structural
feature of BL. Mutations mainly cluster in the 5' non-coding region either disrupting
exon 1, intron 1 or the 5' flanking regions, and include insertions, deletions and
single nucleotide substitutions (Pelicci et al., 1986a; Wiman et al., 1984).
Additionally, the second exon of c-myc is also affected by mutations that modify key
phosphorylation sites necessary for its transactivation function (Rabbitts et al., 1983;
Bhatia et al., 1993). Furthermore, c-Myc mutants possess increased transforming
activity, possibly due to their decreased responsiveness to the pRb family member,
pi07, which negatively regulates c-Myc (Hoang et al., 1995) or by their resistance to
ubiquitin-mediated degradation, resulting in increased stability (Bahram et al., 2000).
1.7.4.2 Regulation of c-Myc in BL
The levels of c-myc RNA and protein expressed in BL are typically not strikingly
higher than those seen in EBV-immortalised B cells, although they are elevated when
compared to that observed in quiescent cells (Wiman et al., 1984). Transcription of
c-myc in BL predominantly arises from the translocated allele, while the
unrearranged allele is repressed or expressed at very low levels (Croce and Nowell,
1985). Activation of the translocated allele is believed to occur by the influence of
cA-acting Ig enhancer elements that are transcriptionally active in B cells. Thus, the
rearranged allele escapes the repression mechanisms that usually inactivate the
normal c-myc allele in the later stages of B cell maturation (Spencer and Groudine,
1991).
Alternatively, loss of regulation of c-myc from the translocated allele could occur by
the truncation of exon 1 as seen in sporadic BL (see above), or by the presence of
structural alterations in the 5' region of the translocated allele (Pelicci et al., 1986a)
and see above). This might inactivate important negative regulatory elements such as
the block to transcriptional elongation near the 3' end of exon 1, leading to the
constitutive transcriptional activation of c-myc, as seen in BL cells (Cesarman et al.,
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1987). Cells that constitutively express c-Myc are maintained in a state of continuous
proliferation, are highly apoptosis-prone (Evan et al., 1992), and rarely undergo
transformation unless they incur a second aberrant genetic event (Adams et al.,
1983). Thus additional changes that counteract apoptosis, such as activation of bcl-2
(see section 1.8.7.2), mutations in p53, RB and Bax (Farrell et al., 1991; Cinti et al.,
2000; Gutierrez et al., 1999), or silencing of INK4a by methylation (Klangby et al.,
1998), are often present in primary BL and BL cell lines.
1.8 Bcl-2
1.8.1 Discovery of bcl-2
The B cell lymphoma/Ieukaemia-2 {bcl-2) gene was so named because of its
characteristic association with B cell malignancies. This proto-oncogene was
originally identified by virtue of its involvement in the t( 14:18) translocation
breakpoint of follicular B cell NHL (Tsujimoto et al., 1984). This discovery led to a
new class of oncogenes whose primary function is regulation of programmed cell
death (apoptosis) and cell survival, instead of promoting (c-myc) or inhibiting
proliferation (p53 and RB) (Korsmeyer, 1992).
1.8.2 Structure of the bcl-2 gene and protein
The bcl-2 gene is located on chromosome 18 (band q21), has three exons and utilises
two different promoters to generate transcripts that encode two proteins namely p26a
(Dittmer et al., 1998) and p22p by alternative splicing (Reed et al., 1988; Seto et al.,
1988). The Bcl-2 protein is an integral membrane protein, which is localised to
mitochondrial, nuclear and endoplasmic reticulum membranes (Krajewski et al.,
1993). A stretch of 19 hydrophobic amino acids at the C-terminus of p26a, critical
for its anti-apoptotic function, serves to anchor the protein into membranes, with a
majority of the amino terminus exposed to the cytosol (Chen-Levy and Cleary,
1990; Hockenbery et al., 1990). The truncated p22p form lacks this hydrophobic tail
(Tsujimoto and Croce, 1986).
41
1.8.3 The Bcl-2 protein family
The Bcl-2 family comprises at least 16 members (Adams and Cory, 1998). All
members possess sequence homology in one or more of four conserved motifs
known as Bcl-2 homology domains (BH1 to BH4) that mediate protein-protein
interactions (Yin et al., 1994).
Although Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic) are capable of functioning
independently, dimerisation among Bcl-2 family members provides an important
mechanism of regulating their activity (Knudson and Korsmeyer, 1997). The BH3
domain is critical for both hetero-dimerisation with anti-apoptotic proteins and for
induction of apoptosis (Theodorakis et al., 1996). The BH4 domain, which is found
only in the anti-apoptotic members such as Bcl-2 and Bcl-XL, is required for the
binding and sequestration of Caenorhabditis elegans, Ced-4 homologues, thereby
inhibiting apoptosis (Huang et al., 1998; Korsmeyer, 1999 and see below).
1.8.4 Expression and physiological role of Bcl-2
Consistent with its role in cell survival, Bcl-2 is widely expressed during
embryogenesis, notably in many neuronal populations, the retina and limb buds,
although it is not absolutely required for embryonic development (Veis et al., 1993).
In the adult, expression is limited to T and B lymphocytes, haematopoietic cells,
epithelia and peripheral neurons (Hockenbery et al., 1991).
The physiological role of Bcl-2 has been elucidated by its topographical distribution
in mature tissues, particularly the secondary germinal centres. The protein is
expressed in early progenitor T and B cells, downregulated during the critical stage
of lymphocyte development and selection, and re-expressed in mature T and B cells
that have been selected for survival, thus implying a role in the selection and
maintenance of plasma and memory B cells (Hockenbery et al., 1991).
1.8.5 Role for the Bcl-2 family members in cell death regulation
A critical role for this gene as an intracellular apoptosis-suppressor came from the
observation that overexpression of Bcl-2 increases the viability and survival of
certain cytokine-dependent haematopoietic cell lines upon cytokine withdrawal
(Vaux et al., 1988). Furthermore, Bcl-2 prevents cell death in response to diverse
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insults such as y- and ultraviolet-radiation, growth factor withdrawal, oncogenes,
viral proteins, oxidative stress and others (Yang and Korsmeyer, 1996).
Hetero-dimerisation with Bax is not essential for the anti-apoptotic function of Bcl-2.
An important factor in determining susceptibility to apoptosis is the ratio of Bcl-2 to
Bax that is present in the cell (Oltvai et al., 1993). Bcl-2 exerts its anti-apoptotic
activity through a variety of mechanisms, most of which involve prevention of
cytochrome c release and subsequent activation of the apoptotic signal transduction
pathway (Susin et al., 1996; reviewed in Green and Reed, 1998). Pro-survival
proteins can also inhibit apoptosis downstream of the release of cytochrome c by
direct binding to the cytoplasmic pro-apoptotic protein, Apaf-1 (Ced-4 homologue),
inhibiting its association with procaspase-9 and its activation (Hu et al., 1998; Reed,
1997).
1.8.6 Bcl-2 and the cell cycle
Under sub-optimal growth conditions, Bcl-2 promotes exit of cells from the cell
cycle and delays re-entry into cycle. This cell cycle inhibitory effect is genetically
separable from its survival function (Huang et al., 1997). Cell cycle inhibition by
Bcl-2 is believed to have evolved to reduce its oncogenicity, and provide additional
protection against apoptotic stimuli that proliferating cells encounter (Adams and
Cory, 1998).
1.8.7 Involvement of bcl-2 in cancer
1.8.7.1 bcl-2 alterations in lymphomas
85% of follicular lymphomas (Yunis et al., 1982) and 30% of diffuse B cell
lymphomas (Aisenberg et al., 1988) harbour the t( 14:18) reciprocal translocation that
juxtaposes the bcl-2 gene and the IgH regulatory sequences. Nearly 70% of the
breakpoints occur within the 3' untranslated region called the major breakpoint
region (MBR) and 25% occur at a distance approximately 20kb 3' of the gene, called
the minor cluster region (mcr) (Tsujimoto et al., 1985; Cleary et al., 1986). The
corresponding breakpoints on chromosome 14 occur at or close to members of the
joining region genes (JH) (Bakhshi et al., 1987). Occasionally, the breakpoint may
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occur 5' to the bcl-2 gene (Yabumoto et al., 1996), although these rearrangements
involve not only IgH but also light chain genes as partners (see figure 13). These
translocations are believed to occur as a result of endonucleolytic cleavages at the
heavy chain diversity (D) and joining (J) segments by the enzyme recombinase
during pre-B cell development, thus exposing sites of double-strand breaks to faulty
recombinational events (Tsujimoto et al., 1985).
The translocation places the bcl-2 gene in the same transcriptional orientation as the
IgH locus, thus giving rise to bcl-2/IgH chimeric transcripts (see figure 13). Since the
protein-coding region of bcl-2 is left intact, both normal and translocated alleles
encode for a normal 25kDa Bcl-2 protein. Transcriptional deregulation and
inappropriately elevated levels of the protein are commonly observed in lymphomas
as a consequence of the translocation, which is thought to confer a survival
advantage to the malignant B cells (Seto et al., 1988).
Somatic mutations have been shown to accumulate in the translocated bcl-2 allele in
a subset of NHL, possibly due to the proximity of the gene to the hypermutable Ig
region. The functional significance of these mutations is unclear (Tanaka et al.,
1992). Mutations near the amino-terminal BH4 domain of Bcl-2, a region responsible
for the cell cycle inhibitory function of the protein, occurs in follicular lymphomas
(Matolcsy et al., 1996). It has been suggested that these mutations might relieve cell
cycle inhibition without affecting the anti-apoptotic function of Bcl-2, thus
contributing to the more aggressive phenotype characteristic of progressed follicular
lymphoma (Huang et al., 1997; Matolcsy et al., 1996).
Healthy individuals frequently (20 to 60%) harbour the t( 14:18) translocation
(Limpens et al., 1995; Aster et al., 1992; Summers et al., 2001), indicating that a
translocation involving bcl-2 is in itself insufficient to cause cancer, and additional
events are necessary for malignant transformation to occur (McDonnell and
Korsmeyer, 1991; see below). Nonetheless, detection of t(14:18) is a believed to be a
marker for monitoring minimal residual disease and remission following therapy
(Gribben and Nadler, 1995).
1.8.7.2 Co-operation between the bcl-2 family and c-Myc and p53 in neoplasia
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for transformation (Strasser et al., 1990), were first noted in vitro (Vaux et al., 1988)
and subsequently observed in naturally occurring lymphoid tumours in vivo (Lee et
al., 1989). This potent oncogenic combination probably reflects the ability of each
gene to counter the anti-oncogenic properties of the other. In other words, Bcl-2
compensates the apoptotic function of deregulated c-Myc allowing unrestricted
proliferation, whereas growth inhibition induced by Bcl-2 is overcome by the
mitogenic effects of c-Myc (Cory et al., 1999; Hueber and Evan, 1998; Fanidi et al.,
1992).
p53 is required for inducing apoptosis in response to genotoxic damage and often but
not always upregulates expression of Bax (see section 1.3.3). Bcl-2 is capable of
inhibiting both p53-dependent and independent mechanisms of cell death.
Thymocytes from p53"A mice are resistant to y-irradiation and etoposide, but not
glucocorticoids, interferon-y and TGF-p. However, Bcl-2 is very effective at
blocking cell death induced by these agents (Francis et al., 2000; Strasser et al.,
1994).
1.8.7.3 Prognostic significance of bcl-2 expression
Elevated expression of Bcl-2 is not restricted to B-lymphomas with a t(14:18)
translocation, but is also common in lymphoproliferative disorders, and cancers of
the lung, breast, colon and prostate, independent of the translocation (Pezzella et al.,
1990; reviewed in Jaattela, 1999). A distinct correlation between high Bcl-2
expression and poor prognosis has been reported in NHL and AML (Gascoyne et al.,
1997). In contrast, high levels of Bcl-2 are considered to be markers of favourable
clinical outcome in breast cancer (Silvestrini et al., 1994). Furthermore, loss of
function mutations in Bax, and an elevated Bcl-2/Bax ratio is considered to be an
indicator of poor prognosis, particularly in haematopoietic malignancies (Meijerink
et al., 1998; reviewed in Jaattela, 1999).
1.9 Bcl-6
1.9.1 Cloning and characterisation of bcl-6
Based on cytogenetic observations of recurrent chromosomal translocations affecting
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band 3q27 in diffuse large cell lymphomas (DLCL), the genomic region within 3q27
was cloned from a lymphoma with a t(3:14) (q27:q32) breakpoint (Baron et al.,
1993). Subsequent nucleotide sequencing of the corresponding cDNA led to the
identification of a novel putative proto-oncogene, bcl-6, for B cell lymphoma-6, also
called LAZ3 (lymphoma-associated zinc finger gene on chromosome 3) (Ye et al.,
1993).
1.9.2 Structure of the bcl-6 gene and protein
The bcl-6 gene has 10 exons spanning 26kb, with a lOkb intron between non-coding
exons 1 and 2 (see figure 14A). Two transcription initiation sites have been mapped
to exon 1. Exons 3 to 10 encode a 95 kDa phosphoprotein that contains six kriippel-
type C2H2 zinc-finger (ZF) motifs typically found in sequence-specific transcription
factors, and an evolutionarily conserved poxvirus and zinc finger (POZ) domain at
the N-terminus (see figure 14B). This motif serves to mediate protein-protein
interactions and is required for homo- or hetero-dimerisation, as well as
transcriptional activation and repression. This region is also capable of regulating
sequence-specific DNA binding by the zinc-finger domain. The POZ domain along
with the central portion of the gene, which contains multiple phosphorylation sites
embedded in PEST motifs, regulates its stability (Niu et al., 1998; see figure 14).
1.9.3 Pattern and regulation of Bcl-6 expression
The pattern of bcl-6 mRNA and protein expression is highly discordant, suggesting
post-transcriptional and translational mechanisms of regulation (Allman et al., 1996).
The mRNA is expressed at variable levels in many tissues and organs, highest levels
being in skeletal muscle. However protein expression is far more restricted. Within
the B cell lineage, the protein is detected only within the germinal centre and not in
the immature B cells or differentiated plasma cells (Yen-Moore et al., 2000). In the
T-cell lineage, it is expressed in a subset of CD4+ T cells within the GC and cortical
thymocytes (Cattoretti et al., 1995). In non-lymphoid tissue, the protein can be found
in proliferating chondrocytes, mature myocytes, and differentiating keratinocytes.
This suggests that protein expression is tissue-specific and confined to cells at
specific stages of differentiation (Knudson et al., 2001).
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Figure 14. Structure of the bcl-6 gene and protein
14 A Structure of the bcl-6 gene








The dark purple boxes indicate the coding regions of the exons and the mauve boxes
the non-coding regions. The mutation cluster region within the 5' non-coding region
of the gene is indicated. A 740bp region encompassing the fragments E1.10, E1.11,
and E1.12, wherein >90% of mutations reside, is indicated by bold red lines.
14 B Structure of the Bcl-6 protein
Transrepression
Homodimerisation MAPK phosphorylation
^ ^ (STAT-6 binding site)
Protein interaction Ubiquitination DNA binding
I I
POZ PEST Zinc fingers
I — I I I I I I
NH2 terminus COOH terminus
The Bcl-6 protein is a 95kDa nuclear phosphoprotein. The N-terminal POZ domain is
irresponsible for protein-protein interactions, including homo-dimerisation and binding to
trauidlear co-repressors. The C-terminal domain, which is composed of six regularly
spaced C2H2-type zinc fingers, mediates sequence-specific DNA recognition. The
central region of the protein contains multiple phosphorylation sites embedded in PEST
motifs. Trans-repression function of Bcl-6 requires both the POZ domain and the central
PEST region. The STAT-6 binding site is indicated. POZ: poxvirus and zinc finger
domain PEST: Proline (P), glutamic acid (E), serine (S) and threonine (T).
Adapted from Dalla-Favera eta!., 1999.
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Relatively little is known about the upstream signals that induce Bcl-6. However,
signalling pathways that downregulate the protein, have been identified. Antigen-
receptor signalling in B cells can induce mitogen-activated protein kinase (MAPK)-
mediated phosphorylation and subsequent degradation of the protein by the
ubiquitin/proteosome pathway (Niu et al., 1998). In addition, the protein can also be
downregulated by CD40 signalling or by the CD40 functional homologue EBV
LMP1 (Kenney et al., 1998; Allman et al., 1996; Ye et al., 1997).
1.9.4 Transcriptional repression function of Bcl-6
The POZ domain mediates Bcl-6 transcriptional repression activity (Seyfert et al.,
1996) by interacting with nuclear co-repressors that recruit histone deacetylases,
which in turn modify the activity of RNA polymerase II (Chang et al., 1996). Target
genes repressed by Bcl-6 are reviewed in Shaffer et al (2000). Inhibition of
differentiation and enhanced proliferation through repression of target genes by
deregulated or constitutively expressed Bcl-6, might have important consequences in
the development of B cell lymphomas that harbour translocated bcl-6 (Shaffer et al.,
2000).
1.9.5 Role for Bcl-6 in B and T cell development
The function of Bcl-6 in B and T cell development has been elucidated in studies
carried out in bcl-6 knockout mice. Mice deficient in Bcl-6 display normal B and T
cell development but have a selective defect in T cell-dependent antibody responses
with lack of affinity maturation, due to the inability of follicular B cells to proliferate
and form germinal centres (Ye et al., 1997). Further support for the function of Bcl-6
as a transcriptional switch in GC formation and post-GC differentiation comes from
the observation that it is upregulated in B cells that enter the GC, and downregulated
abruptly when they exit (Ye et al., 1997).
Bcl-6 can modulate specific T cell-mediated responses, bcl-6'1' mice die at an early
age of a severe inflammatory disease in multiple organs characterised by infiltrations
of eosinophils and IgE-bearing B cells typical of a Th2-mediated hyperimmune
response. This may be explained by the ability of Bcl-6 to bind and repress activation
by STAT-6, a central mediator of IL-4-driven Th2 cell differentiation (Ye et al.,
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1997).
1.9.5 Genetic alterations in bcl-6
1.9.5.1 bcl-6 translocations in NHL
Rearrangements in bcl-6 have been demonstrated in around 40% of DLCL, but are
less frequently observed in follicular lymphoma (FL) (6 to 15%) and marginal zone
B cell lymphoma (9%), and virtually absent in other lymphoid malignancies (Lo
Coco et al., 1994). In the setting of immunodeficiency, bcl-6 alterations are
detectable in 20% ofAIDS-DLCL (Gaidano et al., 1994).
An unusual feature of 3q27 reciprocal translocations is the heterogeneous nature of
the partner chromosome. At least 33 different chromosomal loci have been described
as participating in these translocations, including the Ig heavy and light chains and
many non-Ig loci (Ye, 2000). 3q27 breakpoints are dispersed over a lOkb region
(major translocation cluster, MTC) clustering mainly in the 5' flanking region within
the first non-coding exon or intron of bcl-6. The 5' regulatory sequences which
include the promoter in many cases, is removed, leaving the coding regions intact
(Ye et al., 1993). Thus, the germline promoter of the bcl-6 gene is substituted by
heterologous promoters fused in the same transcriptional orientation as the coding
exons of bcl-6 (Ye et al., 1995a). The outcome of such promoter substitutions is
usually a fusion transcript that translates a normal Bcl-6 protein (Chen et al., 1998a;
Ye et al., 1995a). In B lymphoma cells, the germline bcl-6 allele is transcriptionally
inactive indicating that the cellular differentiation state of these cells is non-
permissive for Bcl-6 expression and that translocation allows the expression of a
gene that would normally be silenced (Ye et al., 1995a). Therefore, the functional
consequence of such translocations is transcriptional deregulation of bcl-6, resulting
in a block to normal B cell differentiation and lymphomagenesis (Chen et al.,
1998a).
30% of cases that carry 3q27 abnormalities do not show a break in the MTC of bcl-6
(Ye et al., 1993). Recent studies indicate the possibility of an alternative breakpoint
region (ABR) 200-270 kb telomeric and 5' to bcl-6 (Chen et al., 1998b).
An interesting observation that demonstrates the requirement for co-operative
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interactions between genes to effect tumourigenesis is that bcl-6 translocations are
often accompanied by alterations in other genes, such as bcl-2, bcl-1 and p53 (Butler
et al., 1997). Concomitant rearrangements in bcl-6 and bcl-2 are observed in
transformed lymphomas with a prior history of FL (Butler et al., 1997), and a subset
of high-grade mucosa-associated lymphoma tissue (MALT)-derived tumours display
rearrangements in bcl-6, along with p53 mutations (Gaidano et al., 1997a).
1.9.5.2 Somatic mutations in bcl-6
In contrast to the coding region of bcl-6, its 5' non-coding region displays extensive
structural instability, which can result in deregulated expression (Capello et al.,
2000; Ye et al., 1993). In addition to translocations and small intragenic deletions
(Nakamura et al., 1999; Ye et al., 1995b), this region is frequently targeted by
3 2somatic mutations, both in GC derived tumours (1.4x10" to 1.6x10" per bp) as well
as normal B cells (6.8xl0"4 to 1.9xl0"3 per bp) (Migliazza et al., 1995; Shen et al.,
1998; see figure 14A). These 5' bcl-6 mutations are detectable in about 70% of
DLCL and 45% of FL. Multiple biallelic mutations are present in both the germline
and translocated bcl-6 alleles. Furthermore, it is known that mutations in bcl-6 can
occur independently of translocation, as observed in 70% of AIDS-NHL (excluding
DLCL), certain B-NHL without a 3q27 abnormality, and 28 to 50% of non-AIDS BL
without detectable gross rearrangements (Capello et al., 1997; Gaidano et al.,
1997c). More recently Zan et al have demonstrated that such mutations can occur
out-with the Ig locus, and suggest the existence of cA-acting regulatory elements,
similar to those in the Ig locus, in bcl-6 (Zan et al., 2000).
Of considerable interest is the observation that somatic mutations in bcl-6 can also
occur in normal GC and memory B cells, although at a much lower frequency (see
above), indicating that bcl-6 mutations may reflect a GC-related physiological
process rather than a lymphoma specific phenomenon (Pasqualucci et al., 1998).
1.9.5.3 Prognostic and histogenetic implications of bcl-6 gene alterations and
expression
bcl-6 mutations are more likely to reflect the GC or post-GC origin of tumours, since
they are regarded as a marker of transition of a given B cell through the GC. This is
further corroborated by the fact that rare neoplasms of precursor B cells are
significantly devoid of mutations in this gene, although they are frequently detected
in DLCL, FL, BL and AIDS-NHL (Migliazza et al., 1995).
Analysis of Bcl-6 protein expression has also contributed substantially to the
histogenesis of AIDS-NFIL and Hodgkin's disease. Analysis of AIDS-NHL shows
that 100% of AIDS-BL express Bcl-6, whereas in AIDS-DLCL, expression is
restricted to the cases displaying LNCCL morphology and generally absent in the
immunoblastic type (Carbone et al., 1997, 1998).
The significance of bcl-6 rearrangement as a useful prognostic marker is
controversial (Pescarmona et al., 1997; Offit et al., 1994). As a disease-specific
diagnostic marker however, the persistence of tumour cells with bcl-6 translocations
after treatment can be used to monitor minimal residual disease. Somatic mutations
in bcl-6 have been considered as a reliable indicator of the more aggressive forms of
post-transplant lymphoproliferative disorder, such as NHL and multiple myeloma,
(Cesarman et al., 1998).
1.10 Tumour-associated viruses
The first evidence of the tumour-inducing potential of viruses came in 1911, from the
observation that a virus (Rous-sarcoma virus) could cause sarcomas in fowl (Rous,
1911). Since then viruses belonging to the retro-, herpes-, hepadna- papova- and
adeno-virus families have been shown to be associated with a diverse range of
neoplasias in humans and other hosts (for review see Wyke, 1997).
Three viruses associated with cancer both in immunocompetent and compromised
(AIDS patients and organ transplant recipients) hosts are Epstein-Barr virus (EBV)
(in Burkitt's lymphoma, AIDS-NHL and post-transplant lymphoproliferative
disorder) (see below); Kaposi's sarcoma-associated herpesvirus (KSHV) (in Kaposi's
sarcoma and primary effusion lymphoma) (see below); and human papillomavirus
(HPV) (in anogenital, and cervical carcinoma) (Goedert et al., 1998). However, only
a small number of infected people develop virus-associated malignancy, reflecting
the multi-step nature of carcinogenesis, with viral infection representing only one of
these steps.
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1.11 Epstein-Barr Virus (EBV)
EBV, a prototype gamma (y) herpesvirus (Family Herpesviridae, genus
Lymphocryptovirus), was first identified by Epstein and colleagues in cultured
tumour biopsy cells from a case of endemic (African) Burkitt's lymphoma (BL)
(Epstein et al., 1964). Subsequently, the virus has been linked to diseases of both
epithelial and lymphoid origin, in immunocompetent and immunocompromised hosts
(reviewed in Brooks and Thomas, 1995, see Table 3).
Table 3
EBV-associated diseases
Association Disease Cell of origin References
Causative Acute infectious mononucleosis (IM) Lymphoid Niederman et al., 1970
agent
Etiologic Burkitt's lymphoma (BL) Lymphoid Epstein et al., 1964
association
Nasopharyngeal carcinoma (NPC) Epithelial* Wolfe/ al., 1973
Post-transplant lymphoproliferative Lymphoid Crawford et al., 1980
disorder (PTLD) Hanto et al., 1985
AIDS-related lymphomas (ARL) Lymphoid Hamilton-Dutoit et al.,
1991
Oral Hairy Leukoplakia (OHL) Epithelial* Greenspan et al., 1985
X-linked lymphoproliferative disease Lymphoid Purtilo et al., 1975
(XLPD)
Hodgkin's disease (a subset) Lymphoid Weiss et al., 1989
T-cell lymphoma (a subset) Lymphoid Jones et al., 1988
Suspected Gastric carcinoma (~10%) Epithelial* Imai et al., 1994
association
Carcinoma of the parotid gland Epithelial* Raab-Traub et al., 1991
Breast cancer Epithelial Bonnet et al., 1999
Leiomyosarcomas smooth muscle McClain et al., 1995
* Epithelial cell infection/lesions are included for completion but are not discussed further.
1.11.1 Genome organisation
EBV is an enveloped virus, with a 172kb double-stranded linear DNA genome
enclosed in an icosahedral capsid. The genome contains dispersed regions of repeat
(internal repeats {IR} 1-4) and unique (U) sequences (short {US} and long {UL})
along its entire length, and is flanked by reiterated 500bp terminal direct repeats that
are required for covalent circularisation of the genome in latently infected cells. The
genome has the coding capacity for approximately 70 proteins. The latent and lytic
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cycle genes are described in Table 4 (reviewed in Epstein and Crawford, 1998;
Rickinson and Kieff, 1996).
Table 4
Classification and function of selected EBV genes
Class Gene* Function
LATENT EBNA LP Immortalisation, binds p53 and pRb
EBNAla Episome maintenance
EBNA2 Immortalisation, Transactivates viral & cellular
genes (p21 and hMDM2)
EBNAs 3a, 3b and 3c 3a and 3c, immortalisation
3c, viral transactivator, binds pRb
LMPla Immortalisation, upregulates anti-apoptotic bcl-2 and
A20, tumourigenic in nude mice
LMP2a and 2b Facilitate immortalisation. LMP2a inhibits EBV
reactivation from latency
EBERs bind and inhibit protein kinase, PKR
BARTs role in signal transduction and growth control
LYTIC
Immediate BRLF1 and BZLF1 (Zta) switch from latent to lytic infection; Zta, effects
early growth arrest by inducing p53, p21 and p27; BRLF1,
activates E2F1 and viral replication
Early Early antigen (EA) Viral replication
Late Membrane antigen (MA) Viral infectivity and spread
Viral capsid antigen (VCA) Viral structural protein
*, Only selective genes have been mentioned; a, expressed during both latent and lytic infection;
EBNA, Epstein-Barr nuclear antigen; LMP, latent membrane protein; EBERs, EBV-encoded RNAs;
BARTs, BamHl A rightward transcripts; LP, Leader protein; PKR, double stranded RNA protein
kinase
1.11.2 EBV infection of B lymphocytes
EBV infects B cells (rarely T lymphocytes and epithelial cells) both in vitro and in
vivo. Latent infection results in the expression of viral latent genes without virus
production. Viral infection of lymphocytes is mediated by binding of the viral
envelope glycoprotein (gp350/220) to the C3d/CR2 complement receptor (CD21),
which is found on all mature B lymphocytes, peripheral T cells and thymocytes
(Fingeroth et al., 1984). In vitro infection of B cells leads to the activation and
immortalisation of these cells resulting in the generation of continuously
proliferating lymphoblastoid cell lines (LCL) (Pope et al., 1968). The linear genome
enters the nucleus and circularises to form an episome, which amplifies and then
replicates concurrently with, but does not integrate, into, host cell DNA. Between 0.1
to 5% of LCL cells enter the lytic cycle at any one time resulting in infectious virus
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production and cell death.
1.11.3 Models of EBV latency
EBV can establish three different patterns of latency in infected cells - Latency I, II
and III, both in vitro and in vivo, with each pattern being characterised by the
expression of a specific set of latent genes (Rowe et al., 1992; reviewed in Rickinson
and Kieff, 1996; see Table 5).
Table 5
Pattern of EBV latency in EBV-associated malignancies
Latency BARTs EBERs EBNA LMP Cancer type
1 2 3a 3b 3c LP 1 2a/b
I + + + Burkitt's lymphoma
AIDS-associated SNCCL





III + + + + + + + + + +
PTLD
AIDS-associated DLCL
Adapted from Niedobitek et al., 1997.
BARTs, BamHl A rightward transcripts; EBERs, Epstein-Barr encoded RNAs; EBNA, Epstein-Barr
nuclear antigen; LMP, Latent membrane protein; NHL, Non-Hodgkin's lymphoma; DLCL, diffuse
large-cell lymphoma; SNCCL, small non-cleaved cell lymphoma; PTLD, Post-transplant
lymphoproliferative disorder; NPC, Nasopharyngeal carcinoma
1.11.4 EBV infection in vivo
EBV has a world-wide distribution and more than 90% of adults show evidence of
past infection (Henle and Henle, 1966). The virus is transmitted predominantly
through saliva (Yao et al., 1985). In a majority of individuals primary infection
occurs in the first 2 years of life and is usually asymptomatic. However, delayed
primary infection in adolescence often manifests clinically as infectious
mononucleosis (IM) (Diehl et al., 1968; reviewed in Steven, 1996).
Following primary infection, life-long persistence is established, with 5-500 cells in
every 10 million circulating B cells carrying the virus in a latent form (Miyashita et
al., 1995). Low level viral replication in the pharynx and intermittent shedding of
infectious virus into saliva is observed during the carrier-state (Yao et al., 1985).
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1.11.5 Malignancies in immunosuppressed individuals
In immunocompetent individuals, EBV persistence is controlled by both cellular and
humoral mechanisms. An antibody response to EBV antigens (mainly the lytic cycle
antigens) is detectable during primary infection and convalescence, with IgG
antibodies to the viral capsid antigen and EBNA-1 persisting in the serum throughout
life (Henle et al., 1987). Antibodies against gp350/220 are neutralising, and are
present in both the serum and saliva of carriers (Yao et al., 1991). However, it is the
EBV-specific CD8+ cytotoxic T cells (CTLs) that are primarily responsible for
maintaining a stable virus-host balance (Moss et al., 1978). Displacement of this
equilibrium is classically seen in immunodeficient states, which leads to enhanced
virus replication, increase in the number of EBV-carrying B cells, and elevated
serum antibody levels to EBV lytic cycle antigens (Birx et al., 1986; Thomas et al.,
1991).
1.11.5.1 AIDS-related Non-Hodgkin's lymphoma (NHL)
Unlike post-transplant lymphoproliferative disorders (PTLDs), AIDS-associated
lymphomas are not uniformly associated with EBV, questioning whether the virus is
involved in the development and pathogenesis of these lesions, or merely a
passenger.
Among systemic AIDS-NHL, EBV is associated with around 70 to 80% of diffuse
large cell lymphomas (DLCLs), and a similar proportion of Burkitt's-like lymphoma
(BLL). The majority of DLCLs have a latency II or III phenotype and frequently,
though not always, express the transforming antigens LMP-1 and EBNA-2,
suggesting that the virus has a pathogenic role in the genesis of these tumours
(Carbone et al., 1993; Hamilton-Dutoit et al., 1993).
At a frequency similar to sporadic BL, around 30% ofAIDS-BL carry EBV and have
a latency I phenotype (Ballerini et al., 1993). Virus in BL is generally monoclonal,
consistent with the hypothesis that the virus was present before clonal expansion, and
might therefore contribute to lymphoma development (Neri et al., 1991).
Furthermore, positive identification of EBV DNA in the lymph nodes of HIV-
infected individuals is considered to be a predisposing factor for subsequent
development of lymphomas (Shibata et al., 1991). However, EBV-positive AIDS-BL
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fail to express EBNA-2 and LMP-1, which are key inducers of the transformed
phenotype in other B cell tumour models (Carbone et al., 1993). Moreover, the
absence of EBV in around 70% of AIDS-BL challenges the contribution of the virus
to the pathogenesis of these lesions.
AIDS-related PCNSL are consistently associated with EBV (MacMahon et al., 1991)
and display a latency III EBV phenotype, similar to that of systemic immunoblastic
NHL. Expression of EBV-LMP-1 is detected in approximately 50% of cases,
suggesting a transforming role for the virus in the pathogenesis of these lymphomas
(Larocca et al., 1998)
1.12 Kaposi's Sarcoma-associated Herpes Virus (KSHV)
Kaposi's sarcoma (KS) was first noted in 1872 by a Hungarian dermatologist, Moriz
Kaposi, as purplish skin lesions (frequently accompanied by lymphoedema) that
appeared on the lower extremities. Much later, these pigmented sarcomas were re-
described in elderly men of Eastern European and Mediterranean descent (classic
KS), African men and children (endemic KS) and organ transplant recipients
(iatrogenic KS). With the onset of the AIDS epidemic a vast increase in KS cases
was noted. Now AIDS-associated KS (AIDS-KS) is the most common neoplasm
observed in AIDS patients (particularly young homosexual men), whose risk of
developing the disease is 20,000 fold above that of the general population (Beral,
1991; Antman and Chang, 2000). In 1994, Chang and colleagues identified a
previously unrecognised herpesvirus in the skin lesions of an individual with AIDS-
KS, which came to be known as Kaposi's sarcoma-associated herpesvirus (KSHV) or
human herpesvirus-8 (HHV-8) (Chang et al., 1994).
1.12.1 Genome structure
KSHV is a y-herpes virus, which is more similar to the simian herpesvirus saimiri
(HVS) than it is to EBV. It consists of a double-stranded 165 to 172kb genome with
a long unique region (LUR, ~140kb) flanked by terminal repeats. The LUR
comprises the entire coding region for the virus and encodes over 80 genes. Genes
that are conserved among all herpesvirus subfamilies are present along the length of
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the genome and include those that code for structural proteins and DNA synthetic
enzymes. Interspersed between these conserved gene blocks are regions unique to
KSHV (open reading frames (ORFs) Kl-15) and other rhadinoviruses, some of
which can mimic cell cycle regulatory genes, cytokines and signal transduction
proteins (Russo et al., 1996, reviewed in Moore and Chang, 1998).
1.12.2 Gene expression and function
Taking into account tissue-specific differences in transcription patterns, KSHV gene
expression has been broadly classified into 3 classes based on their ability to be
stimulated by 12-(9-tetradecanoylphorbol-13-acetate (TPA) or sodium butyrate in
body cavity cell lines (BC-1) in vitro (Sarid et al., 1998, and see Table 6).
Table 6
KSHV gene expression
Class* Inducible by TPA Selected genes
I - v-cyclin (v-cyc), v-FLIP, LNA
II + v-IL6, v-GPCR, v-Bcl2
III ++ K12 (kaposin)
*, Pattern of gene transcription examined in a body cavity lymphoma cell line (BC-1). -, Constitutive
and not induced by TPA (latent mRNAs); +, constitutive and inducible by TPA; ++, only inducible by
TPA (late lytic genes). Only selective Class I, II and III transcripts have been shown due to space
constraints (for a detailed list refer Sarid et al., 1998). LNA, latency associated nuclear antigen; FLIP,
FLICE inhibitory protein; GPCR, G-protein coupled receptor; IL6, Interleukin-6
1.12.3 In vitro infection of B cells
KSHV can persistently infect primary peripheral blood B cells in vitro in the
presence of EBV, and such infection leads to the outgrowth of continuously growing
KSHV /EBV+ LCLs. KSHV latent viral transcripts were expressed in non-stimulated
KSHV+/EBV+ LCLs, and induction with phorbol ester and «-butyrate resulted in
lytic expression (Kliche et al., 1998).
1.12.4 Latent infection
Similar to other herpesviruses, KSHV persists as a covalently closed circular
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episome in latently infected cells with limited viral gene expression. Two latency-
associated Class I transcripts are encoded at the right hand end of the genome. A
5.32kb transcript (latent transcript 1) encodes ORF73 (LNA), ORF72 (vCYC) and
ORF71 (vFLIP), while splicing of the 5.32kb transcript yields a 1.7kb transcript
(latent transcript 2) that encodes only ORF72 and ORF71 (Talbot et al., 1999; see
figure 15). ORF73 encodes an immunoreactive latent nuclear antigen (LNA),
analogous to the EBNA1 protein of EBV, and is constitutively expressed in cells
latently infected with KSHV (Kellam et al., 1997). This protein has been shown to be
necessary and sufficient for viral episome maintenance, persistence and segregation
during mitosis, by tethering the KSHV genome to the chromosome (Ballestas et al.,
1999). Recent evidence demonstrates that LNA can interact with p53 and inhibit
transcriptional activation and apoptosis mediated by p53 (Friborg et al., 1999). In
addition, the virus can interact with the pRb tumour suppressor both in vitro and in
vivo and transactivate E2F regulatory sequences (Radkov et al., 2000).
1.12.5 KSHV transmission and seroprevalence
KSHV can be transmitted sexually, and is thought to be more readily transmissible
through homosexual than heterosexual practices (Martin et al., 1998). In areas where
KS is endemic vertical transmission accounts for a portion of childhood cases,
although the precise mode of transmission in late childhood and adolescence is still
unknown (Bourboulia et al., 1998). Viral DNA can be detected in the saliva, oral
tissues, semen, peripheral blood and lymphoid tissue of seropositive people as well
as in the gastrointestinal (GI) mucosa of HIV-infected individuals, suggesting other
routes of transmission (Koelle et al., 1997; Thomas et al., 1996).
Unlike EBV, KSHV is not ubiquitous (Gao et al., 1996a). The seroprevalence of
KSHV in the general population, is highest in Africa (50%) where KS is endemic,
whereas it is between 5 and 10% in the United States and 0.2% in Japan where KS is
rare (Lennette et al., 1996). In the American HIV-infected population, the incidence
is 30% in homosexual men and 3 to 4% in women and haemophiliacs.
1.12.6 KSHV-associated diseases in HIV infection
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peripheral blood B cells (Whitby et al., 1995). However, the virus also has a
predilection for spindle cells of endothelial origin (Boshoff et al., 1995), as seen in
KS, and primary human keratinocytes in culture (Cerimele et al., 2001). KSHV has
been etiologically linked to diseases with prominent vasculature such as KS and
multicentric Castleman's disease, as well as a rare B cell lymphoma, primary effusion
lymphoma, in both individuals who have a preserved immune function and those
with AIDS (reviewed in Cannon and Cesarman, 2000 and see below).
(i) AIDS-associated KS (AIDS-KS)
A causal relationship between KSHV and KS has been established by studies that
have demonstrated evidence of infection prior to the development of KS, as well as
the presence of KSHV sequences in all forms of KS (Dupin et al., 1995).
Seroconversion to KSHV is a prognostic indicator ofKS development (Whitby et al.,
1995; Gao et al., 1996b).
KS lesions are histologically complex containing proliferating spindle cells of
endothelial origin, but which often express markers characteristic of endothelial,
macrophage and smooth muscle cells. Infiltrating plasma and mononuclear cells as
well as abundant slit-like neovascular spaces are present in these lesions. AIDS-KS is
particularly aggressive and frequently fatal, due to disseminated infection involving
the lung, GI tract, liver and spleen (Friedman-Kien and Saltzman, 1990). The highly
aggressive phenotype of AIDS-KS is believed to be induced by extracellular HIV-
Tat, which synergises with, and mobilises sequestered basic fibroblast growth factor
(bFGF), increasing endothelial cell growth and invasion in response to bFGF, by
mimicking extracellular matrix proteins (Barillari et al., 1999; Ensoli et al., 1994).
Most infected cells in a KS lesion are latently infected with lytic expression being
limited to only 0.5 to 1% of cells. Productive infection occurs in the peripheral blood
B cells of individuals with KS (Decker et al., 1996).
(ii) Primary effusion lymphoma (PEL)
KSHV-associated lymphomas represent a distinct diagnostic entity, called body
cavity-based lymphoma or PEL (Nador et al., 1996). This malignancy accounts for 3
to 5% of AIDS-related NHL and has unique morphological and genetic
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characteristics that distinguish it from other AIDS-NHL (Carbone et al., 1996a).
Clinically, PEL is an aggressive lymphoma that presents as lymphomatous effusions
in the pleural, peritoneal and/or pericardial cavity without a contiguous tumour mass.
However, 15% of KSHV-associated lymphomas present as solid extranodal tumours,
with half of these developing a subsequent lymphomatous effusion. These
lymphomas are B cell in origin and histologically comprise a mixture of anaplastic
and immunoblast-like cells. Co-infection with EBV occurs in 90% of PELs (Fassone
et al., 2000); (Nador et al., 1996). Apart from 5' non-coding mutations in bcl-6 in
20% of cases (Gaidano et al., 1997d), these lesions lack molecular defects commonly
associated with B cell neoplasia, such as rearrangement of c-myc, activation of bcl-2,
and mutations in p53 and ras (Nador et al., 1996; Carbone et al., 1996a; Cesarman
and Knowles, 1999).
(iii) Multicentric Castleman's disease (MCD)
MCD is an atypical lymphoproliferative disorder, which is characterised by a
vascular proliferation in the germinal centres, and clinical presentation of multiple
lymphadenopathies, autoimmune phenomena, skin rashes and intercurrent infection.
Patients with MCD frequently develop other malignancies, most commonly KS and
NHL (Soulier et al., 1995). KSHV is consistently detected in MCD associated with
AIDS, although it has also been identified in 40% of MCD cases in HIV-negative
individuals (Soulier et al., 1995). MCD in HIV positive patients frequently occurs in
conjunction with KS (75%), although the virus is also present independent of KS in
these individuals (Oksenhendler et al., 1996). Elevated serum levels of IL-6 are
thought to contribute to the characteristic polyclonal plasmacytosis and
hypergammaglobulinemia observed. Notably, vIL6 of KSHV is expressed in a few
B cells surrounding the lymphoid follicles, suggesting a paracrine mechanism to
drive proliferation and differentiation of B cells in KSHV-associated MCD
(Parravicini et al., 2000; Staskus et al., 1999).
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1.13 Molecular features ofAIDS-NHL
1.13.1 AIDS-SNCCL
AIDS-BL typically harbour translocations between the c-myc oncogene on
chromosome 8 and one of the Ig gene loci on chromosomes 14,22 or 2 (Ballerini et
al., 1993; Subar et al., 1988; Gaidano et al., 1997b). Furthermore, the translocated c-
myc alleles are frequently affected by mutations in exon 2, which alter the amino-
acid sequence of the c-Myc protein (Bhatia et al., 1994).
Inactivating mutations of the p53 tumour suppressor gene were reported in 37% of
AIDS-NHL, although the majority (60%) of these occur in the AIDS-BL sub-type
(Ballerini et al., 1993). This figure is twice as high as that observed in NHL of the
immunocompetent host (Gaidano and Dalla-Favera, 1993). In contrast to sporadic
and endemic BL, AIDS-BLs are consistently devoid of molecular lesions in bax
(Gaidano et al., 2000), a proapoptotic gene that is transcriptionally activated by p53
(Miyashita and Reed, 1995).
The molecular pathogenesis of AIDS-BLL is different from that of AIDS-BL, in that
p53 mutation is rare and c-myc translocations less frequent in the former than the
latter (20-60% versus 100%) (Davi et al., 1998; see Table 7). However, similar to
AIDS-BL, approximately 70% of AIDS-BLL harbour bcl-6 mutations (Gaidano et
al., 1997b). Furthermore, although rearrangements of bcl-2 have been detected in a
fraction of BLL in the immunocompetent host (Yano et al., 1992), such
abnormalities have not been detected across the spectrum ofAIDS-NHL in the small
number of studies that have been carried out (Gaidano et al., 1997b).
1.13.2 AIDS-DLCL
Mutations and rearrangements of c-myc are observed less frequently (20-50%) in
AIDS-DLCL than in AIDS-SNCCL (Ballerini et al., 1993; Gaidano et al., 1997b;
Delecluse et al., 1993a; see Table 7). However molecular alterations affecting bcl-6
are associated with a significant fraction of these tumours (Strasser et al., 1994).
Rearrangements of bcl-6 are detected in 20% of AIDS-DLCL and in 40% of DLCLs
in the immunocompetent host (Gaidano et al., 1994, 1997c). Mutations in the 5'
regulatory region of the gene occurs in 70% of these tumours, similar to that
63
observed in the immunocompetent host (Capello et al., 2000; Gaidano et al., 1997d).
Mutations in p53 are rarely observed among this subset of tumours (Ballerini et al.,
1993; see Table 7).
Table 7











LNCCL rare 20-50% 20% 70% - 40%
IBL rare 20% - 70% - >90%
SNCCL
BL 60% 100% - 60% - 30%
BLL - 20-60% - 70% - 30%
PCNSL nd - - 70% + 100%
nd, not done; +, positive expression; absence of genetic lesion/expression; DLCL, diffuse large-cell
lymphoma; LNCCL, large non-cleaved cell lymphoma; IBL, immunoblastic lymphoma; SNCCL,
small non-cleaved cell lymphoma; BL, Burkitt's lymphoma; BLL, Burkitt-like lymphoma; PCNSL,
primary central nervous system lymphoma; EBV, Epstein-Barr virus
1.13.3 AIDS-PCNSL
Although the Bcl-6 protein is expressed by all PCNSLs in the immunocompetent
host, AIDS-PCNSL are classified as Bcl-6-expressing or non-expressing cases
(Carbone et al., 1998). The IBL variants are characterised by an absence of Bcl-6
expression and rearrangement, and almost consistent expression of Bcl-2 and EBV
LMP-1 (Kenney et al., 1998; Carbone et al., 1997). Conversely, the LNCCL variants
express Bcl-6 and include rearranged and non-rearranged bcl-6. These tumours fail
to express Bcl-2 and LMP-1, when infected with EBV (Larocca et al., 1998).
Mutations in bcl-6 are relatively frequent among AIDS-PCNSLs, similar to that
observed in the other subsets ofAIDS-NHL (Larocca et al., 1998; see Table 7).
1.13.4 Other genetic lesions associated with AIDS lymphomas
Besides the genetic alterations involving the c-myc, p53 and bcl-6 genes, structural
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changes in other genes have been reported, albeit less frequently. Mutations in the
ras oncogene occur predominantly in the AIDS-SNCCL subtype (approximately
15% of cases analysed) (Ballerini et al., 1993) despite being absent in NHL of the
immunocompetent host (Neri et al., 1988). Furthermore, extensive structural analysis
of the functional domains of the retinoblastoma gene (RB) locus in AIDS-NHL has
indicated an absence of alterations (Ballerini et al., 1993).
Deletions of the long arm of chromosome 6 (Vitolo et al., 1998), a frequent genetic
alteration of B-NHL in the immunocompetent host, has been reported in a fraction of
AIDS-DLCL (around 20%), whereas it is consistently absent among other types of
AIDS-NHL (Pastore et al., 1996). In addition, AIDS-BL particularly those that are
EBV-positive, demonstrate recurrent 1 q21 -25 chromosome abnormalities, suggesting
that this genomic site harbours an unknown gene with relevance to AIDS-related
lymphomagenesis (Polito et al., 1995).
AIMS OF THE PROJECT
The aim of this project was to define the molecular genetic and virological
characteristics of persistent generalised lymphadenopathy (PGL) in HIV-infected
individuals, in an attempt to identify early lesions that might be predictive of future
lymphoma development in these individuals. This was achieved by genetic
(structural), epigenetic and/or expression analysis of selected tumour suppressor
genes (p53, p63, p73 and INK4 genes), oncogenes (c-myc, bcl-2 and bcl-6) and






All cell culture reagents were supplied by Life Technologies unless otherwise stated.
General reagents, unless specified, were supplied by Merck Ltd. Radiolabeled
isotopes were supplied by ICN Biomedicals Ltd. and Amersham Pharmacia Biotec.
Unless otherwise stated, Roche Diagnostics and Biochemicals Ltd. supplied
restriction endonucleases and buffers. All oligonucleotides were synthesised by Life
Technologies. Commercial suppliers are listed in appendix 3.
Reagent Supplier
1Kb DNA ladder Life Technologies
1 OObp DNA ladder Life Technologies
X DNA restricted with Hind III Roche
Agarose ICN
Ammonium persulphate Bio-rad Laboratories
Ampicillin Sigma






DNA Polymerization Mix Amersham Pharmacia
Ethidium bromide Life Technologies
FCS Harlan Sera Lab
Ficoll™ 400 Amersham Pharmacia
Formamide Life Technologies




LA Taq polymerase BioWhittaker
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Mineral oil Sigma
NICK™ column Amersham Pharmacia
NuSieve® 3:1 agarose Flowgen
PBS tablets Oxoid






Sheared salmon sperm DNA CP Labs
Sequagel® MD National Diagnostics Ltd






X Ray Developer and Fixer Jet X-Ray
2.2 Equipment
Benchtop centrifugation was carried out using a Mistral 3000E MSE (Sanyo).
Thermal cycling was carried out using the Hybaid Touchdown, Hybaid Omnigene
(Hybaid) and the Robocycler Gradient 96 (Stratagene). Hybridisations were done in
Shake N' Stack cabinets (Hybaid). General plastic-ware was supplied by SLS and
Anachem. Tissue culture plastic-ware was supplied by Fred Baker, SLS and Life
Technologies, unless specified otherwise.
2.3 General Solutions
All solutions were prepared in sterile distilled water (SDW)
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Freezing Medium
90% v/v Fetal calf serum, 10% v/v DMSO
Culture Medium
2mM L-glutamine, 100 IU/ml Penicillin, 100 pg/ml Streptomycin, 5 or 10% v/v
FCS, made up in lxRPMI 1640
Phosphate buffered saline (PBS)
1 PBS tablet dissolved in 100ml of dH20
TaqStart Antibody [1.1 pg/pl]
(in lOmM Tris-HCl pH7.0, 50mM KC1, 50% glycerol)
lOxTris-Borate-EDTA (TBE) Buffer
10.8% v/v Tris, 5.5% w/v Boric acid, 4% v/v 0.5M EDTA (pH 8.0)
20xStandard Saline Citrate (SSC)
3M sodium chloride, 0.3M trisodium citrate (pH 7.0)
Tris-EDTA (TE)
lOmM Tris-HCl (pH 8.0), ImM EDTA pH 8.0
Denaturing Solution
1.5 mM NaCl, 0.5M NaOH
Neutralising Solution
1.5mM NaCl, 0.5M Tris-HCl (pH 7.2), 0.001M EDTA (pH 8.0)
10% w/v Sodium Dodecyl Suphate (SDS)
made up in dH20
lOxDNA Loading Buffer
lOOmM EDTA (pH 8.0), 6% w/v Sucrose, 0.1% v/v BPB, 0.1% Xylene cyanol
Stop solution
95% formamide, 20mM EDTA, 0.05% w/v BPB, 0.05% w/v Xylene cyanol
Formamide
Deionised in 10% w/v Mixed-bed resin.
lOOxDenhardt's solution
2% w/v BSA, 2% w/v Ficoll™, 2% w/v PVP
Pre-Hybridisation Solution
50% v/v Formamide, 25% v/v 20xSSC, 10% v/v 50xDenhardt's solution, 5% w/v
SDS, 1% v/v sheared salmon sperm DNA
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Sheared Salmon Sperm DNA
lOmg/mL 1% v/v
Hybridisation solution
Prehybridisation solution with 32P-labelled probe and fresh 1% v/v sheared salmon
sperm DNA
T4 Polynucleotide Kinase [5U/mL] (from a recombinant E. coli bacterium strain)
lOxKinase buffer
700mM Tris-HCl (pH 7.6), lOOmM MgCl2,50mM DTT
Membrane wash solutions
2xSSC/ 0.1% w/v SDS and lxSSC/ 0.1% w/v SDS
Luria-Bertani medium (LB, supplied by Veterinary Pathology Media service)
1% bacto-tryptone, 0.5% Bacto-yeast extract, 1% sodium chloride adjusted to pH 7.2
using 1M sodium hydroxide
LB agar
LB supplemented with 1.5% agar
SOC medium
2% tryptone, 0.5% yeast extract, lOmM sodium chloride, 2.5mM potassium chloride,
lOmM magnesium chloride, lOmM magnesium sulphate and 20mM glucose
2.3.1 DNA Size Markers
0.5pg of the DNA markers were used on each gel.
lOObp DNA ladder [50pg/ml]
(in lOmM Tris-HCl pH7.5, ImM EDTA)
lkb DNA ladder [200pg/ml]
(in lOmM Tris-HCl, pH7.5, 50mM NaCl, 0. ImM EDTA)
<(>X174 DNA////«f I dephosphorylated markers [50pg/ml]
(in lOmM Tris-HCl, pH7.5, ImM EDTA)
A.DNA restricted with Hind III [250pg/ml]
(in 10mm Tris-HCL, ImM EDTA pH8.0)
2.3.2 Bacterial Strains







Invitrogen, Holland (Bernard et al., 1994)
Invitrogen, Holland (Shuman, 1994)
2.4 Cell culture techniques
All cell culture techniques were carried out in an aseptic manner inside
microbiological (class II) safety cabinets using sterile equipment and solutions.
2.4.1 Control Cell Lines
A store of control cell lines was kept under liquid nitrogen, and is shown in Table 8.
Table 8
Control Cell Lines
Cell line Cell type EBV/KSHV status Reference
BCP-1 Body cavity lymphoma -/+ Boshoff et al., 1998
BJAB BL -/- Menezes et al., 1975
Namalwa BL +/- Klein and Dombos, 1973
P3HR1 BL +/- Hinuma et al., 1967
Raji BL +/- Pulvertaft, 1965
Ramos BL -/- Klein et al., 1975
BL, Burkitt's lymphoma
2.4.2 Thawing cells
Cells were recovered from liquid nitrogen by thawing in a 37°C water bath for a few
minutes and then slowly adding 9 times the volume of wash medium (HBSS). The
cells were then spun down at 400g (g-number = 11.2 x r x n2 x 10"6, where r is the
centrifugal radius in cm from axis to middle of tube and n is the speed in rpm) for 7
minutes in a bench centrifuge. This was followed by re-suspension of the cell pellet
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in 5ml of tissue culture medium in a 25cm2 culture flask, and incubation at 37°C.
2.4.3 Culturing cells
All cells were cultured in a humidified 5% CO2 incubator (Heraeus) at 37°C and fed
every 2-3 days, as required, with tissue culture medium.
2.4.4 Counting cells
lOpl of cell suspension was mixed with lOpl of 0.5% w/v trypan blue in PBS. lOpl
of the mixture was placed on a haemocytometer (Weber Improved Neubauer,
Merck). Cells were counted using a light microscope (Leitz). The cells that excluded
the dye (viable cells) were counted.
2.4.5 Freezing cells
Around 107 cells were spun at 400g for 7 minutes in a bench centrifuge, followed by
two washes with wash medium at 400g for 7 minutes. The cells were then re-
suspended in 1 ml of freezing medium in a cryotube (Nunc, Life Technologies)
which was placed at -70°C. 24 hours later the cells were transferred to a liquid
nitrogen tank (Jencons).
2.5 Processing and storing of tissue
2.5.1 Processing of lymph nodes
Hyperplastic lymph node tissue, biopsied from 23 HIV-infected individuals with
lymphadenopathy, was kindly provided by Prof. Ian Weller, UCL, London. 9
reactive control lymph nodes frozen in OCT (Optimum Tissue Cutting medium)
compound were kindly provided by Dr. Andrew Krajewsky, Department of
Pathology, Edinburgh University.
Tissue was recovered from liquid nitrogen and thawed briefly on ice. The tissue was
placed on a petri dish and cut into smaller pieces with a sterile scalpel. The cut tissue
was placed in clean eppendorfs, snap-frozen in isopentane and stored at -70°C or
liquid nitrogen.
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2.5.2 Processing of tonsillar tissue
7 fresh tonsils obtained from routine tonsillectomies performed at the City Hospital,
Edinburgh, were collected in 10ml of saline. The specimen was placed on a petri dish
and lymphoid tissue was dissected from the surrounding fibrous connective tissue.
The tissue was then cut and stored as described in section 2.5.1.
2.6 DNA Extraction and Methods
2.6.1 Extraction of DNA from tissue
(i) Extraction of DNA using the Invitrogen Easy DNA Kit (Invitrogen)
DNA was extracted from snap-frozen PBMCs using the Invitrogen Easy-DNA kit
T 7
according to the manufacturer's instructions (Invitrogen). Briefly 10-10 cells were
thawed on ice and resuspended in 200pl of PBS (2.3). Tissue kept frozen at -70°C
was thawed on ice, homogenised using sterile homogenisers (SLS), and resuspended
in 200pl of PBS. 350pl of solution A (lysis solution) was added, the solution
vortexed and incubated at 65°C for 10 minutes. 150pl of solution B (precipitation
solution) was added and the solution vortexed vigorously, followed by the addition
of 500pl of chloroform. The phases were separated by spinning the solution at
lOOOOg for 20 minutes in a microfuge. The upper aqueous layer was carefully
transferred to a clean eppendorf. 1ml of 100% ethanol was added to the solution and
left at -20°C overnight, to precipitate the DNA. The DNA was pelleted by
centrifugation, washed with 70% ethanol, air-dried and re-suspended in 30-50pl of
sterile distilled water. Ribonuclease (RNase) was then added to a final concentration
of40pg/ml and incubated at 37°C, to remove contaminating RNA.
(ii) Extraction ofDNA by the microfuge method
This method was used for the extraction of genomic DNA using autoclaved 1.5ml
centrifuge tubes. 106 to 5xl06 cells were washed twice in cold PBS, and transferred
to a microfuge tube in 1ml of PBS. The cells were then spun at 2000g for 1 minute
and re-suspended in 500pl ofDNA lysis buffer (lOmM Tris pH 8.0, ImM EDTA pH
8.0, 5mM NaCl and 0.5% SDS w/v). lOOpg/ml of Proteinase K was added and the
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lysate incubated at 37°C overnight. The aqueous layer of DNA was extracted with
the addition of 500gtl of TE-equilibrated phenol (pH 7.5) to remove proteins. The
solutions were mixed, and then separated by spinning at lOOOOg for 10 minutes in the
microfuge. The aqueous layer was carefully transferred to a fresh tube and further
extractions were performed by adding an equal volume of phenol chloroform (1:1),
using the same procedure until the interface of the organic and aqueous phase was
clear. To ensure the complete removal of phenol (which would co-precipitate with
DNA), a final extraction was performed with chloroform alone.
For ethanol precipitation of the DNA 0.1 volumes of 3M sodium acetate and 2.5
volumes of ice-cold absolute ethanol were added to the DNA solution, mixed well,
and left at -20°C overnight or at -70°C for 1 hour. The DNA was pelleted by
centrifugation for 10 minutes at room temperature in a microfuge. The precipitate
was washed in 70% ethanol, dried and re-suspended in 50-100p.l of sterile distilled
water (SDW).
2.6.2 Extraction and purification of DNA from agarose gels
The QIAquick Gel Extraction Kit commercially available from Qiagen™ was used
to extract DNA from agarose gels. The solutions and protocol were supplied with
the kit.
The DNA fragment of interest was excised from the gel with a clean scalpel and
weighed in a microfuge tube. Binding buffer QG was added to the gel in the ratio of
3:1 and incubated at 50°C for 10 minutes until the gel slice was completely
dissolved. 1 gel volume of isopropanol was added to the solution and mixed. The
solution was applied to a Qiaquick column and centrifuged for 1 minute at lOOOOg.
The flow through was discarded and 500pl of binding buffer QG was added to the
column and centrifuged for a further minute. The flow through was discarded and
750pl ofwash buffer PE containing ethanol was added to the column and centrifuged
at lOOOOg for one minute. The column was spun for an additional minute at lOOOOg
to remove any residual ethanol. 30jul of buffer EB (lOmM Tris-EICl, pEl 8.5) was
added to the centre of the column, allowed to stand for one minute and then
centrifuged at lOOOOg for a further minute to elute the DNA.
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2.6.3 Measurement of DNA/RNA concentration
The amount of DNA or RNA present in the sample is directly proportional to the
amount of UV radiation absorbed by the sample. The concentration of nucleic acid
was determined by spectrophotometry (GeneQuant II, Amersham Pharmacia Biotec).
Absorbance was measured at wavelengths of 260 and 280nm.
DNA concentration = Absorption at 260nm (A260) x 50 x dilution factor
RNA concentration = Absorption at 260nm (A260) x 40 x dilution factor
where an A260 of 1.0 is equivalent to 50mg/ml of DNA and 40mg/ml of RNA. The
purity ofDNA was calculated as a ratio of OD260/OD280.
A value greater than 1.8 for DNA and 1.9 for RNA indicates that the sample is free
of protein contamination.
2.7 RNA extraction and methods
Precautions were taken to preserve the integrity of RNA throughout the following
procedures. Particular emphasis was placed on avoiding contamination with RNases.
Sterile disposable plastic-ware was used, and all glassware was autoclaved prior to
use. Gloves were changed frequently. Ultrapure (molecular biology grade) distilled
water was used to prepare solutions, all of which were autoclaved prior to use.
2.7.1 Isolation of RNA by the RNAzol method
Total RNA was isolated using RNAzol™B, which is commercially available from
Biogenesis Ltd., based on the acidic guanidinium-phenol-chloroform method
described by Chomczynski and Sacchi (1987).
(i) Homogenisation
Tissue, which was kept frozen at -70°C, was placed on ice and 0.8-lml ofRNAzol B
was added depending on the amount of tissue present. The tissue was homogenised
using sterile homogenisers. RNA was extracted by the addition of 80-lOOpil of
chloroform. The samples were shaken vigorously, left on ice for 5 minutes to allow
the phases to separate, and then centrifuged at lOOOOg for 15 minutes at 4°C.
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(ii) RNA precipitation
The aqueous phase was carefully transferred to a clean Eppendorf tube and an equal
volume of isopropanol was added. The solutions were mixed well and allowed to
precipitate at -20°C overnight. The RNA was pelleted by centrifugation as above.
(iii) RNA wash
The supernatant was removed and the pellet was washed once with 500pl of 75%
ethanol, followed by centrifugation for 8 minutes (7500g, 4°C). At the end of the
centrifugation the ethanol was removed carefully and briefly spun to remove any
residual ethanol. The precipitated RNA was re-suspended in 30-50pl of
RNase/DNase free water and the concentration of RNA was measured by UV
spectrophotometry (see section 2.6.3).
2.7.2 First strand cDNA synthesis using Reverse Transcriptase (RT)
cDNA was synthesised using the Pro-Star First Strand RT-PCR Kit (Stratagene)
according to the manufacturer's instructions. RNA was reverse transcribed using
random primers and RT to give a heterogeneous population of cDNA templates,
which were subsequently used as the starting template for RT-PCR. Briefly lpg of
RNA was dissolved in DEPC-treated water to give a final volume of 38pl. 3pi of
random hexamer oligonucleotides was added to the RNA and incubated at 65°C for 5
minutes, followed by cooling at room temperature to allow annealing of the primers.
The following reagents were then added to the reaction in the stated order:
1 Ox 1 st strand buffer 5pi
RNase block ribonuclease inhibitor (40U/pl) lpl
lOOmMdNTPs 2pl
Mouse Moloney LV reverse transcriptase (MMLV-RT) (50U/pl) lpl
The reactions were gently mixed and incubated for 1 hour in a 37°C water bath. The
cDNA was heated for 5 minutes at 90°C prior to its use in PCR reactions.
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2.8 Polymerase chain reaction (PCR)
2.8.1 Safe PCR Practice
Care was taken throughout the preparation of PCR reactions to avoid contamination
of samples with amplified products, or unwanted DNA. Amplifications were carried
out in a room designated for PCR work only. Gloves were worn and changed
regularly, and sterile tubes and aerosol resistant tips were used throughout the
procedure. All PCR reagents were aliquotted and stored in smaller volumes.
2.8.2 Genomic PCR
PCR was carried out essentially as described by (Saiki et al., 1985, 1988).
2.8.2.1 Primers for the detection of viral DNA and human P-globin
The EBV W-repeat PCR detects the BamHl W repeat sequence of the EBV genome.
The KSHV PCR detects a 376bp fragment of open reading frame 73 (ORF-73),
which encodes the latent nuclear antigen (LNA). PCR for detecting the human P-
globin gene was carried out on all samples to check for amplifiable DNA. The
sequences of the oligonucleotides are shown in Table 9.
2.8.2.2 Reaction mixture
Amplification was carried out in a final volume of lOOpl for the P-globin and Bam
HI W PCRs and 50pl for the KSHV LNA PCR, using 500ng of genomic DNA as
template. For every run, appropriate positive and negative controls were included.
Sterile distilled water was always included as a control for DNA contamination.
Each reaction mixture consisted of 50mM KC1, lOmM Tris-HCl (pH 9.0), 0.1%
Triton X-100, 1.5mM MgCh, lpM each primer (0.4pM for the LNA PCR), 200|uM
each dNTP and 2.5 units of Taq (Thermus aquaticus strain YT1) DNA polymerase.
2.8.2.3 Amplification
The DNA template was initially denatured at 94°C for 5 minutes. The reaction
mixture was overlaid with two drops of mineral oil, and cycled using the conditions
shown in Table 10 (see Table 26, page 114 for optimised conditions).
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Table 9
Primers and probes for the amplification of EBV, KSHV and human P-globin











CTT TAG AGG CGA ATG GGC GC
AGG ACC ACT TTA TAC CAG GG











TGA GTG TGG AGG TGT AGT CTG
GCC GAC TCC ATC GAC GGC CG









ACA CAA CTG TGT TCA CTA GC
CAA CTT CAT CCA CGT TCA CC







'Genbank accession numbers are as follows: EBV BamHl W (V01555), KSHV LNA (U75698) and
P-globin (V00499)
Table 10
PCR Amplification Programs for the EBV, KSHV and P-globin PCR
Gene Denaturation Annealing Extension Final Extension Number
Temp. Time Temp. Time Temp. Time Temp. Time of
(°C) (sees) (°C) (sees) (°C) (sees) (°C) (mins) Cycles
EBV
BamHl
94 60 57 120 72 120 28
KSHV
LNA






94 60 49 120 72 120 28
Temp. , Temperature
2.8.3 Semi-quantitative analysis of EBV load
A ten-fold dilution series from 1-106 cells of the Burkitt's lymphoma cell line
Namalwa (which contains 1-2 copies of the EBV genome per cell) in a background
of 106 cells from an EBV negative cell line BJAB was carried out. BamHl W PCR
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was performed on DNA at each dilution. The dilution series was run alongside each
set of patient samples, and the band intensity measured using scanning densitometric
analysis. The density of the test sample was compared with the densities of the
dilution series to obtain a semi-quantitative value of EBV genome copy number in
each of the samples.
2.8.4 KSHV LNA-1 dilution series
To test the sensitivity of the KSHV PCR, a ten-fold dilution series of the body
cavity-based lymphoma cell line BCP-1 (which contains 30-50 copies of the KSHV
gene per cell) was made in a background of KSHV negative cell line BJAB. The
dilution series, which ranged from 105 to 1 BCP-1 cell in a background of 106
negative cells, was run alongside the patient and control samples.
2.8.5 Reverse Transcriptase (RT)-PCR
RT-PCR was carried out essentially as described by Saiki et al., 1985, 1988 and Hart
et al., 1988. cDNA was made from the samples on 2 separate occasions and analysed
twice for the expression of a particular gene, using (3-actin to confirm the presence of
amplifiable cDNA on each occasion. For each RT-PCR a positive control (see Table
12, page 81) and SDW as a cDNA template-free negative control were included.
2.8.5.1 Primer pairs and probes for RT-PCR
The oligonucleotides primer pairs and probes used for RT-PCR were from published
primer sequences and are shown in Table 11. The primer pairs for the pl5INK4b and
the KSHV LNA genes were designed from gene sequences deposited in Genbank
(accession number L36844 and U75698 respectively) (Table 11) as was the probe for
the exon 2 deleted variant of p73 (a2 p73) (accession number AF079082). cDNA
plasmids for the detection of pl61NK4a and pl4ARF transcripts were kindly supplied by
Dr. Gordon Peters (ICRF, Fondon) and Dr. Tim Crook (FICR, Fondon) respectively.
79
Table 11
Primer and probe sequences for RT-PCR











GTG GGG CGC CCC AGG CAC CA
CTC CTT AAT GTC ACG CAC GAT
TTC












ATG TCC CAG AGC ACA CAG
AGC TCA TGG TTG GGG CAC











CAG ACT CAA TTT AGT GAG
AGC TCA TGG TTG GGG CAC
TAT AAC ACA GAC CAC GCG CAG











ACT TTG AGA TCC TGA TGA AG
CAG ATG GTC ATG CGG TAC TG













ACG CAG CGA AAC CGG GGC CCG
GCC GCG CGG CTG CTC ATC TGG
GGA TTC CAG CAT GGA CGT CTT
CC












AGC CTT CGG CTG ACT GGC TGG










TAC TGA GGA GCC AGC GTC TA









GTT TAC GGC CAA CGG TGG
AGC ACC ACC AGC GTG TCC










TGG AGG CAG CTG CGC CAC
CTT GCC AGC TGA GGA ACT AC







The Genbank accession numbers used for the primer and probe sequences are as follows: P-actin
(X00351); TAp63 (NM003722); AN p63 (AF075431); p73 (Y11416); A2 p73 (NM005427); pl6INK4a
(L27211); pl4ARF (S78535); P15,NK4b (L36844) and KSHV ORF 71-73 (U75698); *, full length p73
(344bp), A2 p73 (242bp).
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2.8.5.2 Controls for RT-PCR
Positive control cDNA known to express the transcript under investigation, are
summarised in Table 12. Positive controls for all RT-PCR experiments, except where
mentioned, were kindly provided by Dr. Tim Crook (LICR, London) and Ms. Jenny
O'nions (LICR, London). The H-358 lung cancer cell line was provided by Dr. Scott
Bader (Molecular Medicine Centre, Western General Hospital), and the
lymphoblastoid cell line (LCL) KB, by Dr. Ingo Johannessen (Clinical and
Diagnostic Virology, University of Edinburgh). The LCLs (kindly provided by Ms.
O'nions and Dr. Johannessen) were generated by infection of human primary B cells,
isolated from buffy coat residues, with an EBV-preparation from a B95-8 EBV-
positive marmoset cell line. A template cDNA-free reaction was included in each
RT-PCR run as a negative control, where sterile distilled water, replaced target DNA.
Table 12
Positive controls for RT-PCR
Gene cDNA from Cell line or tumour biopsy
TA p63 Lymphoblastoid cell line (PD-LCL)
AN p63 Squamous cell cancer (SI)
p73 Vulval squamous carcinomas (T1 and T2)
A2 p73 Vulval squamous carcinoma (5T and 11T)
pl6INK4a Lymphoblastoid cell lines (PD-LCL and OTIS)
Breast adenocarcinomas
pl5INK4b BL cell line (BL-41)
pl4ARF Vulval squamous cancer (T1 and T2)
Lung cancer cell line (H358)
KSHV ORF 71-73 Body cavity lymphoma cell line (BCP-1)
BL, Burkitt's lymphoma; LCL, Lymphoblastoid cell line
2.8.5.3 Reaction mixture
cDNA synthesised from 40-100ng of RNA from each sample was used as the
template in each reaction. Amplification of KSHV ORF 71-73, p73, A2 p73, TA p63,
and AN p63 transcripts was carried out in a total volume of 50pl; amplification of
pjgiNK4a^ pi5'NK4b ancj p^ARF transcrjpts was carried out in a volume of 30pl and
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that for p-actin in lOOpl. Each reaction mixture consisted of 50mM KC1, lOmM Tris-
HC1 (pH 9.0), 0.1% Triton X-100, and 0.5-lpM of each primer. Additionally, the
amplification reactions for pl6INlc4a, pl5INK4b and pl4ARF included 10% DMSO. Each
reaction was over-laid with 2 drops of sterile mineral oil to prevent evaporation
during amplification.
The concentrations of MgCh, primer and Taq DNA polymerase that were used for
each individual RT-PCR is summarised in Table 26 (page 114). The reaction
conditions for each primer pair were optimised (Table 26, page 114) using published
conditions as a reference point (Table 25, page 107).
2.8.5.4 Amplification
PCR amplification was carried out in a Hybaid thermal cycler, and a summary of the
PCR programmes is shown in Table 13. Optimisation of PCR reaction conditions for
each primer pair (Table 26, page 114) was carried out using published conditions as a
reference point (Table 25, page 107). For the P-actin and the AN p73 primer pairs,
the annealing and extension temperatures were the same (1-step).
2.8.6 PCR amplification for sequencing using Platinum Pfx DNA Polymerase
To overcome the inherent errors and mis-incorporations of nucleotides by Taq
polymerase (0.2-2xl0~4 errors per bp per cycle) (Smith et al., 1997; Cline et al.,
1996), Platinum Pfx DNA polymerase (Life Technologies) was used for the
amplification of PCR products that were to be subsequently sequenced. Pfx
polymerase is a high fidelity, proofreading enzyme with 3' to 5' exonuclease activity
and is supplied in an inactive form bound to an antibody. The enzyme is rendered
active at 94°C providing an automatic "hot start" for PCR. The high specificity and
accuracy offered by the enzyme makes it very suitable for cloning and sequencing.
The following components were added to an eppendorf on ice, in a total reaction
volume of 50pl; lxPfx amplification buffer, 300pM each dNTP, ImM MgSO^
0.3pM each primer, 300ng of template DNA and 1.25 units ofPfx DNA polymerase.
The template was denatured initially for 2 minutes at 94°C, followed by 30 cycles of
denaturation at 94°C for 30 seconds, annealing at 63-66°C for 45 seconds and




Gene Denaturation Annealing Extension Final Extension Number
Temp. Time Temp. Time Temp. Time Temp. Time of
(°C) (sees) (°C) (sees) (°C) (sees) (°C) (mins) Cycles











- - - - 1
35
TA p63 94 30 52 30 72 60 - - 28
AN p63 94 30 52 30 72 60 - - 28
pl6INK4a 94 180 - - - - - - 1




pJS'NMl, 95 120 - - - - - - 1








94 30 57 30 72 60 - - 35
The annealing and extension steps are performed at the same temperature (1-step)
2.8.7 Long Distance PCR (LD-PCR)
LD-PCR is a recent advancement in PCR technology, which gives efficient
amplification of DNA fragments >10kb (Cheng et al., 1994), by incorporating a
mixture of thermostable and proofreading polymerases, improved buffers and
thermal cycling profiles. The Long and accurate (LA) PCR Kit Ver 2.1
(BioWhittaker) which includes the improved enzyme TaKaRa LA Taq™ was used
effectively for the amplification of targets between 4 and 20 kb.
83
2.8.7.1 Primers for LD-PCR
The primers and probes used for the amplification of the c-myc t(8:14) and bcl-2
t(14:18) translocations were derived from published sequences and are shown in
Table 14.
Due to the head-to-head orientation of the c-myc gene with the IgH locus the sense
primer is located in exon 2 of c-myc (external to exonl/intron). Since the breakpoints
within the IgH locus are located preferentially in the switch regions, the antisense
primers are located in the constant regions of the IgH locus (Ca, Cy and Cp) (figure
12, page 39). The c-myc probe recognises a sequence in exon 2 of the c-myc gene
(Table 14).
The bcl-2 and IgH genes are fused in the same transcriptional orientation. The sense
primers were located in the MBR or mcr regions of bcl-2 and upstream of these
regions (Table 14), whereas the antisense primer was located in the IgH specific
enhancer region (Ep) (figure 13, page 45).
The oligonucleotide probe for the identification of the t( 14:18) translocation (Ep
probe, Table 14) was designed in this study from a published sequence of the IgH
region (Neale and Kitchingman, 1991), and lies just internal to the Ep primer within
the IgH locus.
2.8.7.2 Control cell lines and templates for LD-PCR
The control cell lines and templates that were used to detect translocations involving
the c-myc and bcl-2 genes, by LD-PCR is shown in Table 15, page 86. The P3HR1
cell line obtained from an endemic Burkitt's lymphoma was used as a negative
control for the c-myc LD-PCR. The breakpoint on chromosome 8 is located around
190kb upstream of the c-myc gene, and hence outside the region amplified by the
primers used in this study (Joos et al., 1992). For the bcl-2/IgH LD-PCR analysis,
lymph node biopsy 761 was used as the negative control and lymph nodes 1119 and
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Table 15
Control cell lines and templates for LD-PCR
Cell line/Template Type Translocation Primers
Raji BL cell line c-mycl Sy c-mycl Cy
Ramos BL cell line c-mycl Sp c-myd Cp
BL-41 BL cell line c-myd Sa c-mycl Ca
P3HR1 BL cell line 190kb 5' of c-myc
*
1119a Lymph node biopsy bcl-2 MBR MBR-1 and MBR-2/ Ep
1143a Lymph node biopsy bcl-2 mcr mcr-1 and mcr-2/ Ep
761a Lymph node biopsy None **
BL, Burkitt's lymphoma; Sy and Cy, switch and constant regions y of the IgH locus respectively; Sp
and Cp, switch and constant regions p of the IgH locus respectively; Sa and Ca, switch and constant
regions a of the IgH locus respectively; MBR, major breakpoint region; mcr, minor cluster region; *,
negative control for t(8:14) using primers used in this study; **, negative control for t(14:18); a,
Personal communication from A. Krajewsky
2.8.7.3 Reaction mixture and amplification
Briefly, the reaction mixture was prepared by combining the following reagents to a
total volume of 50pl in thin-walled PCR tubes. lxLA PCR Buffer II with 2.5mM
MgCb, 400pM each dNTP, 0.4pM of each primer, 200ng genomic DNA, and 2.5
units of TaKaRa LA Taq™. The reaction was overlaid with mineral oil and subjected
to the following thermal cycling profile:
1 cycle of denaturation at 94°C for 1 minute
14 cycles of denaturation at 98°C for 20 seconds, primer annealing and DNA
extension at 68°C for 20 minutes
16 cycles of denaturation at 98°C for 20 seconds, annealing and extension at 68°C
for 20 minutes with 15-second increments per cycle (auto-segment extension)
1 cycle of final extension at 72°C for 10 minutes.
2.8.8 "Hot-Start" PCR
An automatic hot-start was employed for PCR, to prevent mis-priming and
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amplification of non-specific products. The TaqStart™ Antibody was used to "hot-
start LD-PCR amplification of t(8:14) and t( 14:18) translocations. This monoclonal
antibody which binds to, and blocks Taq polymerase activity at ambient temperature,
dissociates from the enzyme above 70°C, thus providing an automatic "hot-start".
The antibody is mixed with Taq at a micromolar ratio of 28:1, and incubated for 5
minutes at room temperature before its use in PCR.
"Hot-start" was also employed for the amplification of the a2 p73 transcript using the
enzyme AmpliTaq Gold® polymerase (Roche). The enzyme was heat-inactivated for
12 minutes at 95°C before thermal cycling. This enzyme was also used as a "hot-
start" for the methylation-specific PCR assay (see section 2.19.2).
2.9 Agarose gel electrophoresis
2.9.1 Preparation of agarose gels
The range of efficient separation of linear DNA molecules in agarose gels of
different concentration is shown in Table 16 (Sambrook et al., 1989).
Table 16
Percentage of Agarose for optimal resolution ofDNA
Percentage agarose in the
gel






The appropriate amount of Nusieve® 3:1 agarose (3 parts Nusieve agarose, 1 part
SeaKem® agarose) as determined using Table 16 (page 87) was dissolved in lxTBE
and heated while stirring until the agarose was completely dissolved. 1 pg/ml of EtBr
was added to the gel solution to visualise the DNA. The molten gel was poured into
the appropriate casting tray and allowed to set at room temperature.
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2.9.2 Running agarose gels
The cast gel was submerged in lxTBE. Samples and DNA markers (see section
2.3.1) were mixed with loading buffer in a ratio of 10:1, and loaded into the wells.
Electrophoresis was carried out at 70mA until sufficient resolution of the DNA was
achieved.
2.9.3 Imaging of the gel
The DNA was visualised and photographed using an UV Gel Documentation System
(Ultra Violet Products Ltd., Cambridge, UK).
2.10 Southern transfer of DNA to nylon membranes
DNA was transferred to positively charged nylon membranes (Hybond-N+,
Amersham Pharmacia) by the method of Southern (1975).
After electrophoresis the gels were rinsed with dfBO and washed in denaturing and
neutralising solutions (section 2.3) for 20 minutes each. The prepared gel was placed
on a 'wick' consisting of a sheet of pre-wet Whatman (3MM) paper placed on a plate
over a tray containing 2xSSC (section 2.3), such that the ends of the paper were
immersed in the solution. A piece of nylon membrane, cut to the size of the gel, was
placed on top of the gel carefully to avoid any air-bubbles. The exposed area of the
paper and tray were covered with cling-film to prevent any evaporation. 3 pieces of
3MM paper were placed on top of the membrane, followed by 3-4 inches of
absorbent towels, a glass plate and a 400gram weight. The transfer was allowed to
take place overnight at room temperature. After the transfer the membrane was
washed briefly in 2xSSC, air-dried and UV cross-linked using a Stratalinker
(Stratagene).
2.11 Pre-Hybridisation of Membranes
Nylon membranes were prehybridised in a hybridising oven for at least 3 hours in
pre-hybridisation solution (see section 2.3) at 42°C (end-labelled probes) or 65°C
(random-labelled probes) (see section 2.12).
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2.12 Preparation of radioactive probes
(i) End-labelled oligonucleotide probes
Oligonucleotides were labelled with [y32P] ATP as follows:
1 jliI oligonucleotide (5pmol/pl)
2pl lOxKinase buffer
5pi [y 32P] ATP (50pCi)
lpl T4 polynucleotide kinase (lOU/pl)
dH20 to a total volume of 20pl
The reaction was incubated at 37°C for 30 minutes.
(ii) Random-labelled probes
Random labelled probes were prepared using the Multiprime DNA labelling system
(Amersham Pharmacia), by the method described by (Feinberg and Vogelstein
1983). The protocol and materials were supplied with the kit.
25ng DNA dissolved in dH20 was heated at 95-100°C for 5 minutes and cooled
rapidly on ice. The following were then added:
1 Opl of Buffer (containing dATP, dGTP and dTTP in a solution containing
Tris-Hcl, pH7.8, MgCl2 and 2-mercaptoethanol)
5pi of primer (Random hexanucleotides)
5pi of [a32P] dCTP (1OpCi/pl)
1 pi Klenow enzyme (1 unit/pl in 50mM potassium phosphate, pH6.5, lOmM
2-mercaptoethanol and 50% glycerol)
This reaction was gently mixed and incubated at 37°C for 30 minutes.
Labelled probes were purified by fractionation on Sephadex G-50 NICK™ columns
(Amersham Pharmacia) according to the manufacturer's instructions, to remove
unincorporated label.
2.13 Hybridisation of 32P-labelled probes to DNA
The eluate from the column was collected and added to 25ml of prehybridisation
solution (2.3). For random labelling, probes were denatured at 95°C for 5 minutes
before being added to the prehybridisation solution. lOOpg/ml of denatured salmon
sperm DNA was added to the mix, and incubated for at least 12 hours at
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temperatures appropriate for end-labelled (42°C) or random-labelled (65°C) probes.
2.14 Washing and autoradiography
(i) End-labelled probes
The hybridisation mix was discarded and the non-specifically bound probe was
washed off the nylon membrane by 2 washes in 2xSSC, 0.1% w/v SDS for 30
minutes each.
(ii) Random-labelled probes
25 ml washes at 65°C for 10 minutes each were used. Initial washes were in 2xSSC,
0.1% w/v SDS increasing to a stringency of l-0.5xSSC, 0.1% w/v SDS over a series
of twice repeated washes.
Monitoring the filter with a P-monitor was used to assess the adequacy of the washes
and to determine whether a more stringent wash was required. The filter was then
wrapped in cling-film and exposed to Hyper-MP film (Amersham Pharmacia) in a
cassette with intensifying screens for up to a week at -70°C.
2.15 Stripping a membrane for re-probing
The membrane to be re-probed was placed in a hybridisation tube at 65°C,
containing 100ml of 0.4M sodium hydroxide. After 30 minutes the sodium hydroxide
solution was replaced with 100ml of a neutralising solution (O.lxSSC, 0.1% w/v
SDS, 200mM Tris-HCl, pH 7.5) for two 15-minute incubations at 65°C. The
membrane was exposed overnight to ensure all signals had been stripped.
Alternatively the membrane was stripped by boiling in a 0.5% w/v SDS solution and
then allowed to cool to room temperature for approximately 2 hours.
2.16 Single strand conformation polymorphism (SSCP)
Single strand conformation polymorphism is a technique used to detect sequence
changes in DNA and cDNA. The technique is based on the effect of sequence on the
folding (intramolecular secondary structure) of single-stranded DNA, which affects
its conformation and hence its migration through a non-denaturing polyacrylamide
gel.
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2.16.1 Primers for PCR-SSCP analysis ofp53, INK4 genes and bcl-6
The sequences and genome co-ordinates of the published oligonucleotide primer
pairs used for SSCP-PCR in this study are shown in Tables 17 to 19.
Table 17
SSCP-PCR primers for p53




TCC TCT TGC AGC AGC CAG ACT GC






CAC CCA TCT ACA GTC CCC CTT GC






CTC TTC CTG CAG TAC TCC CCT GC





GAT TGC TCT TAG GTC TGG CCC CTC









GTG TTG TCT CCT AGG TTG GCT CTG
CAA GTG GCT CCT GAC CTG GAG TC
139 13986-14009
14124-14102
ACC TGA TTT CCT TAC TGC CTC TGG C











GCC TCT TTC CTA GCA CTG CCC AAC
CCC AAG ACT TAG TAC CTG AAG GGT G
TGT TGC TGC AGA TCC GTG GGC GT







TGT GAT GTC ATC TCT CCT CCC TGC
GGC TGT CAG TGG GGA ACA AGA AGT
153 18560-18583
18712-18689
Genbank accession number U94788. Primer sequences from Visscher et al., 1996
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Table 18
SSCP-PCR primers for INK4 Locus
Gene Sequence (5'—>3') Size (bp) Coordinates'
INK4a Exon la
5' TCT GCG GAG AGG GGG AGA GCA GGC A 278 28512-28531
3' GCG CTA CCT GAT TCC AAT TC 28790-28767
ARF Exon ip*
5' TAC TGA GGA GCC AGC GTC TA 188
287-306
3' AGC ACC ACC AGC GTG TC 474-458
Exon 2a
5' CCA GGC ATC GCG CAC GTC CA 243 24943-24962
3' ACA AGC TTC CTT TCC GTC ATG CCG 25186-25163
Exon 2b
5' TCT GAC CTT TGG AAG CTC TCA G 241 24764-24785
3' TTC CTG GAC ACG CTG GTG GT 25005-24986
Genbank accession numbers for exon la, exon 2a and exon 2b is AC000048, and S78535 for exon
ip. Primer sequences from (Zhang et al., 1994); *, Exon ip was amplified from cDNA (Gazzeri et al.,
1998)
Table 19
SSCP-PCR primers for bcl-6
Gene Sequence (5'—>3') Size (bp) Coordinates'
El.10
5' CTC TTG CCA AAT GCT TTG 267 1749-1766
3' TAA TTC CCC TCC TTC CTC 2013-1996
El.11
5' AGG AAG GAG GGG AAT TAG 215 1997-2014
3' AAG CAG TTT GCA AGC GAG 2210-2193
El.12
5' TTC TCG CTT GCA AAC TGC 295 2191-2208
3' CAC GAT ACT TCA TCT CAT C 2483-2465
, Genbank accession number Z79581. Primer sequences from Migliazza et al., 1995
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2.16.2 Controls for SSCP-PCR
Appropriate positive and negative controls for each exon/fragment were used and are
described in Table 20. Biopsy material was kindly provided by Mr. Robert Morris,
Western General Hospital, Edinburgh and Dr. Tim Crook, LICR, London.
Nasopharyngeal carcinoma (NPC) cell lines, C17 and CI8, were kindly provided by
Dr. Louise Brooks, LICR, London.
Table 20
Controls for p53, INK4 locus and bcl-6 SSCP-PCR
Gene Exon/Fragment DNA from biopsy1 or cell line2
Positive control Negative control
p53 2/3 - Human genomic DNA3








9 C17 and C18 Human genomic DNA3
10 C17 Human genomic DNA3
11 C17 Human genomic DNA3
INK4 locus Exon la - Human genomic DNA3
Exon ip - Human genomic DNA3
Exon 2 - Human genomic DNA3
bcl-6 El.10 P3HR1 Raji
El.11 Raji Namalwa
El.12 Raji Namalwa
Biopsies with a suffix T indicates tumour tissue and with a suffix N indicates normal tissue; 2, Cell
lines CI7 and C18 are nasopharyngeal carcinoma cell lines and Raji, Namalwa and P3HR1 are
Burkitt's lymphoma cell lines; 3, Human genomic DNA obtained from normal diploid fibroblasts; R,
Arginine; P, Proline (codon 72); BC, breast cancer
2.16.3 Amplification
PCR was initially performed without radioactivity for exons 2-11 ofp53, exons la,
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1(3 and 2 (2a, 2b) of the INK4 locus, and a 735bp region in the first intron of bcl-6 to
assess the efficiency of the PCR conditions, along with (3-globin amplification to
check for amplifiable DNA. Amplification ofp53 and INK4 was carried out in a total
volume of lOOpl, each reaction containing lOmM Tris-HCl, 50mM KC1, 1.5mM
MgCh, 200pM of each dNTP, lpM of each primer, 500ng of DNA and 1.25-2.5
units of Taq polymerase. The reaction mixture for the amplification of the INK4
locus also contained 5% DMSO. Amplification of bcl-6 was carried out in a final
volume of 1 Ojul, with the reaction containing lOmM Tris-HCl, 50mM KC1, 1.5mM
MgCh, 0.2pM of each primer, 10p.M each dNTP, lOOng of DNA and 0.5 units of
Taq polymerase. The template was initially denatured at 94°C for 5 minutes. The
reaction mixture was overlaid with mineral oil, and subjected to the amplification
conditions shown in Table 21. The amplified products were run on a 2% agarose gel
containing EtBr and visualised under UV light (see section 2.9).
Table 21
SSCP-PCR Amplification Programs for p53, INK4 locus and bcl-6
Gene Denaturation Annealing Extension Number
Temp. Time Temp. Time Temp. Time of
(°C) (sees) (°C) (sees) (°C) (sees) Cycles
p53 Exons 2-11 95 30 70 45 72 90 5
95 30 66 45 72 90 30
INK4 Locus
Exons la, 2a, 2b 94 50 62 50 72 50 35
Exon 1(3 95 30 50 30 72 30 30
bcl-6
El.10 94 30 56 15 72 45 35
El.11 94 30 58 15 72 45 35
El.12 94 30 54 15 72 45 35
Temp, Temperature
2.16.4 SSCP-PCR using radioactive 32P and 33P
SSCP-PCR was performed initially for exons 5 and 6 of p53, in a 50pl reaction
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containing lOmM Tris-HCl, 50mM KC1, 1.5mM MgCh, 200pM each dNTP, lpM of
each primer and 1 unit of Taq polymerase. 2pCi of [a32P] dCTP was added to each
reaction and cycled at the conditions shown in Table 21. 32P is a high-energy beta
33
emitter, with a maximum range of 6m in air, whereas P is a low-energy beta
emitter, with a maximum range of only 50cm in air. Because of its lower average
energy (0.08MeV vs. 0.69MeV for 32P), 33P is a considered a safer alternative to 32P.
Therefore, it was decided to use [a33P] dCTP for SSCP-PCR. The reactions and
cycling conditions were carried out exactly as described above, except that lOpCi of
to ■j'y
P was substituted for P in each reaction.
2.16.5 SSCP Gel running
The PCR products were separated on a polyacrylamide gel containing 10% v/v
glycerol, 25% v/v Sequagel® MD and 6% v/v lOxTBE. 0.6xTBE (2.1.6) was used as
the running buffer. 400pl of a 10% ammonium persulfate (APS) solution and 40pl of
TEMED was added to polymerise the gel. The gel was cast between a pair of plates
(380mmx 170mm) separated by 0.3mm spacers.
The samples were heated at 94°C for 5 minutes and immediately placed on ice to
keep the DNA denatured. 3 pi of the PCR product was mixed with 3pi of stop
solution (2.3), loaded into wells created by insertion of a "sharks tooth" comb and
run slowly overnight at 3-4 W.
The gel was allowed to cool for 15 minutes before the plates were separated. The gel
was blotted onto a sheet of Whatman 3MM paper, covered with ding-film and dried
for 2 hours. The gel was then placed in an autoradiograph cassette and exposed to
Hyperfilm AP (Amersham Pharmacia) at -70°C from 3 days up to a week, with
intensifying screens.
2.17 Cloning
Cloning of PCR products was carried out using various commercially available
systems. The pGEM®-T Vector Systems (Promega), and the TOPO TA Cloning® kit
(Invitrogen), utilise the nontemplate-dependent activity of Taq polymerase which
adds a single deoxyadenosine ('A') to the 3' ends of PCR products. The supplied,
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linearised vectors have a single 3' deoxythymidine ('T') residue, which allows the
PCR inserts to ligate efficiently to the vector.
The pGEM®-T vectors contain a multiple cloning region with the a-peptide coding
region of the enzyme (3-galactosidase fused to the lacZ gene. Insertional inactivation
of the a-peptide allows recombinant clones to be directly identified by colour
screening on IPTG-X-Gal plates.
The TOPO TA Cloning® exploits the ligation reaction of topoisomerase I by
providing an "activated" linearised TA vector using proprietary technology (Shuman,
1994). Ligation of the vector with a PCR product containing 3' 'A' overhangs is very
efficient and occurs spontaneously within 5 minutes at Room temperature.
The Zero Blunt'" PCR cloning kit is designed to clone blunt-ended PCR fragments.
Recombinants are directly selected via disruption of a lethal gene. The system is
based on vectors containing the lethal Escherichia coli gene, ccdB (Bernard et al.,
1994). The vector pCR®-BLUNT is supplied linearised and blunt-ended with the
ccdB gene fused to the C-terminus of lacZa. When a PCR product is cloned it
disrupts expression of the lacZa-ccdB fusion gene, permitting growth only of
positive recombinants after transformation.
2.17.1 Ligation reactions
Typically 25-50ng of vector was ligated to the insert at a range of molar ratios, in the
range of 3:1 to 10:1 (insert: vector). Vector and insert DNA were added to
lOxligation buffer (500mM Tris-HCl pH 7.5, lOOmM magnesium chloride, lOOmM
DTT, lOmM ATP) and T4 DNA ligase. Reactions were incubated at 16°C for an
hour or overnight at 4°C.
2.17.1.1 pGEM®-T Vector Systems
Whenever possible, fresh PCR products were used for cloning. However, if old PCR
products were being used, then the PCR product was incubated at 72°C for 15
minutes with 1 unit of Taq DNA polymerase and 200pM dNTP, followed by
inactivation of Taq at 97°C for 10 minutes, for the addition of an 'A' overhang.






(300mM Tris-HCl, pH 7.8, lOOmM MgCl2,
lOOmM DTT, lOmMATP)
50ng/pl pGEM®-T Easy vector 1 .Opl
Sterile water to a total volume of lOpl
T4 DNA ligase (3 Weiss units) 1 .Opl
The ligation reaction was incubated overnight at 4°C.
(i) Transformation
2pl of the ligation reaction was added to 50pl of JM109 High Efficiency competent
cells and incubated on ice for 20 minutes. The cells were heat-shocked for 45
seconds at 42°C and then placed back on ice for a further 2 minutes. 950pl of SOC
medium (section 2.3) was added to the cells and incubated at 37°C for 1.5 hours in a
shaking water bath. 1 OOju.1 of the transformation was spread on a LB agar (section
2.3) plate containing ampicillin (lOOpg/ml), 200pM IPTG and 0.004% X-Gal in
DMF. The plates were incubated at 37°C overnight and then placed at 4°C to allow
colour development. White colonies were tested for the presence of insert (section
2.17.4).
2.17.1.2 TOPO TA® Cloning Kitfor sequencing
5pi TOPO-Cloning reaction was set up as follows:
PCR product 0.5-2pl
Salt solution lpl
Sterile water to a total volume of 5pi
The TOPO-Cloning reaction was incubated for 30-60 minutes at room temperature,
(i) Transformation
2pl of the TOPO-Cloning reaction were added to 50pl of TOP 10 competent cells
and incubated on ice for 30 minutes. The cells were heat-shocked for exactly 30
PCR®4-TOPO® vector lpl
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seconds at 42°C and then placed back on ice for a further 2 minutes. 250pl of SOC
medium was added to the cells and incubated at 37°C for 30 minutes (ampicillin
selection) or 1 hour (kanamycin selection) while being agitated by rotation. 50pl and
lOOpl of the transformation were spread on LB agar plates containing kanamycin or
ampicillin. The plates were incubated at 37°C overnight and colonies were analysed
for the presence of insert (section 2.17.4).
2.17.1.3 The Zero-Blunt™PCR Cloning Kit.
lOpl ligation reaction was set up as follows:
Linearised, pCR®-BLUNT lpl
The ligation reaction was incubated at 16°C for one hour.
(i) Transformation
2pl of the ligation reaction were added to 50pl of TOP 10 competent cells and
incubated on ice for 30 minutes. The cells were heat-shocked for exactly 45 seconds
at 42°C and then placed back on ice for a further 2 minutes. 250pl of pre-warmed
SOC medium was added to the cells and incubated at 37°C for 1 hour in a shaking
water bath. 50-1OOpil of the transformation was spread onto LB plates containing
50pg/ml kanamycin. The plates were incubated at 37°C overnight and colonies tested
for the presence of the insert (section 2.17.4).
2.17.2 Colony screening
Where PCR cloning was inefficient, colonies were screened using this protocol for
(25ng)
Blunt PCR product
1 Ox ligation buffer (with ATP)
(60mM Tris-HCl, pH 7.5, 60mM MgCl2,
50mM NaCl, lmg/ml BSA,
70mM P-mercaptoethanol, ImM ATP,
20mM DTT, lOmM spermidine)




T4 DNA ligase (4U/pl)
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the ease of subsequently selecting positive clones. Using autoclaved toothpicks,
individual colonies were scratched across the surface of a Hybond-N+ membrane
(Amersham Pharmacia), which had been stamped with a 50-square matrix, and
placed on a selective media plate. The same colony was also scratched on a selective
media plate at the same position as indicated from a matrix stuck to the underside of
the plate. Both plates were incubated overnight at 37°C. The membranes were placed
colony side up on blotting paper soaked in 2xSSC, 5% SDS for 2 minutes. The
membranes were microwaved at full power for 45 seconds, which lyses the cells and
denatures and fixes the DNA. The membranes were then available for
prehybridisation (section 2.11) and subsequent hybridisation with a radioactively
labelled probe (sections 2.12 and 2.13).
2.17.3 Minipreparation of plasmid DNA
The QIAprep Spin Miniprep Kit commercially available from Qiagen™ was used to
extract plasmid DNA on a small scale. The solutions and protocol were supplied with
the kit. A single colony was used to inoculate 5ml of LB (supplemented with an
appropriate antibiotic) and grown overnight at 37°C with shaking. 1.5ml of the cells
were pelleted using a microcentrifuge (lOOOOg, 4 minutes) and re-suspended in
250pl of cell suspension buffer PI containing RNase. The cells were lysed by the
addition of 250pl of buffer P2 and then neutralised by the addition of 350pl of buffer
N3. The cell debris was pelleted by microcentrifugation (lOOOOg, 10 minutes). The
supernatant was decanted into a QIAprep column and after centrifugation (lOOOOg,
60 seconds) the flow through was discarded. The column was washed with 500pl of
buffer PB, followed by a second wash with 750pl of Buffer PE containing ethanol,
and centrifuged as above. The flow through was discarded and the column
centrifuged for an additional 1 minute to remove residual ethanol. The DNA was
eluted from the column by the addition of 50pl of buffer EB.
2.17.4 Endonuclease restriction digest
DNA restrictions were typically carried out for 2-3 hours at 37°C using
commercially available restriction endonucleases. 3-10 units of enzyme were usually
used to restrict 1 pg ofDNA in a 20pl volume of the recommended buffer.
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Restriction endonuclease buffers were supplied at 10x the final concentration. The
Roche incubation buffer range was used for single enzyme restrictions (Table 22).
Table 22
Composition of Roche restriction endonuclease buffers










pH at 37°C 8.0 7.5
2.18 DNA sequencing and analysis
2.18.1 Automated sequencing of double-stranded DNA templates
(i) Sequencing using the Sequitherm Excel™ II Kit
Cloned DNA was sequenced using the LICOR 4000L automated sequencer (MWG
Biotech, Milton Keynes, UK), and the Sequitherm Excel™ II kit (Cambio,
Cambridge, UK). Labelled Ml3 forward and reverse primers were purchased from
MWG Biotech. Sequencing was kindly performed by Mr. Ian Bennet (Department of
Veterinary Pathology, Edinburgh).
2.18.2 Isolation of DNA for sequencing following PCR using [a32P] dCTP
The following procedure was used to isolate and identify DNA fragments of interest
that could not be detected by ethidium bromide staining of agarose gels and
subsequent visualisation under UV light.
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(i) Radioactive PCR using [a32P] dCTP
PCR was carried out using either genomic or cDNA as a template and lOpCi of
[a32P] dCTP per reaction, using reaction conditions and cycling profiles as described
for the individual PCRs (see sections 2.8.2 and 2.8.5).
(ii) Polyacrylamide gel electrophoresis
5pi of PCR product was mixed with 5pi of loading dye, containing formamide and
resolved on a 6% polyacrylamide gel. The gel was run at 80W for 2 hours,
transferred onto Whatman 3MM paper and finally dried under vacuum at 80°C.
Dried gels were then exposed to 2 films overnight at room temperature, one of which
served as a template for excising the bands of interest and the other which was
retained as a record. To allow accurate alignment of the developed autoradiograph
with the dried gel, luminescent autoradiograph markers, Glogos II (Stratagene)
were placed on the four corners of the gel.
(iii) Isolation of DNA fragments
The autoradiograph was positioned on top of the dried gel as accurately as possible
using the markers as a guide. The area surrounding the band of interest was cut out
using a sterile scalpel blade making a window in the autoradiograph. The excised
band from the dried gel was then placed in a sterile 1.5ml eppendorf containing
lOOpl of sterile distilled water. The DNA was eluted by incubating the tube at 65°C
for 30 minutes and then at 4°C overnight.
(iv) Re-amplification of DNA
2pl of eluted DNA was re-amplified in a PCR using the same reaction and thermal
cycling conditions used to initially amplify the DNA product of interest, but omitting
the [a32P] dCTP from the reaction mix. 20pl of the re-amplified product was
resolved on a 2% w/v NuSieve® agarose gel containing lpg/ml EtBr and visualized
under UV light (see section 2.9).
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(v) Cloning and sequencing of the re-amplified DNA
The re-amplified PCR products containing the DNA of interest were ligated into the
pCR®4-TOPO® vector (2.17.1.2) and up to 5 clones recovered from each
transformation were sequenced using the Sequitherm Excel™ II kit (2.18.2).
2.19 Methylation analysis
Methylation specific PCR (MSP) is a rapid inexpensive method for the analysis of
the methylation status of CpG islands (cytosines located 5' to guanines) that are
present in the regulatory regions of many genes. It is therefore an important
technique for the study of abnormally methylated genes in neoplasia and of
imprinted genes. The procedure takes advantage of the sequence difference between
methylated and unmethylated alleles following sodium bisulphite treatment of DNA,
which converts unmethylated, but not methylated, cytosines to uracil. The modified
DNA is then used as a template for amplification using primers for a given locus,
which are designed to distinguish methylated DNA from unmethylated DNA.
2.19.1 Bisulphite modification of DNA
Modification of DNA using sodium bisulphite was performed using reagents and
protocols supplied with the CpGenome™ Modification Kit (Intergen, U.S.A).
Briefly, lpg of DNA was denatured with 3M NaOH at 37°C for 10 minutes, before
the addition of 550pl of DNA Modification Reagent I containing sodium bisulphite
and hydroquinone, and incubation at 50°C for 20 hours. This was followed by the
addition of 5pl and 750pl of DNA Modification Reagents III and II containing
NaOH and incubation at room temperature for 10 minutes to complete the chemical
conversion. DNA purification was carried out by 3 washes in 70% ethanol followed
by the addition of 50pl of 20mM NaOH/90% ethanol and incubation at room
temperature for 5 minutes. The DNA pellet recovered after 2 washes in 90% ethanol
was resuspended in 25pi of TE (lOmM Tris/O.lmM EDTA, pH 7.5) and incubated at
50°C for 15 minutes to elute the DNA. The samples were centrifuged at lOOOOg for 3
minutes and the supernatant containing the eluted DNA transferred to a fresh
eppendorf and stored at -20°C until used for PCR.
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2.19.2 Methylation specific PCR (MSP)
2.19.2.1 Primers and reaction mixture
Following bisulphite modification of DNA, MSP was carried out using primers that
could distinguish methylated from unmethylated DNA (Table 23, page 104). The
CpG WIZ™ Amplification kit (Intergen, U.S.A) was used for the methylation
analysis of pl6INK4a and pl5INIC4b, according to the manufacturer's instructions.
Methylated and unmethylated control DNA (Intergen), chemically modified, was
used as positive and negative controls respectively. Briefly, a hot-start PCR, using
AmpliTaq Gold (section 2.8.8), was employed to eliminate mis-priming and PCR-
related artefacts. Separate reaction mixes were made up using primers specific for the
methylated (M) and unmethylated (U) reactions and were as follows:
lOxUniversal buffer 2.5pl
2.5mM dNTP mix 2.5pl
U or M primers 1 .Opl
AmpliTaq Gold Polymerase 1 unit
Modified template DNA 50-100ng
dH20 Up to 25 pi
2.19.2.2 Amplification
The reactions were then subjected to the following thermal cycling conditions:
1 cycle for
Activation ofAmpliTaq Gold 95 °C for 12 minutes
35 cycles of
Denaturation 95°C for 45 seconds
Annealing 60°C for 45 seconds
Extension 72°C for 60 seconds
For the p73 MSP reaction, the reaction mix was made up to a total volume of 25pl,
using primers specified in Table 23, and were as follows:
1 Ox GeneAmp PCR Buffer II 2.5pi
(lOOmM Tris-HCl, pH8.3, 500mM KC1)
25mM MgCf 2.5pl
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5mM dNTP mix 4(j.l
U or M primers 0.4pM each
AmpliTaq Gold Polymerase 1 unit
Modified template DNA 50-100ng
The reactions were then subjected to the following thermal cycling conditions:
1 cycle for
Activation ofAmpliTaq Gold 95°C for 12 minutes
35 cycles of
Denaturation 95°C for 30 seconds
Annealing 60°C for 45 seconds
Extension 72°C for 30 seconds
25j.il of PCR-amplified products were resolved on 3% w/v NuSieve® agarose gels
containing lpg/ml EtBr and visualized under UV light (2.9).
Table 23
Primers for methylation analysis of pl6INK4a, p!5INK4b and p73



















GGA CGT AGC GAA ATC GGG GTT C
ACC CCG AAC ATC GAC GTC CG
AGG GGA TGT AGT GAA ATT GGG GTT T
ATC ACA ACC CCA AAC ATC AAC ATC CA
60
69
M, methylated; U, unmethylated; F, forward; R, reverse; *, Primer sequences from Corn et al., 1999
2.20 Statistical analysis
The statistical tests used in this study were (i) The Fisher's exact test for calculating p
values from small sample numbers using 2x2 contingency tables and (ii) the Mann-






3.1 Standardisation of study and control material
3.1.1 Study and Control Population
Frozen lymph node tissue from 23 HIV-infected individuals with persistent
generalised lymphadenopathy (PGL) obtained in 1983-84, were used as the study
population.
Tissue from nine HIV-negative reactive lymph nodes (coded 2425, 2435, 2437,
2462, 2478, 2495, 2498, 2499 and 2512), was obtained from the Department of
Pathology, University of Edinburgh. 7 tonsils (numbered T1-T7), removed at routine
tonsillectomy, were kindly provided by the ENT Department, City Hospital,
Edinburgh. Both lymph nodes and tonsils from the HIV-uninfected individuals
served as negative controls.
3.1.2 Standardisation of starting material
The aim of these preliminary studies was to determine the most efficient method of
extracting DNA free from contaminating RNA and proteins, from the lymph node
and tonsil material used in this study. A tonsil (Tl) from an HIV-uninfected
individual was used as the prototype for this experiment.
A fresh frozen tonsil was processed by cutting a small piece of tissue from the main
block or cutting it into 10, 10-micron sections. DNA was then extracted using either
the microfuge phenol-chloroform method, or the Invitrogen Easy DNA Kit (see
section 2.6.1).
The purity of the DNA, as determined by the OD 260/280 ratio was 1.79 using the
phenol-chloroform extraction method, irrespective of whether the tissue was cut or
sectioned. Using the Invitrogen method, the OD 260/280 ratio of the DNA extracted
from the cut and sectioned tissue was 1.8 and 1.76 respectively (see Table 24).
The purity of the DNA was unaffected by the way in which the tissue was processed
or the protocol used (Table 24). Furthermore, no significant difference in DNA yield
was observed using either experiment (Table 24). Therefore, it was decided to use
the Invitrogen Easy DNA Kit to extract DNA from cut tissue, since it is a more rapid
and convenient method ofDNA extraction than the phenol-chloroform method.
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Table 24









Phenol-chloroform small cut piece 1.79 247.2
Ten 10 micron sections 1.79 203
Invitrogen small cut piece 1.8 344
Ten 10 micron sections 1.76 204
OD, optical density
3.2 Optimisation of PCR parameters
Specificity and yield of PCR amplified products is influenced by (i) MgCh (ii)
Annealing temperature (iii) dNTPs (iv) Taq polymerase and (v) number of cycles
(see below). To establish optimal conditions (specificity and sensitivity) for PCR
amplification with each primer pair, reaction conditions were standardised for the
above parameters. Published reaction conditions were used as reference points (see
Table 25).
Table 25







Primer (pM) Cycle number
(3-actin * 652 * * 35
P63 (TA and AN) * 52 * * 40
p73 1.5 59 2.5a 0.4 35
A2 p73 * 722 * * 25
pl6.NK4a * 56 * * 22
pl4ARF * 60 * * 35
KSHV ORF 71-73 * 57 * * 30
BarnHI W 1.5 45 2.5b 1 35
Ann. Temp, annealing temperature; References for the primer pairs used are given in Tables 9 and
ll;2, annealing and extension as 1 -step; *, conditions not published;a, U/50pl;b, U/lOOpl
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(i) Optimisation of magnesium concentration
Taq polymerase is dependent on the presence of free Mg2+ ions for its enzymatic
function. A high concentration inhibits the enzyme whereas the product yield is
reduced if the Mg2+ concentration is too low (Linz et al., 1990).
cDNA synthesised from 40ng of RNA from a LCL, KB, was subjected to a 35-cycle
amplification for [3-actin mRNA. The MgCB concentration was varied from 0.5mM
to 4mM and included the established concentration of 1.5mM (see Table 25).
Figure 16 shows the results obtained with the primer pair for human P-actin. A
540bp PCR fragment was detected following amplification of cDNA from a human
tonsil, with Mg2+ concentrations of 0.5mM to 3mM in 0.5mM increments (lanes 2 to
7), and 4mM (lane 8). The efficiency of amplification was reduced and non-specific
bands were observed with Mg2+ concentrations above 1.5mM (lanes 6 to 8). The
efficiency of amplification was similar at a Mg2+ concentration of 1.0 and 1.5mM.
The optimal Mg2+ concentration was taken as the published value of 1.5mM for the
human P-actin primer pair. The optimal Mg2+ concentration for the other primer pairs
was established in a similar fashion. The results are shown in Table 26, page 114.
(ii) Optimisation of annealing temperature
The efficiency of primer annealing to the target and the outcome of the PCR reaction
is dependent on accurate annealing temperatures (Kocher and Wilson, 1991).
cDNA synthesised from 40ng of RNA from the BL-41 Burkitt's lymphoma cell line
was subjected to a 35-cycle amplification for pl5INK4b mRNA, containing the
established optimal MgCb concentration (see Table 26, page 114). The annealing
temperature (Tm) of the pl51NK4b primer pair was calculated to be 59°C using the
formula [(2xA/T)+(4xG/C)]. The PCR run included annealing temperatures of 54°C
to 62°C in 2°C increments.
Figure 17 shows the results obtained with the primer pair for human pl5INK4b. A
346bp PCR fragment was detected following amplification at annealing temperatures
of 54, 56°C, 58°C and 60°C (lanes 1 to 4). The efficiency of the amplification and
quality of the product (as judged by the intensity of bands on the gel) was found to be
similar at 56°C and 58°C, but no amplification was noted at 62°C. The optimal
annealing temperature was taken as 58°C for the pl5INK4b primer pair.
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cDNA synthesised from 40ng of RNA was subjected to amplification (35 cycles) in a 50pl
reaction using p-actin primers. 20pl of the amplified product was resolved on a 2% w/v
agarose gel. The bands were visualised under UV light. M: 100bp DNA size marker
(fragment sizes in bp). Lane 1: Sterile distilled water Lanes 2-8: 0.5mM, 1.0mM, 1.5mM,
2.0mM, 2.5mM, 3.0mM, and 4.0mM Mg2+ per reaction, respectively. The p-actin PCR product
(540bp) is indicated.















cDNA synthesised from 40ng of RNA was subjected to amplification (35 cycles) in a 30pl
reaction using pi5iNK4b prjmers 20jul of the amplified product was resolved on a 2% w/v
agarose gel and the bands were visualised under UV light. M: 100bp DNA size marker
(fragment sizes in bp). Lanes 1-5: Annealing temperatures of 54°C, 56°C, 58°C, 60°C, and
62°C respectively Lane 6: Sterile distilled water. The p"|5|NK4t> PCR product (346bp) is
indicated.
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The optimal annealing temperature for the other primer pairs was established in a
similar fashion, either using published conditions (Table 25, page 107) or calculated
Tm as starting values. The results are shown in Table 26 on page 114.
(iii) Optimisation of primer concentration
An excess of primers can lead to the amplification of non-target sequences, while too
low a concentration can limit the efficiency of the PCR (Sambrook et al., 1989).
cDNA synthesised from 40ng of RNA from a human lung cancer cell line (H-358)
was subjected to a 35-cycle amplification for pl4ARF mRNA containing established
optimal Mg2+ concentration and annealing temperature (Table 26, page 114).
Figure 18 shows the amplification of a 188bp PCR product with the primer pair for
pl4ARF. The PCR run included primer concentrations of 0.25, 0.5, 1, 1.25 and 1.5p.M
(lanes 2 to 6 respectively). The efficiency of the amplification was reduced, and
increasing non-specific products were observed, with primer concentrations above
0.5pM. Amplification was completely inhibited at a primer concentration of 1.5pM.
The optimal primer concentration was taken to be 0.5pM for the pl4ARF primer pair.
The optimal primer concentration for the other primer pairs was established in a
similar fashion. The results are shown in Table 26 on page 114.
(iv) Optimal Taq DNA polymerase concentration
The amount of Taq polymerase required in a reaction is dependent on the target
DNA, the primers and the volume of the reaction. Insufficient enzyme results in a
poor yield, whereas excess causes nucleotide misincorporation and amplification of
non-target sequences (Sambrook et al., 1989; Kocher and Wilson, 1991).
cDNA synthesised from 40ng ofRNA from a LCL, KB, was subjected to a 35-cycle
amplification for pl6INK4a mRNA, in a reaction volume of 30pl, containing the
2+established optimal Mg and primer concentration and annealing temperature (see
Table 26, page 114). The PCR run included reactions containing 0.5-4.5 units (U) of
Taq polymerase, in 1U increments.
Figure 19 shows the results obtained with the primer pair for pl6INK4a. A 139bp PCR
fragment was detected following amplification of the LCL, KB, with the
concentration of Taq polymerase enzyme in the range of 0.5-3.5 U (lanes 2 to 5), but
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Figure 18. Optimisation of primer concentration for PCR using
p14ARF primers
cDNA synthesised from 40ng of RNA was subjected to amplification (35 cycles) in a 30pl
reaction using p14ARF primers. 20pl of the amplified product was resolved on a 2% w/v
agarose gel. The bands were visualised under UV light. M: 100bp DNA size marker
(fragment sizes in bp). Lane 1: Sterile distilled water Lanes 2-6: 0.25pM, 0.5pM, 1pM,
1.25pM and 1.5pM primers per reaction, respectively. The p14ARF PCR product (188bp) is
indicated.
Figure 19. Optimisation of Taq polymerase concentration for
PCR using p16INK4a primers
cDNA synthesised from 40ng of RNA was subjected to amplification (35 cycles) in a
30pl reaction using p16INK4a primers. 20pl of the amplified product was resolved on a 2%
w/v agarose gel. The bands were visualised under UV light. M: 100bp DNA size marker
(fragment sizes in bp). Lane 1: Sterile distilled water Lanes 2-6: 0.5U, 1.5U, 2.5U, 3.5U,
and 4.5U of Taq DNA polymerase per 30 pi reaction, respectively. The p16INK4a PCR
product (139bp) is indicated.
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amplification was completely inhibited with 4.5 U of the enzyme (lane 6). The
efficiency of the amplification and quality of the product (as judged by the intensity
of bands on the gel) decreased with enzyme concentrations above 0.5 U. The
optimum Taq polymerase concentration was therefore taken to be 0.5 U/30pl for the
pl6INK4a primer pair. The optimum enzyme concentration for the other primer pairs
was established in a similar fashion. The results are shown in Table 26 on page 114.
(v) Optimisation of cycle number
The number of PCR cycles required for amplification of target sequence depends on
the amount of available target DNA and the efficiency of the PCR reaction (Taylor,
1991).
cDNA synthesised from 40ng of RNA from a tonsil was subjected to a 35-cycle
amplification for p-actin mRNA at the established optimal annealing temperature,
primer, Taq and Mg2+ concentrations (see Table 26, page 114). The PCR run
included reactions carried out in increments of 5 cycles from 15 cycles to 40 cycles
and included the published cycle number of 35 cycles (Table 25, page 107).
Figures 20A and 20B show the results obtained with the primer pair for P-actin. A
540bp PCR fragment was detected using 20 to 40 cycles of amplification (lanes 3 to
7), but was not detectable at 15 cycles (Figure 20A, lane 2). Following hybridisation
32with a P-labelled oligonucleotide, a 540bp fragment could be detected at a cycle
number of 15 (figure 20B, lane 2). The intensity of the bands was measured using
scanning densitometry (UVP Gel Works) and a graph was plotted of cycle number
against band volume. From the graph, the intensity of the amplified fragments was
found to be similar when using 30 or more cycles (figure 20C). Therefore, the
optimum number of PCR cycles for the P-actin primer pair was taken to be 28 cycles
(between 25 and 30 cycles), which is on the linear slope of the curve (figure 20C).
However, lower number of cycles is appropriate for semi-quantitative PCR analysis.
The optimum cycle number for the other primer pairs was established in a similar













cDNA synthesised from 40ng of RNA was subjected to amplification in a 50pl reaction for
35 cycles using p-actin primers. 20pl of the amplified product was resolved on a 2%w/v
agarose gel. The bands were visualised under UV light. M: 100bp DNA size marker
(fragment sizes in bp). Lane 1: Sterile distilled water Lanes 2-7: 15, 20, 25, 30, 35 and 40
PCR cycles respectively. The p-actin PCR product (540bp) is indicated.
PCR products were Southern transferred to a Hybond N+ membrane and hybridized with a
32P-labelled oligonucleotide probe specific for the amplified fragment. M: Hinfl digested <()X-
174 DNA size marker (fragment sizes in bp). L: 100bp DNA size marker. Lane 1: Sterile
distilled water Lanes 2-7: 15, 20, 25, 30, 35 and 40 PCR cycles respectively. The p-actin
PCR product (540bp) is indicated.
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The intensity of the bands, obtained after hybridization of the p-actin PCR products with a 32P-
labelled oligonucleotide probe, was measured using scanning densitometry (UVP Gel Works).
A graph was then plotted with the cycle number on the X-axis and the band volume on the Y-
axis. The optimal cycle number for the p-actin PCR was determined to be 28 cycles, which is
on the exponential portion of the amplification curve.
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3.2.1 Summary of optimisation experiments for genomic and RT-PCR
A summary of the optimised PCR conditions for each primer pair is shown in Table
26. dNTPs were used at concentrations of 200pM each (Sambrook et al., 1989).
Reaction conditions for the P-globin PCR were kindly optimised by Dr. Tanzina
Haque.
Table 26











p-actin 1.5 65 1.5" 1 28
p63 (TA and AN) 1.5 52 1° 0.5 28
p73 1.5 59 2.5° 0.25 35
A2 p73 1.5 721 lc 0.5 35
p16,NK4a 2 56 0.5d 0.5 25
pl4ARF 2 56 0.5d 0.5 22a
P15,NK4b 2 58 0.5d 0.5 25
LNA 1.5 60 2.5C 0.4 30
KSHV ORF 71-73 1.5 57 1.0C 0.4 35
BamHl W 1.5 57 2.5b 1 28
Ann. Temp, annealing temperature; annealing and extension as 1-step; a, cycle number for semi¬
quantitative PCR;b, U/lOOpl;c, U/50pl;d, U/30pl
3.3 Determination of primer sensitivity for Methylation-specific PCR (MSP)
Aberrant methylation of CpG islands in the promoter region of a gene is an important
mechanism of inactivation of the function of some tumour suppressor genes. In
preliminary work, primers and conditions for MSP were evaluated. These
experiments were designed to assess the sensitivity of the assay in detecting
methylated alleles present in a background of unmethylated DNA. Serial 10-fold
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dilutions of DNA from the BL cell lines, Raji (with documented methylation in the
plgiNK4a an[j pj<uNK4b genes) ancj Namalwa (with methylation in p73 as assessed in
this study), in a total of 1 fag of lymphoblastoid cell DNA was carried out. The DNA
from each dilution series was chemically modified using the CpGenome™
Modification Kit (Intergen) and 40ng of DNA was subjected to MSP analysis using
primers specific for methylated and unmethylated alleles.
Figures 21A and 21B demonstrate the sensitivity of the MSP analysis for detecting
methylated alleles of pl6INK4a and p73 genes respectively using the primers specified
in Table 23, page 104. In the case of the pl6INK4a gene a band of 145bp could be
detected at a dilution of 10"3 (4pg of methylated DNA) (figure 21A, lane 4). A
similar result was obtained with the MSP for the p73 gene using the Namalwa cell
line. A band of 60bp could be detected at a dilution of 10~3 (~ 4pg of methylated
DNA) (figure 2 IB, lane 4). The sensitivity of the pl51NK4b primer pair was similarly
established, and methylated alleles could be detected at a dilution of 10"3 (~ 4pg of
methylated DNA).
3.4 Optimisation of conditions for Long-Distance (LD)-PCR
Junctional sequences created by the fusion of two genes occur in particular subtypes
of lymphomas and leukaemias, and hence detection of such sequences can provide
valuable information for diagnosis and subsequent management of haematological
neoplasms (Dalla-Favera et al., 1982b; Tsujimoto et al., 1984; Ye et al., 1993). The
breakpoint on the partner chromosome can be distributed over a large region, such
that the region enclosed by the primers is too large to yield a PCR product by
standard PCR techniques. Therefore, a long-distance PCR strategy (Akasaka et al.,
1996; see section 2.8.7) was used in this study to investigate chromosomal
translocations involving the c-myc and bcl-2 genes.
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Figure 21. Sensitivity of MSP analysis for the detection of
methylated alleles
A ten-fold dilution series of the BL cell line, Raji, in a total of 1 jag of lymphoblastoid cell line
(LCL) DNA was prepared and subjected to sodium bisulfite modification. 40ng of each
dilution was subjected to amplification in a 35-cycle hot-start PCR for p16INK4a using the
appropriate primers for the methylated reaction. 25pl of PCR product was resolved on a
2.5% w/v agarose gel. The bands were visualised under UV light. M: 100bp DNA size
marker (fragment sizes in bp). Lanes 1,2,3 and 4: 1, 101, 10"2, and 10"3 dilutions
respectively of Raji DNA in LCL DNA. The p16INK4a methylated product (145bp) is
indicated.
21 B
A ten-fold dilution series of the BL cell line, Namalwa, in a total of 1pg of lymphoblastoid
cell line (LCL) DNA was prepared and subjected to sodium bisulfite modification. 40ng of
each dilution was subjected to amplification in a 35-cycle hot-start PCR for p73 using the
appropriate primers for the methylated reaction. 25pl of PCR product was resolved on a
2.5% w/v agarose gel. The bands were visualised under UV light. M: 100bp DNA size
marker (fragment sizes in bp). Lane 1: Sterile distilled water. Lanes 2,3 and 4: 10_1,
and 10"3 dilutions respectively of Namalwa DNA in LCL DNA. The p73 methylated
product (60bp) is indicated.
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3.4.1 Optimisation of LD-PCR conditions for the detection of translocations
involving the c-myc and bcl-2 genes
The specificity, sensitivity, optimal magnesium concentration and annealing
temperature for each primer pair used in the LD-PCR analysis of the c-myc and bcl-2
translocations was established, and representative experiments are shown below.
3.4.1.1 Specificity of primers used for LD-PCR analysis
To test the specificity of the primers used for the c-myc LD-PCR analysis (Table 14,
page 85), genomic DNA from cell lines that have been shown to harbour
translocations specific to a primer set (Akasaka et ah, 1996; Table 15, page 86) was
amplified (Figure 22, page 119).
A 7.6kb fragment from the Raji cell line was amplified with the c-myc/Cy primer set
(figure 22, lane 1).
A 4.0kb fragment from the BL-41 cell line was amplified with the c-myc/Ca primer
set (figure 22, lane 2).
A 4.9kb fragment from the Ramos cell line was amplified with the c-myc/C\x primer
set (figure 22, lane 3).
No amplification was observed when the Raji cell line, which has a c-myc/Sy
translocation, was tested with the c-myc/C\i primer set (figure 22, lane 4). Negative
amplification with the P3HR1 cell line, wherein the breakpoint on chromosome 8 is
located around 190kb upstream of the c-myc gene (Joos et al., 1992), further
confirmed the specificity of the primers (figure 22, lane 5).
The specificity of the primer pairs for the analysis of bcl-2IIgH translocations (Table
14, page 85) was established in a similar fashion. Lymph nodes with known
translocations between the MBR (1119) and mcr (1143) regions on chromosome 18
and the JH region of chromosome 14 (Krajewsky, A, personal communication),
amplified with the MBR/Ep and mcr/Ep primer pairs respectively. A lymph node
with no known t( 14:18) translocation did not amplify with any of the primer pairs
(Table 15, page 86).
117
3.4.1.2 Optimisation of Mg2+ concentration for LD-PCR
Since sub-optimal concentrations of Mg2+ can inhibit Taq polymerase activity (Linz
et al., 1990), the following experiment was carried out to optimise Mg2+ ion
concentration for the LD-PCR.
Figure 23 shows a 7.6kb region, which was amplified from DNA extracted from the
BL cell line, Raji, in a 35-cycle RT-PCR reaction using the c-myc/Cy primer pair and
Mg2+ concentrations of 2.0mM, 2.5mM and 3.0mM (lanes 1 to 3 respectively). The
efficiency of amplification was reduced at a Mg2+ concentration of 2.0mM, and non-
2+
specific bands were observed with increasing concentrations of Mg . From the
above experiment the optimum Mg2+ concentration was taken as the published
concentration of 2.5mM for the c-myc/Cy primer pair (figure 23, lane 2).
The optimum MgCf concentration for the other primer pairs was established in a
similar fashion and found to be 2.5mM.
3.4.1.3 Optimisation of annealing temperature for LD-PCR
The following experiment was carried out to ascertain the optimal annealing
temperature for the LD-PCR amplification of the c-myc and bcl-2 translocations.
Figure 24 shows the results obtained when genomic DNA from the BL-41 cell line
was amplified in a 35-cycle LD-PCR reaction using the c-myc/Ca primer pair and at
annealing temperatures of 63°C, 68°C and 73°C (figure 24, lanes 1,2 and 3
respectively). A 4.0kb product was amplified at annealing temperatures of 63°C and
68°C (figure 24 lanes, 1 and 2 respectively), although the efficiency of amplification,
as judged by the intensity and size of the band, was greater at an annealing
temperature of 68°C. Amplification was not observed at an annealing temperature of
73°C. The optimum annealing temperature was taken as the published value of 68°C
for the c-myc/Ca primer pair.
The optimum annealing temperature for all the other primer pairs was established in
a similar fashion and was found to be 68°C in each case.
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Figure 22.
200ng of genomic DNA from the BL-41, Raji and Ramos cell lines were subjected to
amplification in a 35-cycle LD-PCR reaction using the c-myc/Ca, c-myc/Cy and c-myclCy
primer pairs respectively. DNA from the Raji cell line was similarly subjected to amplification
using the c-mycICa primer set. 20pl of the PCR product was resolved on a 0.8% w/v
agarose gel and the bands were visualised under UV light. M: Lambda (X) DNA digested
with Hind III DNA size marker (fragment sizes in bp). Lane 1: Raji cell line (7.6kb
translocation) Lane 2: Ramos cell line (4.9kb translocation) Lane 3: BL-41 cell line (4.0kb
translocation) Lane 4: Raji cell line (c-myclCy primer set) Lane 5: P3HR1 cell line.
Figure 23. Optimisation of Mg2+ concentration for LD-PCR





200ng of genomic DNA from the Raji cell line was subjected to amplification in a 35-cycle
LD-PCR reaction using the c-myc/Cy primer set. 20pl of the PCR product was resolved on
a 0.8% w/v agarose gel and the bands were visualised under UV light. M: Lambda (X) DNA
digested with Hind III DNA size marker (fragment sizes in bp). Lanes 1-3: 2.0mM, 2.5mM
and 3mM Mg2+ per reaction respectively. The c-myc/Sy (7.6kb) translocation is indicated.
Figure 24. Optimisation of annealing temperature for LD-PCR
M 12 3
200ng of genomic DNA from the BL-41 cell line was subjected to amplification in a 35-cycle
LD-PCR reaction using the c-mycICa primer set. 20pl of the PCR product was resolved on a
0.8% w/v agarose gel and the bands were visualised under UV light. M: 1kb DNA size
marker (fragment sizes in bp). Lanes 1-3: Annealing temperatures of 63°C, 68°C and 73°C
respectively. The c-myc/Sa (4.0kb) translocation is indicated.
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3.4.1.4 Sensitivity of the primers used for LD-PCR analysis
To ascertain the sensitivity of the primers used to detect the c-myc and bcl-2
translocations, the Raji cell line and DNA from lymph node biopsy 1119 were used
respectively.
(i) Sensitivity of the primers used for the c-myc LD-PCR
Serial ten-fold dilutions of Raji cells (which harbour a c-myc/Sy translocation) in
increasing numbers of cells from a lymphoblastoid cell line were prepared. lOOng of
DNA extracted from each dilution was then subjected to LD-PCR analysis using the
c-myc/Cy primer set. A band of 7.6kb could be detected at a dilution of 1CT2 (figure
25A, lane 3). Hybridisation of the amplified products with a [y32P] ATP-labelled c-
myc probe increased the sensitivity of detection by one order of magnitude and a
7.6kb band could be detected at a dilution of 10"3 (figure 25B, lane 4). Since lOOng
of DNA is equivalent to 104 cells on average, the sensitivity of detection was
estimated to be 10 copies of the c-myc/IgH translocation.
The sensitivity of detection of the t(8:14) translocations using the other primer pairs
was established in a similar fashion, and in each case was found to be 10 copies.
(ii) Sensitivity of the primers used for the bcl-2 LD-PCR
Since the accurate cell number could not be determined with the lymph node biopsy,
serial ten-fold dilutions of genomic DNA from a lymph node biopsy (1119) which
has a MBR/JH fusion, in increasing amounts ofDNA from a lymphoblastoid cell line
were prepared. lOOng of DNA extracted from each dilution was then subjected to
LD-PCR analysis using the MBR-l/Ep primer set. Hybridisation of the amplified
products with a [y32P] ATP-labelled Ep probe identified a 4.2kb band at a dilution of
1CT3 (figure 26, lane 7). Since lOOng of DNA is equivalent to 104 cells on average,
the sensitivity of detection was estimated to be 10 copies of the MBR/JH fusion.
The sensitivity of detection of bcl-2/IgH fusions using the other primer pairs was
established in a similar manner, and in all cases was found to be 10 copies.
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Serial ten-fold dilutions of Raji cells (which harbor a c-myclSy translocation) in increasing
numbers of cells from a lymphoblastoid cell line (LCL) were prepared. 100ng of DNA from
each dilution was then subjected to LD-PCR analysis using the c-myclCy primer set. 20pl of
the PCR product was resolved on a 0.8% w/v agarose gel. M: Lambda (A) DNA digested with
Hind III DNA size marker (fragment sizes in bp). Lanes 1 to 4: 1, 10"1, 10"2, and 10"3 dilutions
of Raji cells in cells from an LCL, respectively. The c-myclSy (7.6kb) translocation is
indicated.




PCR products were transferred to a Hybond N+ membrane, and hybridised with a [y32P] ATP-
labelled c-myc probe. M: Lambda (A) DNA digested with Hind III DNA size marker (fragment
sizes in bp). Lanes 1 to 4: 1, 10"\ 10"2, and 10"3 dilutions of Raji cells with cells from an LCL,
respectively. The c-myc/Sy (7.6kb) translocation is indicated.
Figure 26. Sensitivity of the primers used for the bcl-2 LD-PCR





Serial ten-fold dilutions of DNA from a lymph node (1119) in increasing amounts of DNA
from a lymphoblastoid cell line, was prepared. 100ng of DNA from each dilution was then
subjected to LD-PCR analysis using the MBR-1/Ep primer set. 20pl of the PCR product
was resolved on a 0.8% w/v agarose gel, transferred to a Hybond N+ membrane, and
hybridised with a [y32P] ATP-labelled Ep probe. M: Lambda (A) DNA digested with Hind III
DNA size marker (fragment sizes in bp). Lanes 1: Blank Lane 2: Sterile distilled water
Lane 3: Lymph node without t(14:18) translocation (761) Lanes 4 to 7: 1, 10_1, 10"2, and
10"3 dilutions of lymph node (1119) DNA in cells from a LCL, respectively. The MBR-1/JH
(4.2kb) translocation is indicated.
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3.5 Screening for amplifiable DNA using P-Globin primers
DNA prepared from PGL tissue, as well as HIV-negative control tonsil and lymph
node, was amplified using P-globin primers (Table 9, page 78) to check for the
presence of amplifiable DNA. A band of 1 lObp was detected in all the PGL samples
(figures 27A and 27B) as well as in all the control tonsils (figure 28A) and lymph
nodes (figure 28B). A lymphoblastoid cell line (LCL), KB, was used as a positive
control for amplification and sterile water was used as a control for PCR
contamination.
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Figure 27. Screening for amplifiable DNA in PGL tissue using
human (3-globin primers
27 A
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
220 _
- 110bP
1 jj.g of DNA prepared from PGL tissue was subjected to amplification in a 28-cycle
PCR reaction using human p-globin primers. 20pl of PCR product was resolved on
a 2% w/v agarose gel and visualised under UV light. M: 1 kb DNA size marker
(fragment sizes in bp). Lane 1: Blank Lane 2: Sterile water Lane 3: Blank Lanes 4-
15: PGL samples. The 110bp p-globin product is indicated.
27 B
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1pg of DNA prepared from PGL tissue was subjected to amplification in a 28-cycle PCR
reaction using human p-globin primers. 20pl of PCR product was resolved on a 2% w/v
agarose gel and visualised under UV light. M: 1kb DNA size marker (fragment sizes in
bp). Lane 1: Blank Lane 2: Sterile water Lane 3: Blank Lanes 4-14: PGL samples Lane
15: Blank Lane 16: Lymphoblastoid cell line (LCL). The 110bp p-globin product is
indicated.
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Figure 28 A Screening for amplifiable DNA in normal tonsil tissue
preparations using human (3-globin primers
1pg of DNA prepared from tonsil tissue was subjected to amplification in a 28-
cycle PCR reaction using human p-globin primers. 20pl of PCR product was
resolved on a 2% w/v agarose gel and visualised under UV light. M: 1kb DNA
size marker (fragment sizes in bp). Lane 1-3: Blank Lane 4: LCL Lane 5: Sterile
water Lanes 6-12: Tonsils. The 110bp p-globin product is indicated.
Figure 28 B Screening for amplifiable DNA in normal lymph node
tissue preparations using human |3-globin primers
M 1 2 34 5 6 7 89 10 11 12
1pg of DNA prepared from lymph node tissue was subjected to amplification in a
28-cycle PCR reaction using human p-globin primers. 20pl of PCR product was
resolved on a 2% w/v agarose gel and visualised under UV light. M: 1kb DNA
size marker (fragment sizes in bp). Lane 1: Blank Lane 2: Lymphoblastoid cell
line (LCL) Lane 3: Sterile water Lanes 4-12: Lymph nodes. The 110bp p-globin
product is indicated.
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3.6 Analysis of the structure and expression of the p53 gene family in PGL
In the immunosuppressed host, particularly in AIDS-NHL mutations in p53 occur at
a frequency of around 38%, with a high percentage (60%) clustering in the AIDS-BL
sub-type (Ballerini et al., 1993).
The role of the p53 family members, p63 and p73 in AIDS-NHL is unknown.
Somatic mutations in both genes are rare in human cancer (Ichimiya et al., 1999;
Ikawa et al., 1999). However, transcriptional silencing of p73 by intragenic
hypermethylation in a subset of haematological malignancies is consistent with a
tumour suppressor role for this gene (Corn et al., 1999). N-terminal variants of p63
(AN p63) are overexpressed in some squamous cancers indicating a potential
oncogenic function for this gene (Yamaguchi et al., 2000; Crook et al., 2000).
Unlike p53, p63 and p73 are spliced at their C-termini, and expression shows tissue
specificity. Similar to AN p63, N-terminal deleted variants of p73 lacking exon 2 (a2
p73) have recently been described in ovarian and breast cancer (Yang et al., 1998;
De Laurenzi et al., 1998, Ng et al., 2000; reviewed in section 1.4).
The objectives of the studies described in this chapter were as follows:
(i) To determine whether somatic mutations in p53 occur in PGL.
(ii) To define patterns of expression of p63 and p73 in normal lymphoid tissue and
PGL.
(iii) To seek experimental evidence in support of a tumour suppressor role for p73 in
PGL.
3.6.1 PCR without radioactive 33P using primers for p53 exons 2-11
DNA from PGL and control tissue was initially amplified without any radioactivity
using primers for p53 exons 2-11, to assess the specificity of the PCR, using the
primers shown in Table 17, page 91. 500ng of DNA from each of the samples were
amplified using the conditions specified in section 2.16.3. A nasopharyngeal
carcinoma (NPC) cell line, CI8, was used as a positive control for amplification and
sterile distilled water as a control for PCR contamination.
Figures 29A to D are representative results of PCRs with primer pairs for exons
5,6,7, and 8 of p53. These experiments clearly demonstrated that the PCR is specific,
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Figure 29 A PCR amplification of exon 5 of p53




500ng of DNA was subjected to amplification in a 35-cycle PCR reaction using the
p53 exon 5 primer pair. 20pl of the PCR product was resolved on a 2% w/v agarose
gel and the bands were visualised under UV light. M: 1kb DNA size marker (fragment
sizes in bp) Lanes 1-2: Blank Lane 3: SDW Lanes 4-12: PGL samples Lane 13:
C18. The exon 5 amplified fragment (211bp) is indicated.
Figure 29 B PCR amplification of exon 6 of p53




500ng of DNA was subjected to amplification in a 35-cycle PCR reaction using the
p53 exon 6 primer pair. 20pl of the PCR product was resolved on a 2% w/v agarose
gel and the bands were visualised under UV light. M: 1kb DNA size marker
(fragment sizes in bp). Lanes 1-2: Blank Lane 3: SDW Lanes 4-12: PGL samples
Lane 13: C18. The exon 6 amplified fragment (185bp) is indicated.
126
Figure 29 C PCR amplification of exon 7 of p53
Ml 234 5678 9 10 11 12
396
500ng of DNA was subjected to amplification in a 35-cycle PCR reaction using the
p53 exon 7 primer pair. 20pl of the PCR product was resolved on a 2% w/v agarose
gel and the bands were visualised under UV light. M: 1 kb DNA size marker
(fragment sizes in bp). Lanes 1: Blank Lane 2: SDW Lane 3: C18 Lane 4: Blank
Lane 5-12: PGL samples. The exon 7 amplified fragment (139bp) is indicated.
Figure 29 D PCR amplification of exon 8 of p53
500ng of DNA was subjected to amplification in a 35-cycle PCR reaction using the
p53 exon 8 primer pair. 20pl of the PCR product was resolved on a 2% w/v agarose
gel and the bands were visualised under UV light. M: 1kb DNA size marker
(fragment sizes in bp). Lanes 1-2: Blank Lane 3: SDW Lanes 4-12: PGL samples
Lane 13: C18. The exon 8 amplified fragment (200bp) is indicated.
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since only a single band was amplified with each primer pair (the sizes of the PCR
products 211 bp (exon 5), 185bp (exon 6), 139bp (exon 7) and 200bp (exon 8) are
indicated in figures 29A to D respectively).
3.6.2 Comparison of radio-isotopes 32P with 33P for SSCP analysis
33P is a low-energy beta emitter, and hence is safer to work with, when compared to
P. To assess whether the P isotope was comparable to the P isotope in detecting
SSCP mobility shifts, the following experiment was carried out.
SSCP-PCR was performed with primers to amplify exon 5 of p53, on PGL samples,
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a positive control (CI8) and a negative control (LCL), using both [a P] dCTP and
[a32P] dCTP.
Figures 30A and 30B are representative SSCP-PCR amplifications of exon 5 of p53
39 33
using P and P isotopes respectively. A positive SSCP shift observed with the
positive control, CI8, in figure 30A was similarly observed in figure 30B.
It was concluded from the above experiment that SSCP-PCR using 33P as the
radioisotope was as sensitive as P in detecting mobility shifts.
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Figure 30. SSCP analysis of exon 5 with radioactive phosphorus
isotopes 32P and 33P
Figure 30 A SSCP analysis of exon 5 using [a32P] dCTP
12 345 678TN
500ng of DNA was subjected to amplification in a 35-cycle PCR using primers PU5 and
PD5 and 2pCi of [a32P] dCTP per reaction. Following amplification, 3pl of radiolabeled
PCR product was mixed with 3pl of loading dye. The samples were heat-denatured at
94°C for 5 minutes and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol.
After being dried the gel was exposed to Kodak XR film at room temperature for 24 hours
with intensifying screens. Lanes 1-8: PGL samples T: C18 (duplication of codons 149-
153, codon 154 deleted) N: LCL.
Figure 30 B SSCP analysis of exon 5 using [a33P] dCTP
1234 5678TN
500ng of DNA was subjected to amplification in a 35-cycle PCR using primers PU5 and
PD5 and 10ptCi of [a33P] dCTP per reaction. Following amplification 3pl of radiolabeled
PCR product was mixed with 3pl of loading dye. The samples were heat-denatured at
94°C for 5 minutes and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol.
After being dried the gel was exposed to Kodak XR film at -70°C for 24 hours with
intensifying screens. Lanes 1-8: PGL samples T: C18 (duplication of codons 149-153,
codon 154 deleted) N: LCL.
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3.6.3 SSCP mobility shifts are detected in PGL tissue
The presence of p53 mutations in the current series of PGL was sought using SSCP
analysis of each coding exon of the gene (exons 2-11) and genomic DNA as a
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substrate. The amplification reactions included lOpCi of [a P] dCTP. The
sequences of the primer pairs are given in Table 17, page 91. Positive and negative
controls are shown in Table 20, page 93. Representative SSCP autoradiographs for
each analysed exon are presented in Figures 31 to 39. Samples with altered migration
are indicated in blue. Positive and negative controls are indicated in red.
Mobility shifts suggestive of sequence changes were detected in 6/23 (26%) analysed
DNA samples from HIV-infected individuals with PGL. These comprised 5 PGL
samples in exon 7 (figure 35 lanes 1,9,11,12 and 21), and 1 PGL sample in exon 10
(figure 38 lane 4). Abnormal migration was also detected in one tonsil (6.3%) from
an HIV-uninfected individual in exon 6 (figure 34 lane 13). In the case of exon 2/3
(figure 31), two distinct patterns of migration were observed, suggestive of a
polymorphism, which occurs in exon 2 (GAC>GAT) (Ahuja et al., 1990). Samples
in lanes 2,5,7,8,10,11, and 12 showed a pattern of migration that differed from those
samples in lanes 1,3,4, and 6. Normal migration patterns in all the other exons were
observed in the remaining PGL samples and controls.
3.6.4 Amplification of DNA using a high-fidelity polymerase- Pfx
Each DNA sample exhibiting a mobility shift was subjected to re-amplification of
the exon containing the suggested mutation, with a high fidelity thermostable DNA
polymerase, Pfx, since it has an error rate ~26 times lower than Taq (Lackovich et
al., 2001). The error rate of Taq, Pfu and Pfx polymerases is shown in Table 27.
Table 27
Error-rates of Taq, Pfu and Pfx polymerase
Polymerase Error-rate (x 10"6) Relative fidelity
Taq 42 ± 19 1
Pfu 3 ± 1 14
Pfx 1.6 ±0.5 26
Adapted from Lackovich et al., 2001 and Takagi et al., 1997
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Figure 31. SSCP analysis of exon 2/3 of p53
12 3456789 10 11 N
500ng of DNA was subjected to amplification using primers PU2 and PD3. 3pl of
radiolabeled PCR product was mixed with 3pl of loading dye. The samples were
heat-denatured and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol.
The dried gel was exposed to Kodak XR film at -70°C for 2-3 days. Lanes 1-8: PGL
samples Lane 9: Blank Lanes 10-11: PGL samples N: Negative control.
Figure 32. SSCP analysis of exon 4 of p53
1 2 3 4 5 6 7 8 9 10 UN 12TN1
500ng of DNA was subjected to amplification using primers PU4 and PD4. 3pl of
radiolabeled PCR product was mixed with 3pl of loading dye. The samples were
heat-denatured and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol.
The dried gel was exposed to Kodak XR film at -70°C for 2-3 days. Lanes 1-10: PGL
samples Lanes 11&12: Blank T: Tumour control (arginine at codon 72) N: Normal
control (arginine at codon 72) N1: Normal control (proline at codon 72).
131
Figure 33. SSCP analysis of exon 5 of p53
1 2 3 4 5 6 7 8 9 10 1112 1314 15 N 16 T
500ng of DNA was subjected to amplification using primers PU5 and PD5. 3pi of
radiolabeled PCR product was mixed with 3pi of loading dye. The samples were heat-
denatured and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol. The dried
gel was exposed to Kodak XR film at -70°C for 2-3 days. Lanes 1-6: Tonsil controls. Lane
7-15: Lymph node controls Lane 16: Blank T: Tumour control C18 (duplication of codons
149-153, codon 154 deleted); N: Normal control 28697N.
Figure 34. SSCP analysis of exon 6 of p53
TN Til 2345678 9 10 1112 13 14 15 16
500ng of DNA was subjected to amplification using primers PU6 and PD6. 3pl of
radiolabeled PCR product was mixed with 3pl of loading dye. The samples were
heat-denatured and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol.
The dried gel was exposed to Kodak XR film at -70°C for 2-3 days. Lanes 1-9:
Lymph node controls Lanes 10-16: Tonsil controls Lane 13: Abnormally migrating
sample (T6) T: Tumour control 03157T (codon 213, CGA-TGA); T1: Tumour control
13758T (codon 202, CGT-CAT) N: Normal control 03157N.
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Figure 35. SSCP analysis of exon 7 of p53
123456789 10
•-Met-
500ng of DNA was subjected to amplification using primers PU7 and PD7. 3pl of
radiolabeled PCR product was mixed with 3pl of loading dye. The samples were
heat-denatured and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol.
The dried gel was exposed to Kodak XR film at -70°C for 2-3 days. Lanes 1-21: PGL
samples Lanes 1,9,11,12 and 21: Abnormally migrating samples (LN 1,9,15,16 and
20 respectively) Lane 22: Blank T: Tumour control 00997T (codon 248, CGG-TGG);
N: Normal control 00997N.
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Figure 36. SSCP analysis of exon 8 of p53
123 45 67 89 10 11 12 NT
500ng of DNA was subjected to amplification using primers PU8 and PD8. 3pl of
radiolabeled PCR product was mixed with 3pl of loading dye. The samples were
heat-denatured and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol.
The dried gel was exposed to Kodak XR film at -70°C for 2-3 days. Lanes 1-4,6 & 8-
12: PGL samples Lanes 5& 7: Blank T: Tumour control 05747T (codon 281, GAC-
AAC); N: Normal control 05747N.
Figure 37. SSCP analysis of exon 9 of p53
123 456 789TNT
500ng of DNA was subjected to amplification using primers PU9 and PD9. 3pl of
radiolabeled PCR product was mixed with 3pl of loading dye. The samples were
heat-denatured and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol.
The dried gel was exposed to Kodak XR film at -70°C for 2-3 days. Lanes 1-9: PGL
samples T: Tumour controls C17 and C18; N: Normal control, DNA from fibroblasts.
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Figure 38.
500ng of DNA was subjected to amplification using primers PU10 and PD10. 3pl of
radiolabeled PCR product was mixed with 3pl of loading dye. The samples were
heat-denatured and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol.
The dried gel was exposed to Kodak XR film at -70°C for 2-3 days. Lanes 1-3,4,6-
8,10-13: PGL samples Lanes 5 and 9: Blank Lane 4: Abnormally migrating sample
(LN5) T: Tumour control, C17; N: Normal control, DNA from fibroblasts.
Figure 39. SSCP analysis of exon 11 of p53
123 456789 ION T
■p
|||gs£
500ng of DNA was subjected to amplification using primers PU11 and PD11. 3pl of
radiolabeled PCR product was mixed with 3pl of loading dye. The samples were
heat-denatured and resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol.
The dried gel was exposed to Kodak XR film at -70°C for 2-3 days. Lanes 1-10: PGL
samples T: Tumour control, C17; N: Normal control, DNA from fibroblasts.
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3.6.4.1 Optimisation of annealing temperature using Pfx polymerase
These studies were carried out to establish the optimal annealing temperature for the
re-amplification of DNA, using Pfx polymerase, which was to be subsequently
cloned and sequenced. 300ng of DNA was amplified in a 35-cycle PCR reaction
containing MgS04, Pfx and primer at concentrations recommended by the
manufacturer (Life Technologies, see section 2.8.6). The minimum recommended
temperature was 55°C. PCR was carried out using primers for exon 7, at annealing
temperatures of 55-63°C, in one-degree increments, as shown in figure 40 (lanes 2 to
10 respectively). The efficiency of amplification and quantity of the product (as
judged by the intensity of the bands on the gel) was similar at temperatures between
61-63°C, whereas at temperatures below 61°C, amplification specificity was
compromised and non-specific bands were observed. The optimum annealing
temperature was determined to be 63°C (figure 40, lane 10). The optimum annealing
temperature for the other primer pairs was established in a similar fashion, and was
found to be 66°C for exon 2/3 and exon 10 primer pairs.
Figure 41 is a representative result of PGL samples amplified using primers for exon
7 of p53 and Pfx polymerase.
3.6.5 p53 mutations are detected in PGL
P/x-amplified PCR fragments were either gel-purified or ligated directly into pCR®-
BLUNT (2.17.1.3). Following restriction enzyme digest of individual clones, 20-30
clones that contained an insert of the right size were sequenced using the LICOR
4000L automated sequencer (MWG Biotech, Milton Keynes, UK), and the
Sequitherm Excel™ II kit (Cambio, Cambridge, UK) using Ml3 forward and reverse
primers. Proposed mutations were confirmed by sequencing both DNA strands as
well as re-amplification of the DNA in an independent PCR reaction, followed by
cloning and sequencing (Table 28, page 138, and figure 42). No sequence changes
were observed in the exon 2/3 fragments with altered mobility shifts. It was thus
concluded that these shifts were an artefact of SSCP analysis. Mutations were
however identified in each of the 6 PGL DNA samples and 1 HIV-uninfected tonsil
that had mobility shifts by SSCP, which are represented in Figures 42 A to G, pages
139-140 and Table 28, page 138. Nucleotide changes are indicated in red.
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Ml 234 56789 10
139bp
300ng of DNA was subjected to amplification in a 35-cycle PCR using exon 7 primers
and Pfx polymerase. The DNA was subjected to amplification using annealing
temperatures between 55°C and 63°C, in one-degree increments. 20pl of PCR product
was resolved on a 2% w/v agarose gel and the bands were visualised under UV light.
M: 100bp DNA size marker (fragment sizes in bp). Lane 1: SDW Lanes 2-10: 55°C -
63°C respectively. The exon 7 amplified product (139bp) is indicated.
Figure 41. PCR amplification of exon 7 using Pfx polymerase
300ng of DNA was subjected to amplification in a 35-cycle PCR using primers for exon 7
and Pfx polymerase. 20pil of PCR product was resolved on a 2% w/v agarose gel and
the bands were visualised under UV light. M: 1kb DNA size marker (fragment sizes in
bp). Lanes 1-3: PGL samples (LN1, LN9 and LN15 respectively). The exon 7 amplified
product (139bp) is indicated.
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Missense mutations were detected in cases LN 1 (codon 229), LN 9 (codon 242), LN
15 (codon 238) and LN 16 (codon 249) in exon 7. A silent mutation was observed in
codon 245 (exon 7) in case LN 24. In case LN 5, deletion of a guanine residue in
codon 361 (exon 10) was observed, resulting in a shift in the reading frame by -1.
Although the nucleotide deletion resulted in no change in the amino acid at codon
361, a termination codon (TGA) observed in codon 369 could result in premature
termination of translation. In the HIV-uninfected tonsil (T6) a silent mutation was
detected in exon 6, codon 222. The nucleotide substitutions and amino acid changes
are shown in Table 28. Although the p53 mutants described in this study have not
been functionally characterised, the phenotype ofmutants involving the same codon
but different amino acid substitutions have also been indicated. The nature of
nucleotide substitutions was a transversion in case numbers 15, 16, and T6 and
transition in case numbers 1,9 and 24. All the mutations occur within evolutionarily
conserved codons and codon 249 (LN 16) is considered to be a mutational hot spot.
Table 28












LN 1 7 229 TGT -» CGT Missense
(Transition)
C -» R nk nk
LN 9 7 242 TGC -» CGC Missense
(Transition)




LN 15 7 238 TGT GGT Missense
(Transversion)




LN 16 7 249 AGG -> ATG Missense
(Transversion)




LN 24 7 245 GGC -* GGT Silent
(Transition)
G -> G NA NA
LN 5 10 361 GGG-» GGAG Nonsense* nk nk
T6 6 222 CCG -» CCT Silent
(Transversion)
P->P NA NA
T= normal tonsil; LN = lymph node from PGL; *, Termination (TGA) codon 369, exon 11; C,
Cysteine; R, Arginine; G, Glycine; M, Methionine; P, Proline; Y, Tyrosine; S, serine; W, Tryptophan;
**, Transdominance tested in yeast, and transactivation of the wafl or hmdm2 promoter; Transdom.,
transdominant; Transact., transactivation; nk, not known; NA, not applicable; ', Campomenosi et al.,
2001; 2, Marutani et al., 1999;3, Crook et al., 1994
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Figure 42. Sequence analysis of p53
Figure 42 A








Sequence of LN 15









Sequence of LN 5










Sequence of LN 24
















Figure 42. Sequence analysis of p53. Samples that showed a positive shift on SSCP
analysis were re-amplified with Pfx polymerase, cloned into plasmid vectors and sequenced
using LICOR 4000L automated sequencer (MWG Biotech, Milton Keynes, UK), and the
Sequitherm Excel™ II kit (Cambio, Cambridge, UK). Labelled M13 forward and reverse
primers were used. Nucleotide substitutions are indicated in red.
Figure 42 A: Sequence of LN 1 (lane 1, figure 35, exon 7)
Figure 42 B: Sequence of LN 9 (lane 9, figure 35, exon 7)
Figure 42 C: Sequence of LN 15 (lane 11, figure 35, exon 7)
Figure 42 D: Sequence of LN 16 (lane 12, figure 35, exon 7)
Figure 42 E: Sequence of LN 5 (lane 4, figure 38, exon 10)
Figure 42 F: Sequence of LN 24 (lane 21, figure 35, exon 7)
Figure 42 G: Sequence of T6 (lane 16, figure 34, exon 6)
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3.6.6 Analysis of p73 expression in HIV-PGL and HIV-uninfected tissue
3.6.6.1 Multiple C-terminal isoforms of p73 are expressed in PGL
RT-PCR was used to analyse expression of the p73 gene using primers located in
exon 10 (sense) and exon 14 (antisense) of the gene (Table 11, page 80). The
location of the primers allowed for the detection of the multiple C-terminal isoforms,
of which 6 have been reported to date (De Laurenzi et al., 1998, 1999). Following
amplification, RT-PCR products were hybridised to a [y32P] ATP-labelled p73
oligonucleotide located in exon 10.
Expression of p73 was detected in 19/19 FHV-infected PGL tissue and in 9 of 15
HIV uninfected tonsils and lymph nodes (figure 43A, lanes 3,4,6,7,8,9,10,13 and 14).
8 individual bands were detected in the PGL samples, whereas only 4 bands were
detected in the normal lymph nodes and tonsils (figure 43B). Note that the pattern of
expression in the vulval cancers (positive controls) is different to that observed in the
HIV-infected and uninfected lymphoid tissue (figure 43C).
3.6.6.2 Detection of the alpha and beta isoforms of p73 using colony
hybridisation and sequencing
To identify the RT-PCR amplified products (see above) and determine whether the
transcripts were p73-specific, colony hybridisation using a [y32P] ATP-labelled p73
oligonucleotide (Table 11, page 80) was carried out (see section 2.17.2). DNA from
the clones that hybridised with the probe was purified (see section 2.17.3) and
sequenced (see section 2.18).
Of the 50 clones screened, 6 hybridised to the p73 probe (figure 44, A-F). The
remaining 44 clones did not hybridise to the probe indicating absence of a p73-
specific product. On subsequent sequencing of these 6 clones, 5 were identified as
the alpha transcript (535bp) of the p73 gene (figure 45, lanes 2,4,6,8 and 10), and 1
as the beta transcript (440bp) (figure 45, lane 12).
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Figure 43. Detection of p73 transcripts in HIV-PGL and HIV-uninfected
tissue
43 A






























A 535bp region of p73 was amplified from cDNA in a 35-cycle RT-PCR reaction using
p73 primers. 20pl of PCR product was resolved on a 3% w/v agarose gel run slowly for
6 hours at 30mA. PCR products were transferred to Hybond N+ membrane and probed
with a 32P-labelled oligonucleotide located in exon 10. M: Hinfl digested <j)X-174 DNA
size marker (fragment sizes in bp). The presence of amplifiable cDNA is indicated by
amplification of p-actin. Figure 43A Lanes 1-19: PGL samples. Figure 43B Lanes 1-
7: HIV-uninfected tonsils. Lanes 8-15: HIV-uninfected lymph nodes. Figure 43C Lane
1: Sterile distilled water. Lanes 2 and 3: cDNA from vulval cancers (T1 and T2
respectively).
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Figure 44. Colony hybridisation to identify p73 transcripts
The p73 RT-PCR product was cloned using the TOPO TA® Cloning Kit and
the colonies recovered were screened using a [y32P] ATP-labelled p73
oligonucleotide located in exon 10. A-F: Colonies that hybridised with the
[y32p] ATP-labelled p73 oligonucleotide.
Figure 45. Restriction enzyme digest of clones that hybridised
with the [y32P] ATP-labelled p73 oligonucleotide
Plasmid DNA extracted from the colonies that hybridised with the 32P-labelled p73
oligonucleotide were digested with the restriction enzyme EcoRI for 3 hours at
37°C. 20pl of the digested DNA was resolved on a 2% w/v agarose gel and the
bands visualised under UV light. M: A 100bp DNA size marker (fragment sizes in
bp). Lanes 1,3,5,7,9 and 11: Undigested DNA. Lanes 2,4,6,8,10 and 12: DNA
digested with EcoRI. The clones that hybridised with the 32P-labelled p73
oligonucleotide (A-F) are indicated. The a fragment (535bp) and the (3 fragment
(440bp) are indicated. Plasmid vector not shown.
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3.6.6.3 Detection of p73 isoforms using radioactive PCR and sequencing
Radioactive PCR, using [a32P] dCTP (2.18.2) and primers specified in Table 11
(page 80) was performed to further identify those transcripts that could not be
detected by the colony hybridisation technique. Individual DNA fragments excised
from the gel, were re-amplified in a 40-cycle RT-PCR reaction and ligated into a
TOPO TA vector (see section 2.17.1.2). Clones representing each DNA fragment
were sequenced and 5 transcripts were identified, which were the a (535bp), (3
(440bp), y (386bp), 8 (291bp) and C, (249bp) transcripts (figure 46). Sequencing of
the other cloned fragments revealed that they did not derive from the p73 gene.
3.6.6.4 a2 isoforms of p73 are expressed in both HIV-PGL and normal lymph
nodes and tonsils
RT-PCR to detect p73 variants that lack exon 2 was performed using primers that
amplify a 344bp region of p73 (Ng et al., 2000). The sense primer was located in
exon 1 and the antisense primer in exon 4 (Table 11, page 80). Following
amplification RT-PCR products were hybridised to a [y32P] ATP-labelled p73
oligonucleotide (Table 11, page 80) located in exon 3.
The full-length transcript was not detectable in any of the samples analysed. A
smaller fragment (242bp), representing the A2 p73 variant was detected in 16/16
HIV-PGL tissue (figure 47A) and in 8/15 HIV-uninfected samples (figure 47B). RT-
PCR products were re-hybridised to a probe in exon 2 (Table 11, page 80). The
absence of detectable product confirmed that only the a2 p73 variant was expressed
in all samples analysed.
3.6.6.5 Hypermethylation of p73 is not detectable in PGL
To assess whether p73 is silenced by hypermethylation in HIV-infected individuals
with PGL, which might suggest a tumour suppressor role for this gene, methylation-
specific PCR (MSP) was performed using primers specific for the methylated and
unmethylated reactions (Table 23, page 104). Methylated and unmethylated human
genomic DNA (Intergen, U.S.A) was used as positive and negative controls
respectively. In addition, Burkitt's lymphoma (BL) cell lines, Raji and Namalwa
were also analysed, which have documented hypermethylation in the pl6INK4a and
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Figure 46. Radioactive RT-PCR to detect splice variants of p73
427/417/413 —
200 —
cDNA synthesised from 40ng of RNA from HIV-infected PGL tissue was
subjected to amplification in a 40-cycle p73 RT-PCR, and 10pCi of [a32P]
dCTP was included in each reaction. 3pl of radiolabeled PCR product was
mixed with 3pl of loading dye, containing formamide, heat-denatured and
resolved on a 6% denaturing polyacrylamide gel. M: Hinfl digested c|>X-174
DNA size marker (fragment sizes in bp). Lanes 1,3 and 5: Blank. Lanes 2,4
and 6: HIV-infected PGL tissue.
Upon sequencing, bands A-E were identified as A: a transcript (535bp), B: p
transcript (440bp), C: y transcript (386bp), D: e transcript (291 bp), F: C,
transcript (249bp) respectively.
146
Figure 47. Detection of the a2 p73 variant in HIV-PGL and
HIV-uninfected tissue
47 A
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
47 B
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
—242bp
P-actin
cDNA synthesised from 40ng of RNA was subjected to amplification in a 35-cycle
RT-PCR reaction using primers for the detection of the A2 p73. 20pl of the RT-
PCR product was resolved on a 2% w/v agarose gel, Southern transferred to a
Hybond N+ membrane and hybridised with a 32P-labelled p73 oligonucleotide
located in exon 3. M: Hinfl digested (|)X-174 DNA size marker (fragment sizes in
bp). The presence of amplifiable cDNA is indicated by amplification of p-actin.
Figure 47A Lane 1: SDW Lane 2&15: Blank Lanes 3-18: PGL samples.
Figure 47B Top panel (96 hour exposure) Lanes 1-7: HIV-uninfected tonsils
Lanes 8-15: HIV-uninfected lymph nodes Lane 16: Vulval squamous carcinoma
(5T). The A2 variant of p73 (242bp) is indicated.
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pl5INK4b genes (Klangby et al., 1998 and see Table 29). The methylation status of the
p73 gene in these cell lines was assessed in this study.
Methylation of the p73 gene was not found in any of the HIV-infected PGL samples.
Methylation analysis of the BL cell lines indicated complete methylation of the
Namalwa cell line (figure 48, lane 23). The Raji cell line contained both methylated
as well as unmethylated copies of the gene (Table 29), but this cell line was not
included for MSP analysis in this experiment. Amplification of the positive control
methylated DNA (figure 48, lane 22) with only the methylated primer set, and the
unmethylated control DNA with the unmethylated primer set (figure 48, lane 21),
confirmed the specificity of the PCR. These results suggest that hypermethylation of
p73 is not characteristic of HIV-infected PGL.
Table 29
Methylation status of pl6INK4a, pl5INK4b and p73 in BL cell lines Raji and
Namalwa
BL cell line pl6,NK4a pl5INK4b p73'
Raji + (+) (+) :
Namalwa + (+) +
BL, Burkitt's lymphoma; +, complete methylation; (+), partial methylation; , methylation status
assessed in this study
3.6.7 Analysis of p63 expression in HIV-PGL and HIV-uninfected tissue
3.6.7.1 TA is the predominant isoform of p63 expressed in lymphoid tissue
RT-PCR was performed to assess expression of TA p63 in lymph node and tonsil
tissue. These primers amplify a 629bp fragment, with the sense primer located in
exon 2 and the antisense primer in exon 5 (Table 11). Following amplification, RT-
PCR products were hybridised to a [y32P] ATP-labelled p63 oligonucleotide (Table
10) located in exon 3.
Expression of TA p63 was observed in 14 of 19 (73%) PGL samples (figure 49A,
lanes 2-6,8,9, and 12-17 and figure 49B, lane 2). The transcript was also detected in
1 tonsil (figure 49B lane 10) and in 5 of 9 (55%) HIV-uninfected lymph nodes
(figure 49B lanes 12,14 and 16-18).
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Figure 48. Methylation status of the p73 gene in HIV-PGL
1 2 3456789 10 11 12
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40 ng of genomic DNA modified by sodium bisulphite was used in a 35-cycle MSP
reaction to amplify 60bp and 69bp fragments of the p73 gene, using primers
specific for the methylated and unmethylated reactions respectively. 20pl of the
PCR product was resolved on a 3% w/v agarose gel and the bands were
visualised under UV light. L: A 100bp DNA size marker (fragment sizes in bp). U:
Unmethylated DNA. M: Methylated DNA.
Lanes 1 to 20: PGL samples. Lane 21: Unmethylated control DNA. Lane 22:
Methylated control DNA. Lane 23: Namalwa cell line. The unmethylated (69bp)
and methylated (60bp) products are indicated.
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Figure 49. Detection of TA p63 transcripts in HIV-PGL and
HIV-uninfected tissue
49 A
Ml 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 181920
726/713 —
553 —
500 —t #1- ft • • t
P-actin — I
49 B
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
t i726/713 — I553 -■ W ~ 629bP500 —j
P-actin
A 629bp region of p63, specific for the TA isoform, was amplified from cDNA in a
30-cycle RT-PCR reaction. 20pl of PCR product was resolved on a 2% w/v
agarose gel. PCR products were transferred to Hybond N+ membrane and probed
with a 32P-labelled oligonucleotide located in exon 3. M: Hinfl digested <(>X-174
DNA size marker (fragment sizes in bp). The presence of amplifiable cDNA is
indicated by the amplification of p-actin. The TA p63 RT-PCR product (629bp) is
indicated.
Figure 49 A
Lane 1: Blank Lanes 2-19: PGL samples Lane 20: cDNAfrom lymphoblastoid cell
line (PD-LCL).
Figure 49 B
Lane 1: Blank Lane 2: PGL sample Lane 3: Sterile distilled water Lanes 4-10:
HIV-uninfected tonsils Lanes 11-19: HIV-uninfected lymph nodes.
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3.6.7.2 The AN isoform of p63 is expressed only in HIV-uninfected tonsils
RT-PCR was performed to analyse the expression of AN p63. Primers were designed
to amplify a 440bp region, with the sense primer located in exon 3' and the antisense
primer located in exon 5 (Table 11, page 80). Following amplification, RT-PCR
products were hybridised to a [y32P] ATP-labelled p63 oligonucleotide (Table 11,
page 80) located in exon 4.
Expression of AN p63 was only observed in the HIV-uninfected tonsils, with a 440bp
fragment being detected in 6 of 7 tonsils (85%) (figure 50B, lanes 4-8 and 10). There
was complete absence of expression in the PGL samples and HIV-uninfected lymph
nodes (figure 50A, lanes 2 to 19 and figure 50B, lanes 11-19).
3.7 Genetic, epigenetic and expression analysis of the INK4 locus in PGL
Tumour suppressor roles for the cyclin-dependent kinase inhibitors, pl6INK4a and
pl5INK4b in human cancer have been well established (see section 1.5.5). A putative
tumour-suppressor role has been suggested for the alternate protein product of the
INK4A locus, designated pl4ARF in humans and pl9ARF (ARF for alternate reading
frame) in the mouse, based on gene targeting studies in mice. Although exon ip
mutations are rare, exon 2 mutations affecting both pl6INK:4a and pl4ARF have been
reported (Sanchez-Cespedes et al., 1999; Rizos et al., 2000). Deletion of exon ip of
p 1 4arf has been reported in hepatocellular and gastric carcinomas (Jin et al., 2000;
lida et al., 2000). In addition, hypermethylation of the promoter region of ARF has
been described in some human colorectal and gastric tumours (Esteller et al., 2000;
lida et al., 2000).
In NHLs that arise in immunocompetent hosts, deletions and transcriptional silencing
via aberrant promoter hypermethylation are the most common mechanisms of INK4a
and INK4b inactivation. Both genes are subject to hypermethylation in high-grade B-
cell lymphomas (Herman et al., 1997). Inactivating mutations in pl51NK4b and those
that target exon la and exon 2 of pl6INK4a are rarely observed (<1%) in these
malignancies.
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Figure 50. Detection of AN p63 transcripts in HIV-PGL
and HIV-uninfected tissue
50 A
Ml 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
726/713 —
50 B
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 1920
A 440p region of p63 was amplified from cDNA in a 30-cycle RT-PCR reaction. 20pl
of PCR product was resolved on a 2% w/v agarose gel. PCR products were
transferred to Hybond N+ membrane and probed with a 32P-labelled oligonucleotide
located in exon 4. M: Hinfl digested cj)X-174 DNA size marker (fragment sizes in
bp). The presence of amplifiable cDNA is indicated by the amplification of p-actin.
The AN p63 RT-PCR product (440bp) is indicated.
Figure 50 A
Lane 1: Blank Lanes 2-19: PGL samples.
Figure 50 B
Lane 1: Blank Lane 2: PGL sample Lane 3: Sterile distilled water Lanes 4-10: HIV-
uninfected tonsils Lanes 11-19: HIV-uninfected lymph nodes Lane 20: cDNA from
squamous cell cancer (S1).
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Given the importance of these genes in neoplasia, the studies described in this
chapter were carried out to assess whether changes in structure, expression and/or
gene hypermethylation ofmembers of the INK4 locus occur in HIV-related PGL.
3.7.1 SSCP analysis of the INK4a/ARF locus
To determine whether the INK4a/ARF locus is structurally altered in HIV-infected
PGL, SSCP-PCR was performed on genomic DNA, using primers that amplify a
278bp fragment in exon la and 243bp and 241bp fragments in exon 2 (fragments 2a
and 2b respectively). Exon 1 (3 was analysed from cDNA (Table 18, page 92). Since it
was not possible to obtain positive controls, it was decided that any sample with a
migration pattern different from that observed in the negative (normal) control would
be cloned and sequenced. Mobility shifts indicative of sequence changes were not
observed in exons la, ip or 2 (figures 51 to 53 respectively) by SSCP analysis of the
corresponding exons.
3.7.2 Analysis of expression of pl6INK4a, pl4ARF and pl5IINK4b in HIV-infected
and uninfected tissue
(i) Expression of pi 6INK4a
The pl6INK4a tumour suppressor gene product acts as a negative regulator of
proliferation by inhibiting the activity of CDK4, thus preventing the phosphorylation
of pRb and subsequent Gl/S progression (see section 1.5). Expression of pl6INK4a
was analysed in HIV-infected lymphoid tissue by RT-PCR, using a sense primer in
exon la and an antisense primer in exon 2, followed by hybridisation of the
amplified products to a 32P-labelled pl6INK:4a cDNA.
pl6INK"4a mRNA was detected in 16 of 16 (100%) HIV-infected PGL samples tested
(figure 54A, lanes 2 to 19). 3 PGL samples were unavailable for analysis due to
insufficient material. In addition, the gene was expressed in all (16/16) of the HIV-
uninfected lymph nodes and tonsils (figure 54B, lanes 2 to 17).
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Figure 51. SSCP analysis of exon 1a in PGL
1 23 456789 10 N
Figure 52. SSCP analysis of exon 1(3 in PGL
1 2 3 4 56 78 9 10 11N
Figure 53. SSCP analysis of exon 2a in PGL
1 23456789 1011 N
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Figure 51. SSCP analysis of exon 1a of p16INK4a. 500ng of DNA was subjected to
amplification using the appropriate primers (Table 18). 3pl of radiolabeled PCR product was
mixed with 3pl of loading dye. Samples were heat-denatured at 94°C for 5 minutes, then
resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol. Dried gels were exposed to
Kodak XR film at -70°C for 2-3 days with intensifying screens. Lanes 1-10: PGL samples N:
Normal control (DNA from fibroblasts).
Figure 52. SSCP analysis of exon 1(3 of p14ARF. 500ng of DNA was subjected to
amplification using the appropriate primers (Table 18). 3pl of radiolabelled PCR product was
mixed with 3pl of loading dye. The samples were heat-denatured at 94°C for 5 minutes, then
resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol. Dried gels were exposed to
Kodak XR film at -70°C for 2-3 days with intensifying screens. Lanes 1-4, 6,8,10,11: PGL
samples Lanes 5,7 & 9: Blank N: Normal control (DNA from fibroblasts).
Figure 53. SSCP analysis of exon 2a of p16INK4a. SSCP of the 5' half of exon 2 (2a) of
p16INK4a. 500ng of DNA was subjected to amplification using the appropriate primers (Table
18). 3pl of radiolabelled PCR product was mixed with 3pl of loading dye. The samples were
heat-denatured at 94°C for 5 minutes, then resolved on a 6% polyacrylamide (PAGE) gel
with 10% glycerol. Dried gels were exposed to Kodak XR film at -70°C for 2-3 days. Lanes
1-11: PGL samples N: Normal control (DNA from fibroblasts).
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A 139bp region of p16INK4a was amplified from cDNA in a 22-cycle RT-PCR
reaction. 20pl of the product was resolved on a 2% w/v agarose gel, then
transferred to a Hybond N+ membrane and probed with a 32P-labelled p16INK4a
cDNA. M: Hinfl digested <j>X-174 DNA size marker (fragment sizes in bp). The
p16'NK4a rt-PCR product (139bp) is indicated. The presence of amplifiable
cDNA is indicated by the amplification of p-actin.
Figure 54 A
Lane 1: Sterile distilled water Lanes 2-17: HIV-infected PGL samples Lane 18:
cDNA from breast tumour Lane 19: Lymphoblastoid cell line (PD-LCL).
Figure 54 B
Lane 1: Blank Lanes 2-8: HIV-uninfected tonsils Lanes 9-17: HIV-uninfected
lymph nodes Lane 18: cDNA from breast tumour Lane 19: Lymphoblastoid cell
line (OTIS).
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(ii) Expression of pl4ARF
Deregulation of pl4ARF occurs in cells that are functionally null for p53. pl4ARF can
suppress oncogenic transformation in primary fibroblasts via p53-dependent as well
independent mechanisms (Pomerantz et al., 1998; Weber et al., 2000). Hence it was
decided to investigate whether the PGL samples with p53 mutations expressed the
p i 4arf transcript at higher levels than those samples, which lacked p53 mutation.
Initial experiments were designed to determine appropriate conditions for semi¬
quantitative assessment of relative expression levels of pl4ARF, by optimising the
cycle number for RT-PCR amplification of the gene (figure 55A and 55B). cDNA
from a vulval squamous cell cancer that was known to be positive for pl4ARF
expression was subjected to 15-30 cycles of amplification, to amplify a 188bp
fragment using a sense primer in exon 1(3 and an antisense primer in exon 2 of
INK4a/ARF (see Table 11, page 80), followed by hybridisation of the amplified
products to a 32P-labelled pl4ARF cDNA as described in sections 2.12 and 2.13
(figure 55A, lanes 1 to 4 respectively). Band intensity was measured using scanning
densitometry (UVP Gel Works). The optimum cycle number was determined to be
22 cycles, between 20 and 25 cycles (exponential phase of the amplification curve)
(figure 55B).
RT-PCR of the HIV-infected and uninfected samples was performed at 22 cycles.
pl4ARF mRNA was detected in 19/19 of the PGL samples (figure 56A, lanes 1-19)
and in all (14/15) the HIV-uninfected samples, except in one lymph node (figure 56B
lane 12). Elevated steady-state levels of pl4ARF mRNA, indicative of possible
deregulation, was not observed in those samples with missense mutations in p53
(figure 56A, lanes 4, 7, 11, 12).
(iii) Expression of pi 5INK4b
p 15tNK4b another member of the INK4 family of proteins that can specifically bind
to CDK4/6 and impose a G1 phase cell cycle arrest, provided the cell contains
functional pRb. RT-PCR to analyse expression of this gene was performed using a
sense primer that was common to both pl6INK4a and pl5INK4b and an antisense primer
located in exon 2 of the pl5INK4b gene, followed by hybridisation of the amplified
products to a 32P-labelled oligonucleotide located in exon 2 of the pl5INK4b gene.
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Figure 55. Determination of optimal cycle number for
semi-quantitative analysis of p14ARF expression
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A 188bp region of p14ARF was amplified at 15, 20, 25 and 30 cycles, using cDNA
from a vulval squamous cancer cell line. 20pl of the PCR product was resolved on a
2% w/v agarose gel, then transferred to a Hybond N+ membrane and probed with a
32P-labelled p14ARF cDNA. M: Hinfl digested t|)X-174 DNA was used as a DNA size
marker (fragment sizes in bp).
Figure 55 A: Lanes 1 to 4: 15, 20, 25 and 30 cycles of amplification respectively.
Figure 55 B: The intensity of the bands, obtained after hybridization of the p14ARF
RT-PCR product with a 32P-labelled cDNA, was measured using scanning
densitometry (UVP Gel Works). A graph was then plotted with the cycle number on
the X-axis and the band volume on the Y-axis. The optimal cycle number for the
p14ARF RT-PCR was determined to be 22 cycles, which is on the exponential portion
of the amplification curve.
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Figure 56. Analysis of p14ARF mRNA expression in HIV-PGL
and HIV-uninfected tissue
56 A
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
A 188bp region of p14ARF was amplified from cDNA in a 22-cycle RT-PCR reaction.
20pl of the PCR product was resolved on a 2% w/v agarose gel, then transferred to a
Hybond N+ membrane and probed with a 32P-labelled p14ARF plasmid. M: Hinfl
digested <(>X-174 DNA size marker (fragment sizes in bp). The p14ARF RT-PCR
product (188bp) is indicated. The presence of amplifiable cDNA is indicated by the
amplification of p-actin.
Figure 56 A: Lanes 1-19: HIV-infected PGL samples. The * indicates PGL samples
with p53 mutation.
Figure 56 B: Lanes 1-7: HIV-uninfected tonsils. Lanes 8-15: HIV-uninfected lymph
nodes. Lanes 16 and 17: cDNA from vulval cancers (T1 and T2). Lane 18: Sterile
distilled water.
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pl5'NK4b mRNA was detected in 16/16 HIV-infected lymph nodes tested (figure 57A,
lanes 2 to 17). 3 PGL samples were unavailable for analysis due to insufficient
material. The gene was expressed in all the HIV-uninfected tonsils (figure 57B, lanes
1 to 7), in contrast to expression in only 1 HIV-uninfected lymph node (figure 57B,
lane 11).
3.7.3 Methylation analysis of pl6,NK4a and pl5INK4b
Although expression of pl6INK4d and pl5INK4b could be detected in all HIV-PGL
samples analysed, it is possible that partial methylation could have contributed to the
low or null expression that was observed in some of the samples (see figures 54A
and 57A). Therefore, to assess the methylation status of the INK4a and INK4b genes
in HIV-PGL, DNA from 22 of 24 HIV-infected PGL samples was chemically
modified using sodium bisulfite (see section 2.19.1), and subjected to MSP analysis
(see section 2.19.2) using primers specific for the unmethylated and methylated
reactions (Table 23, page 104).
Methylation of the pl6INK4a and pl5INK4b genes was not detected in any of the PGL
samples (figures 58 and 59). However methylation was observed in the BL cell lines
Namalwa and Raji (positive controls). Both cell lines contained methylated copies of
the pl6INK4a gene (figure 58, lanes 22 and 23 respectively), whereas the pl51NK4b
gene was found to be partially methylated (containing both methylated and
unmethylated alleles) in both these BL cell lines (figure 59, lanes 23 and 24). These
results are in agreement with previous studies (Klangby et al., 1998).
The data indicates that methylation of pl61NK4a and pl5INK4b is not a common event
in PGL.
3.8 Analysis of structural alterations in c-myc, bcl-2 and bcl-6 in PGL
3.8.1 Analysis of the t(8:14) translocation
The t(8; 14) (q24;q32) translocation between the c-myc gene (8q24) and the
immunoglobulin heavy chain (IgH) locus (14q32) is the most frequent genetic
alteration described in endemic Burkitt's lymphoma (eBL), sporadic BL (sBL) and
AIDS-BL (Dalla-Favera et al., 1982b, Gaidano et al., 1997b). The breakpoint in
AIDS-BL and sBL is preferentially located within intron 1 or exon 1 of c-myc and in
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Figure 57. Analysis of p15INK4b mRNA expression in HIV-PGL
and HIV-uninfected tissue
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
A 346bp region of pi5iNK4b was subjected to amplification in a 28-cycle RT-
PCR reaction. 20pl of the PCR product was resolved on a 2% w/v agarose gel,
then transferred to a Hybond N+ membrane and probed with a 32P-labelled
p15'NK4b oligonucleotide located in exon 2. M: Hinfl digested <j)X-174 DNA size
marker (fragment sizes in bp). The pl5|NK4t> RT-PCR product (346bp) is
indicated. The presence of amplifiable cDNA is indicated by the amplification
of p-actin.
Figure 58 A: Lane 1: Sterile distilled water Lanes 2-17: HIV-infected PGL
samples.
Figure 58 B: Lanes 1-7: HIV-uninfected tonsils Lanes 8-16: HIV-uninfected
lymph nodes Lane 17: BL-41 cell line.
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Figure 58. Methylation status of the p16INK4a gene in HIV-PGL tissue
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40 ng of DNA modified by sodium bisulphite was used in a 35-cycle MSP
reaction to amplify a 145bp and 154bp region of the p16INK4a gene, using
primers specific for the methylated and unmethylated reactions respectively.
20pl of the PCR product was resolved on a 3% w/v agarose gel and the bands
were visualised under UV light.
L: A 100bp DNA size marker (fragment sizes in bp).
U: Unmethylated DNA. M: Methylated DNA.
Lanes 1 to 20: HIV-infected PGL samples. Lane 21: Unmethylated control
DNA. Lane 22: Namalwa cell line. Lane 23: Raji cell line. Lane 24:
Methylated control DNA.
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Figure 59. Methylation status of the p15INK4b gene in HIV-PGL tissue
1 2 3 4 5 6 7 8 9 10 11 12 13
14 15 16 17 18 19 20 21 22 23 24 25
40 ng of DNA modified by sodium bisulphite was used in a 35-cycle MSP
reaction to amplify a 154bp and 162bp region of the pl5INK4b gene, using
primers specific for the methylated and unmethylated reactions respectively.
20pl of the PCR product was resolved on a 3% w/v agarose gel and the bands
were visualised under UV light.
L: A 100bp DNA size marker (fragment sizes in bp). U: unmethylated DNA. M:
Methylated DNA.
Lanes 1 to 21: HIV-infected PGL samples. Lane 22: Unmethylated control
DNA. Lane 23: Namalwa cell line. Lane 24: Raji cell line. Lane 25: Methylated
control DNA.
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the switch region (s) of the IgH locus (Neri et al., 1991).
Thus, to analyse whether rearrangement of c-myc is a characteristic feature of HIV-
associated PGL syndrome, LD-PCR amplification of the c-myc/IgH switch junctions
was carried out, using primers specified in Table 14, page 85.
LD-PCR of the HIV-infected PGL tissue did not reveal any translocations, although
the positive control for each primer pair was successfully amplified: Raji cell line
using the c-myc/Cy primer pair (figure 60A, lane 1), Ramos cell line using the c-
myc/C\x primer pair (figure 60B, lane 1) and the BL-41 cell line using the c-myc/Ca
primer pair (figure 60C, lane 1).
However, LD-PCR analysis for the t(8:14) translocation in HIV-uninfected lymph
nodes and tonsils revealed positive amplification in a single lymph node tissue, case
number 2435, using the c-myc/Cy primer set (figure 60A, lane 9). The breakpoint
region in this material was identified by cloning and sequencing of the PCR product.
In 6/6 clones that were examined the breakpoint was identified in the 5' flanking
region of c-myc, 424bp upstream of the 1st exon (nucleotide position 1904, antisense
strand, Genbank accession X00364), and in the Sy4 region of the IgH locus
(nucleotide position 3431, sense strand, Genbank accession X56796) (figures 61A
and 6IB, page 167). Fusion of the chromosomal segments was imprecise, with an
insertion of 6 nucleotide residues, mapping neither to the c-myc nor Sy4 regions at
the interchromosomal junction (figures 61B and 61C, page 167).
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Figure 60. Analysis of c-myc translocations by LD-PCR
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Figure 60. Analysis of c-myc translocations by LD-PCR. 100ng of genomic DNA from
HIV-infected PGL tissue and HIV-uninfected lymph nodes and tonsils was subjected to
amplification in a 35-cycle LD-PCR reaction using the c-myc/Cy, c-myc/Cy, and c-myc/Ca
primer pairs. 20gl of the PCR products were resolved on a 0.8% w/v agarose gel, transferred
to a Hybond N+ membrane and hybridised with a [y32P] ATP-labelled oligonucleotide probe
specific to exon 2 of the c-myc gene. M: Lambda (X) DNA digested with Hind III DNA size
marker (fragment sizes in bp). The presence of ampiifiable DNA is indicated by amplification
of p-globin.
Figure 60 A. c-myclCy LD-PCR
Lane 1: Raji cell line (7.6kb band is indicated) Lanes 2 to 8: HIV-uninfected tonsils Lane 9:
HIV-uninfected lymph node with a t(8:14) translocation Lanes 10 to 14: HIV-uninfected
lymph nodes Lane 15: P3HR1 cell line (negative control).
Figure 60 B. c-myclC\i LD-PCR
Lane 1: Ramos cell line (4.9kb band is indicated) Lanes 2 to 13: HIV-PGL samples Lane
14: P3HR1 cell line (negative control).
Figure 60 C. c-mycICa LD-PCR
Lane 1: BL-41 cell line (4.0kb band is indicated) Lanes 2 to 13: HIV-PGL samples Lane 14:
P3HR1 cell line (negative control).
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Figure 61. t(8:14) chromosomal breakpoint in an
HIV-uninfected lymph node (case no. 2435)
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Figure 61. t(8:14) chromosomal breakpoint in an HIV-uninfected lymph node (case no.
2435). Genomic DNA from case 2435 was subjected to amplification using the c-myc/Cy
primer pair and the product was ligated directly into the pCR®4-TOPO® vector. Cloned DNA
was then sequenced using the LICOR 4000L automated sequencer (MWG Biotech, Milton
Keynes, UK), and the Sequitherm Excel™ II kit (Cambio, Cambridge, UK).
Figure 61 A. Schematic representation of the t(8:14) breakpoint observed in case 2435.
A black arrow indicates the position of the breakpoint, between the 5' flanking region of c-
myc and the Sy4 region of the IgH locus.
Figure 61 B. Sequence of the t(8:14) chromosomal breakpoint junction. The c-myc
gene is indicated in blue and the Sy4 gene in black. The two genes are placed in a head-to-
head orientation. The positions of the breakpoint in the 5' flanking region of c-myc
(nucleotide position 1904, antisense strand, Genbank accession X00364), and in the Sy4
region of the IgH locus (nucleotide position 3431, sense strand, Genbank accession X56796)
are indicated. An insertion of 6 nucleotide residues at the interchromosomal junction is
indicated in red.
Figure 61 C. Pictorial representation of the c-myc/Sy4 breakpoint sequence. The c-myc
gene is indicated in blue. The Sy4 gene is indicated in black. The insertion of 6 residues at
the breakpoint junction is indicated in red.
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3.8.2 Analysis of the t(14:18) translocation
The t( 14; 18) (q32;q21) translocation involving the immunoglobulin heavy chain
gene (IgH) and the bcl-2 gene respectively, is the most common chromosomal
translocation in follicular lymphoma (85%) and diffuse large-cell lymphomas (30%)
(Yunis et al., 1987). More than 70% of the translocations in the bcl-2 gene are
clustered in a 150bp segment at the 3' untranslated region, designated the major
breakpoint region (MBR) and a small number of translocations have been identified
at a site 30kb 3' to the MBR called the minor cluster region (mcr) (Tsujimoto et al.,
1985; Cleary et al., 1986). The corresponding breakpoints on chromosome 14 occur
predominantly at or close to the members of the joining region genes (JH) (Bakhshi
et al., 1987). To investigate whether bcl-2 translocations occur in HIV-associated
PGL syndrome, LD-PCR of both the MBR and mcr regions and upstream of these
regions on the bcl-2 locus was carried out.
Figures 62A and 62B are representative autoradiographs of LD-PCR amplification of
the t(14:18) translocation using MBR-l/Ep and mcr-2/Ep primer sets respectively.
Although the sensitivity of the primers were confirmed for the bcl-2 LD-PCR
analysis (see section 3.4.1.4) and the primers could detect translocations known to be
present in lymph node positive controls 1119 and 1143 (figure 62A, lane 15 and
figure 62B, lane 1 respectively), translocations were not detected in the present series
of PGL samples or HIV-uninfected individuals.
It was thus concluded that chromosomal aberration involving the bcl-2 gene is not an
early characteristic feature of HIV-associated lymphomas. This observation is
consistent with previous studies that have reported lack of involvement of the bcl-2
gene in AIDS-NHL (Subar et al., 1988; Gaidano et al., 1997b; Davi et al., 1998).
3.8.3 Analysis of bcl-6 mutations in HIV-PGL
In contrast to the coding region of bcl-6, its 5' non-coding region displays extensive
structural instability (Ye et al., 1993; Capello et al., 2000). Rearrangements of bcl-6
with heterogeneous promoters occur in approximately 40% of diffuse large-cell
lymphomas and 6-14% of follicular lymphomas in the immunocompetent host (Lo
Coco et al., 1994). In HIV-infected individuals alterations are detectable in 20% of
AIDS-DLCL (Gaidano et al., 1994).
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Figure 62. Analysis of bcl-2 translocations by LD-PCR
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100ng of genomic DNA from HIV-PGL tissue and HIV-uninfected lymph nodes and
tonsils was subjected to amplification in a 35-cycle LD-PCR reaction using the
MBR-1/Ep, mcr-2/Ep primer pairs. 20pl of the PCR product was resolved on a
0.8% w/v agarose gel, transferred to a Hybond N+ membrane and hybridised with a
[y32P] ATP-labelled oligonucleotide probe in the Ep region of the IgH locus. The
presence of amplifiable DNA is indicated by amplification of p-globin. M: Lambda
(A.) DNA digested with Hind III DNA size marker (fragement sizes in bp).
Figure 63 A: Lane 1: Sterile distilled water Lane 2: Lymph node 761 (negative
control) Lanes 3 to 14: HIV-PGL samples Lane 15: Lymph node 1119 (4.2kb band
is indicated).
Figure 63 B: Lane 1: Lymph node 1143 (6.0kb band is indicated) Lane 2: Sterile
distilled water Lane 3: Lymph node 761 (negative control) Lanes 4 to 15: HIV-PGL
samples.
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In addition to translocations and small intragenic deletions, which can deregulate bcl-
6 expression (Ye et al., 1995a; Nakamura et al., 1999), this region is targeted by
somatic mutations, both in GC-derived tumours and in normal B cells (Migliazza et
al., 1995; Shen et al., 1998). These 5' bcl-6 mutations are detectable in about 70% of
DLCL and 45% of FL, are bi-allelic and present in both germline and translocated
bcl-6 alleles. Furthermore, they also occur independently of translocation, as seen in
70% of AIDS-NHL (excluding DLCL), certain B-NHL without a 3q27 abnormality,
and 28 to 50% of non-AIDS BL (Gaidano et al., 1997d; Capello et al., 1997).
To determine the frequency of mutations in bcl-6 in both FHV-infected and
uninfected tissue, SSCP analysis of a 735bp region was performed, which represents
a mutational hot-spot, harbouring more than 90% of bcl-6 mutations reported in
diffuse large-cell and follicular lymphoma (Migliazza et al., 1995).
3.8.3.1 SSCP variants in bcl-6 are detected in HIV-infected and uninfected tissue
Mutations in bcl-6 were sought in PGL samples and in uninfected lymph nodes and
tonsil controls using SSCP. Three partially overlapping PCR fragments (El. 10,
El.11 and El.12) spanning a 735bp region, located lOObp downstream of the first
bcl-6 non-coding exon (Migliazza et al., 1995) were amplified in separate reactions
using primers specified in Table 19, page 92. The first nucleotide of bcl-6 cDNA
from the reported germline database sequence (Genbank accession number Z79581)
was arbitrarily chosen as position +1 (Migliazza et al., 1995), and the amplified bcl-6
5' intronic region spanned +406 to +1140.
All samples with a mobility pattern different from that of the normal (negative)
control were scored as positive. Abnormally migrating samples are indicated in blue.
SSCP variants were detected in 3/23 PGL samples in El.10 (figure 63B, lanes 3,11
and 20), 7/23 PGL samples in El. 11 (figure 64B, lanes 4,8,11,12,16,18,19) and in
10/23 PGL samples in El.12 (figure 65B, lanes 1,2,5,6,9,12,13,15,16,19; see Table
32, page 181). In the HIV-uninfected tissue, variants were observed in 4/16 samples
in E 1.11 (figure 64A, lanes 2,8,9,10) and in 7/16 samples in El. 12 (figure 65A, lanes
1,2,3,8,10,11,14) (see Table 32, page 181). All those samples with a mobility shift
were re-amplified using a high-fidelity enzyme, Pfx polymerase, and subsequently
cloned (see section 2.17.1.3) and sequenced (see section 2.18.1).
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Figure 63. SSCP analysis of fragment E1.10 of bcl-6. 500ng of DNA was subjected to
amplification using primers E1.10 5' and E1.10 3'. 3pl of radiolabeled PCR product was
mixed with 3pl of loading dye. The samples were heat-denatured at 94°C for 5 minutes and
resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol. After being dried the gel
was exposed to Kodak XR film at -70°C for 2-3 days with intensifying screens. Abnormally
migrating samples are indicated in blue.
Figure 63 A. Lane 1: Blank Lanes 2-8: HIV-uninfected tonsils Lanes 9-17: HIV-uninfected
lymph nodes N: Negative control (Raji cell line).
Figure 63 B. Lanes 1-22: HIV-PGL samples Lanes 3,11 and 20: Abnormally migrating
samples (LN 5, 15 and 24 respectively) N: Negative control (Raji cell line).
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Figure 64. SSCP analysis of fragment E1.11 of bcl-6. 500ng of DNA was subjected to
amplification using primers E1.11 5' and E1.11 3'. 3pl of radiolabeled PCR product was
mixed with 3pl of loading dye. The samples were heat-denatured at 94°C for 5 minutes and
resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol. After being dried the gel
was exposed to Kodak XR film at -70°C for 2-3 days with intensifying screens. Abnormally
migrating samples are indicated in blue.
Figure 64 A. Lanes 1-5: HIV-uninfected tonsils Lanes 6-10: HIV-uninfected lymph nodes
Lanes 2,8,9 and 10: Abnormally migrating samples (T2, 2478, 2495 and 2499 respectively)
N: Negative control (Namalwa cell line).
Figure 64 B. Lanes 1-22: HIV-PGL samples Lanes 4,8,11,12,16,18,19: Abnormally
migrating samples (LN 9,12,1,15,17, 14 and 20 respectively) N: Negative control (Namalwa
cell line).
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Figure 65. SSCP analysis of fragment E1.12 of bcl-6
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Figure 65. SSCP analysis of fragment E1.12 of bcl-6. 500ng of DNA was subjected to
amplification using primers E1.12 5' and E1.12 3'. 3pl of radiolabeled PCR product was
mixed with 3pl of loading dye. The samples were heat-denatured at 94°C for 5 minutes and
resolved on a 6% polyacrylamide (PAGE) gel with 10% glycerol. After being dried the gel
was exposed to Kodak XR film at -70°C for 2-3 days with intensifying screens. Abnormally
migrating samples are indicated in blue.
Figure 65 A. Lanes 1-6: HIV-uninfected tonsils Lanes 7-14: HIV-uninfected lymph nodes
Lanes 1,2,3,8,10,11 and 14: Abnormally migrating samples (T1, T2, T3, 2435, 2462, 2478
and 2499 respectively) T: Positive control (Raji cell line) N: Negative control (Namalwa cell
line).
Figure 65 B. Lanes 1-22: HIV-PGL samples Lanes 1,2,5,6,9,12,13,15,16 and 19:
Abnormally migrating samples (LN1,3,6,8,12,16,17,20,19 and 23 respectively) T: Positive
control (Raji cell line) N: Negative control (Namalwa cell line).
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3.8.3.2 Mutations in bcl-6 are present at a higher frequency in HIV-PGL than in
uninfected control tissue
bcl-6 mutations were detected in 11/23 HIV-infected individuals and in 2/16 HIV-
uninfected controls (48% vs. 12.5% respectively, p<0.05, Fisher's exact test). A total
of 24 mutations were detected in the 735bp region analysed, with 19/24 (79%)
occurring in the PGL samples and 5/24 in the control samples (21%) (pO.OOl,
Fisher's exact test) (Tables 30A to C and Table 32, page 181). The 3 mutations
detected in fragment El. 10 were within a negative regulatory sequence in the first
intron of bcl-6.
The mutation frequency in both the HIV-infected and uninfected population was
calculated using the formula:
Number of mutations/ (Number of clones analysed x Sequence length of region
tested)
The mutation frequency was estimated to be between 9.8xl0"4 to 1.3xl0"3 per bp in
the HIV-infected group and 8.2x10"5 to 5xl0~4per bp in the uninfected group.
Table 30 A
Nucleotide substitutions in the bcl-6 intronic region +406 to +670 (El.10)
HIV status Case no. bcl-6 mutation* Polymorphic (nucleotide)
substitution
Allele
+ 5 T->C (575) None nk
+ 15 Ah>G (609) None nk
+ 24 T->C (556) None nk
*, intronic region amplified is +406 to +670 (+1 corresponds to the first nucleotide of bcl-6 cDNA,
Genbank accession number Z79581); +, positive; nk, not known
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Table 30 B
Nucleotide substitutions in the bcl-6 intronic region +654 to +867 (El.11)
HIV status Case no. bcl-6 mutation* Polymorphic (nucleotide)
substitution
Allele**
+ 1 C—>G (787) None C
C->A (790) C
T—»C (799) c
+ 9 G—»A (820) G-»C (753) A
T-»C (726) B
+ 14 G-vA (684) None nk
+ 15 G-»T (680) G—»C (753) A
+ 20 T-+C (714) G-*C (753) A
+ T—»C (729) G-»C (753) A
- 2499 T-»C (795) G—»C (753) A
T-+C (788) G-+C (753) A
T->G (788) B
*, intronic region amplified is +654 to +867 (+1 corresponds to the first nucleotide of bcl-6 cDNA,
Genbank accession number Z79581); **, polymorphic substitutions are arbitrarily designated on allele
A and are indicated in blue, C indicates mutations that exist on the same allele; negative; +, positive;
nk, not known
Table 30 C
Nucleotide substitutions in the bcl-6 intronic region +848 to +1140 (El.12)
HIV status Case no. bcl-6 mutation* Polymorphic (nucleotide)
substitution
Allele**
+ 6 C—»A (997) B
12 A-+G (1068) B
A-+G (1117) B
T-»G (901) AT (875) A
A->G (969) AT (875) A
+ 19 A—>T (1027) None nk
+ 23 T—»A (1094) B
- 2499 C-»A (903) B
- 2495 G-»A (878) None nk
*, intronic region amplified is +848 to +1140 (+1 corresponds to the first nucleotide of bcl-6 cDNA,
Genbank accession number Z79581);**, polymorphic substitutions are arbitrarily designated on allele
A and are indicated in blue; negative; +, positive; nk, not known
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Single nucleotide substitutions were the only type of mutation that was detected in
this study. Transitions were favoured over transversions accounting for
approximately 63% of mutations observed. Furthermore, preferential bias for T:N
over A:N target bases (see Table 31) was observed. Mutations were bi-allelic and
multiple within the same allele (LN 1 and LN 12). In cases LN 15 and 2499,
mutations were detected in more than one fragment (Tables 30A to C).
Table 31
Nature of bcl-6 mutations
A C G T Total
A -» - - 4 1 5
C-> 3 - 1 - 4
G > 3 - - 1 4
T —» 1 8 2 - 11
Total 7 8 7 2 24
3.8.3.3 Polymorphic variants in bcl-6
Nucleotide substitutions likely to represent population polymorphisms were
observed, a G to C change at position +753 in fragment El. 11 and a single base
thymidine deletion (AT) at position +875 in fragment El. 12. The polymorphism at
+753 was observed in 5/7 PGL samples and 4/4 HIV-uninfected samples with
abnormal mobility shifts by PCR-SSCP, and the polymorphism at +875 in 8/10 PGL
samples and 7/7 HIV-uninfected samples with abnormal PCR-SSCP shifts (see Table
32).
The polymorphic variants identified in this study, which have been described
previously (Migliazza et al., 1995), also permitted the identification of bi-allelic
mutations in bcl-6. Polymorphic substitutions in Tables 30B and 30C are indicated in
blue and are arbitrarily designated on allele A and those designated on allele B are
indicated in red. Mutations were detected in 4/9 individuals with a polymorphic
substitution at position +753 (LN 9,15,20 and 2499) (see Table 30B), and in 4/15
individuals with a substitution at +875 (LN 6, 12, 23 and 2499) (see Table 30C).
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8 of the total 12 mutations found in fragment El. 11 were associated with the
polymorphism at +753. Interestingly, of these mutations 6/8 (75%) was found on the
allele that had a cytosine substitution at position +753 (Table 30A). 7 of the total 9
mutations found in fragment El. 12 were associated with the polymorphism at +875.
5/7 (71%) of these mutations was on the allele that had a thymidine residue present at
position +875 (Table 30B). Polymorphic substitutions were not observed at position
+753 in LN 1 and LN 14 (Table 30B) and at position +875 in LN 19 and 2495 (Table
30C).
Table 32
Summary of structural changes in bcl-6 fragments El.10, El.11 and El.12
bcl-6 fragment SSCP variants Nucleotide substitutions
Polymorphism Mutation
HIV+ HIV" HIV+ HIV HIV+ HIV"
(23) (16)
El.10 3 - - - 3 -
El.11 7 4 5/7 4/4 9 3
El.12 10 7 8/10 7/7 7 2
3.9 Analysis of EBV and KSHV infection in HIV-PGL
Neoplasms arising in HIV-infected individuals are frequently associated with DNA
tumour viruses such as EBV, KSHV and HPV (Mueller, 1999; Feigal, 1999).
Approximately 30% of AIDS-NHL harbour EBV, although the frequency of
association rises to nearly 100% in HIV-related primary central nervous system
lymphoma and diffuse large-cell lymphomas of the immunoblastic subtype
(Knowles, 1997). KSHV is invariably associated with a distinct set of malignancies
in both HIV-infected and uninfected individuals, particularly, Kaposi's sarcoma,
multicentric Castleman's disease and primary effusion lymphomas (Boshoff and
Weiss, 1998; Cannon and Cesarman, 2000).
To address the presence and expression of EBV and KSHV in HIV-associated PGL
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and in uninfected lymph nodes and tonsils, PCR-based analysis of both genomic
DNA and mRNA was performed.
3.9.1 Detection of EBV in HIV-PGL using primers for the BamHl W repeat
sequence
The EBV W-repeat PCR, which detects the BamHl W repeat sequence of the EBV
genome, was used to determine the EBV status of PGL and of control tissues. The
sensitivity of the BamHl W primers was established in initial studies. Ten-fold
dilutions of the BL cell line Namalwa (which contains 1-2 copies of the EBV
genome per cell) in a background of 106 cells from an EBV negative cell line BJAB
were prepared (see section 2.8.3) and subjected to PCR analysis as described in
section 2.8.2.3 and Table 10, page 78. Under these assay conditions, the BamHl W
primers allowed detection of 10 copies of the EBV genome, as indicated by a 298bp
fragment (figure 66A, lane 7). The sensitivity of detection was increased by one
order of magnitude after hybridisation with a 32P-labelled oligonucleotide probe
(figure 66B, lane 8).
EBV was detectable in 12/14 (86%) HIV-uninfected lymph nodes and tonsils (figure
67, lanes 7 to 21). The EBV copy number was between 1 and 10 genomes per
million cells for all the samples that tested positive, except for one HIV-uninfected
lymph node, 2478 (figure 67, lane 16), which had an EBV load of >105 genomes per
million cells. EBV could not be detected in cases 2435 and 2512 (figure 67, lanes 13
and 21) even after repeat amplification in an independent PCR. Samples T3 and 2425
could not be analysed due to insufficient DNA.
EBV was detected in 23 of 23 (100%) PGL samples analysed (figures 68A and 68B).
The EBV genome copy number was greater than 10,000 copies per million cells in
74% (17/23) of the PGL samples, as determined by analysis of band intensity by
scanning densitometry (UVP Gel Works). The EBV genome copy number in 4/23
samples was between 1 and 100 genomes (figure 68A, lane 12; 68B, lanes 20,21 and
25). Samples LN18 and LN19 (figure 68A, lanes 6 and 7) that were initially negative
for the EB viral genome were found to harbour between 1-10 copies of the genome
through repeat amplification in an independent PCR and hybridisation of the PCR
product with a P-labelled oligonucleotide.
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Figure 67. Detection of EBV DNA in HIV-uninfected tissue
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Figure 66. Sensitivity of the EBV BamH1 W primers. The Burkitt's lymphoma cell line
Namalwa which contains 1-2 EBV genomes per cell was diluted ten-fold (106 cells to 1 cell
per reaction) in 106 cells from an EBV negative cell line BJAB. 28 cycles of PCR were
performed using BamH1 W primers. 20pil of the PCR product was resolved on a 2% w/v
agarose gel, visualised under UV light (Figure 66A), transferred to Hybond N+ membrane
and hybridised with a 32P-labelled oligonucleotide probe (Figure 66B).
Figure 66 A and 66 B. M: Hinfl digested <)>X-174 DNA size marker (fragment sizes in bp).
L: 1 kb DNA size marker (fragment sizes in bp). Lane 1: 106 BJAB cells Lane 2: 105
Namalwa cells Lane 3: Sterile distilled water Lanes 4-8: 104, 103, 102, 10 and 1 Namalwa
cell (s) respectively.
Figure 67. Detection of EBV DNA in HIV-uninfected tissue. 28 cycles of PCR were
carried out using BamH1 W primers. 20gl of the PCR product was resolved on a 2% w/v
agarose gel and the bands were visualised under UV light. The PCR products were then
transferred to Hybond N+ membrane and hybridised with a 32P-labelled oligonucleotide
probe. The presence of amplifiable DNA is indicated by the amplification of p-globin. The
BamH1 W fragment (298bp) is indicated. M: Hinfl digested 4>X-174 DNA size marker
(fragment sizes in bp). Lanes 1-6: 105, 104, 103, 102, 10 and 1 Namalwa cell (s) in a
background of 106 BJAB cells respectively Lanes 7-21: HIV-uninfected tonsils and lymph
nodes.
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Figure 68. Detection of EBV DNA in HIV-PGL tissue
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Figure 68. Detection of EBV DNA in HIV-PGL tissue. 28 cycles of PCR were carried out
using BamH1 W primers. 20pl of the PCR product was resolved on a 2% w/v agarose gel
and the bands were visualised under UV light. The PCR products were then transferred to
Hybond N+ membrane and hybridised with a 32P-labelled oligonucleotide probe, specific to
the amplified fragment.
DNA size markers: M: Hinfl digested <|>X-174 DNA size marker (fragment sizes in bp).
L: Unlabelled 1kb DNA size marker (fragment sizes in bp).
Figure 68 A. Lane 1: Blank Lane 2: 103 Namalwa cells Lane 3: Sterile distilled water Lanes
4-14: HIV-infected PGL samples. The BamH1 W fragment (298bp) is indicated.
Figure 68 B. Lane 15: Blank Lanes 16 to 27: HIV-infected PGL samples. The BamH1 W
fragment (298bp) is indicated.
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3.9.2 Detection of the presence and expression of KSHV
3.9.2.1 Analysis for the presence of the KSHV genome
The KSHV LNA PCR, which amplifies a 376bp fragment, was used to determine the
KSHV status of the PGL and of control tissue.
To establish the sensitivity of the KSHV PCR using the LNA primers (Table 9, page
78), a ten-fold dilution series of the body cavity-based lymphoma cell line BCP-1
(which contains 30-50 copies of the KSHV genome per cell) was prepared in a
background of 106 cells from a KSHV negative cell line, BJAB (see section 2.8.4). A
376bp fragment was detected at a dilution of 1 BCP-1 cell in a background of 106
BJAB cells (figure 69, lane 7), confirming the sensitivity of the LNA primers.
KSHV LNA was detected in 2 of 23 (8.7%) PGL samples (figure 69, lanes 12 and
18) and in none of the HIV-uninfected lymph nodes and tonsils (figure 70), despite
the presence of amplifiable DNA as shown by amplification of (3-globin from the
same DNA samples.
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Figure 69. Detection of KSHV DNA in HIV-PGL using LNA primers
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Figure 70. Detection of KSHV DNA in HIV-uninfected tissue
using LNA primers












Figure 69. Detection of KSHV DNA in HIV-PGL using LNA primers. A ten-fold dilution
series of the body cavity-based lymphoma cell line BCP-1 (which contains 30-50 copies of
the KSHV gene per cell) was prepared in a background of 106 cells from the BJAB cell line,
which lacks KSHV sequences. 35 cycles of PCR were performed on the dilution series and
HIV-infected PGL tissue using LNA primers, after which 20pl of the PCR product was
resolved on a 2% w/v agarose gel and visualised under UV light. M: 100bp DNA size marker
(fragment sizes in bp). Lane 1: 105 BCP-1 cells Lane 2: Blank Lanes 3-7: 104, 103 102, 10
and 1 BCP-1 cell (s) respectively Lane 8: 106 BJAB cells Lane 9: Sterile distilled water Lane
10: 106 BCP-1 cells Lane 11: Blank Lane 12: PGL sample (LN 1) Lane 13: 104 BCP-1 cells
Lanes 14-24: PGL samples. The LNA fragment (376bp) is indicated.
Figure 70. Detection of KSHV DNA in HIV-uninfected tissue using LNA primers. A ten¬
fold dilution series of the body cavity-based lymphoma cell line BCP-1 (which contains 30-50
copies of the KSHV gene per cell) was prepared in a background of 10® cells from the BJAB
cell line, which lacks KSHV sequences. 35 cycles of PCR were performed on the dilution
series and the HIV-uninfected tissue using LNA primers, after which 20pl of the PCR product
was resolved on a 2% w/v agarose gel and visualised under UV light. The PCR products
were then transferred to Hybond N+ membrane and hybridised with a 32P-labelled
oligonucleotide probe. M: Hinfl digested 4>X-174 DNA size marker (fragment sizes in bp).
Lane 1: Blank Lane 2: 10® BCP-1 cells Lane 3: 10® BJAB cells Lanes 4-8: 104, 103 102, 10
and 1 BCP-1 cell (s) respectively Lanes 9-15: HIV-uninfected tonsils Lane 16: Sterile
distilled water Lanes 17-25: HIV-uninfected lymph nodes. The LNA fragment (376bp) is
indicated.
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3.9.2.2 Expression of a KSHV transcript encoding ORF 72
3 genes encoding KSHV v-FLIP (ORF 71), v-cyclin (ORF 72) and LNA (ORF 73)
are transcribed from a single promoter as a polycistronic transcript and expressed
during both the lytic and latent phases of the viral life cycle. A ~6kb transcript arises
from the splicing of a small intron (499bp) in the 5' untranslated region, and further
splicing of this transcript, yields a 1.7kb bicistronic message encoding v-cyclin and
v-FLIP (Talbot et al., 1999).
To analyse expression from this promoter and to further confirm the presence of
KSHV detected by the LNA genomic PCR, a 35-cycle RT-PCR reaction was
performed using a sense primer located in the 5' untranslated region of LNA and the
antisense primer within the v-cyclin ORF. Primers and thermal cycling conditions
are shown in Table 11, page 80 and Table 13, page 83). RT-PCR analysis revealed
the presence of a >700bp transcript in one (LN 15) of the 23 PGL samples (figure
71A, lane 12). This sample also harboured KSHV DNA (figure 69, lane 18). Cloning
(see section 2.17.1.3) and sequencing (see section 2.18.1) of the PCR product
identified a 956bp transcript encoding a part of ORF72 and splicing out of LNA,
using the LNA/v-cyclin splice donor site at position 127812 and the v-cyclin splice
acceptor site at position 123777 (figure 71B). RNA was unavailable for the other
PGL sample (LN1) that was positive for KSHV DNA (figure 69, lane 12). Therefore,
KSHV gene expression could not be tested in this sample.
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Figure 71. Expression of a KSHV transcript encoding ORF 72
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■ Splice acceptor (123777)
cDNA synthesised from 40ng of total RNA was subjected to amplification in a 35-
cycle PCR reaction, using a sense primer located in the 5' untranslated region of
LNA and the antisense primer within the v-cyclin ORF. 20pl of the product was
resolved on a 1.5% w/v agarose gel, then transferred to a Hybond N+ membrane
and hybridised with a 32P-labelled oligonucleotide probe, 23bp internal to the
sense primer. M: Hinfl digested 4>X-174 DNA size marker (fragment sizes in bp).
Lane 1: Sterile distilled water Lanes 2 to 19: PGL samples Lane 20: BCP-1 cell





AIDS-associated lymphomas represent a heterogeneous entity that is part of a
continuum, ranging from benign polyclonal lymphoid hyperplasia, to aggressive
high-grade malignancies most commonly of B cell origin (Meyer et al., 1984). PGL
is an early manifestation of HIV infection that is suggested to predispose to AIDS-
related B-NHL (Abrams et al., 1986; Pelicci et al., 1986b; Alonso et al., 1987). It is
now recognised that the majority of individuals with PGL do not, however, progress
to lymphoma, implying that additional molecular genetic events are required to
facilitate lymphomagenesis. Identification of these events would not only provide
insights into mechanisms that promote neoplastic transformation in the setting of
altered immunity, but also help define molecular markers with potential utility in
diagnosis and prognosis.
Molecular genetic changes in AIDS-related lymphomas have been described by a
number of authors (Ballerini et al., 1993; Gaidano et al., 1997b, Gaidano et al.,
1997d, Lo Coco et al., 1994). However, only a few studies have performed
molecular genetic analyses in AIDS-associated lymphadenopathy (Alonso et al.,
1987; Pelicci et al., 1986b). Therefore, in this thesis, a molecular genetic and
virological study of PGL was performed. Structural, epigenetic and expression
changes were analysed in genomic DNA and RNA from lymph nodes of HIV-
infected individuals with PGL syndrome and in a control group of reactive lymph
nodes and tonsils from HIV-uninfected individuals. The changes identified are
discussed in the context of a model of multi-step carcinogenesis occurring in the
chronically immunocompromised host.
Analysis of tumour suppressor genes
4.1 p53 mutations are detectable in some cases of PGL
p53 mutations have been identified in approximately 50% of human cancers
(reviewed in section 1.3.4 and Levine, 1997). In AIDS-NHL, mutations in p53 occur
at a frequency of around 30-40%, clustering predominantly in the small non-cleaved
cell lymphoma sub-type (60%), and to a lesser extent in immunoblastic lymphomas
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(14%) (Ballerini et al., 1993; Nakamura et al., 1993). These findings prompted a
structural analysis of p53 in PGL. Using established SSCP and DNA sequencing
methodology, p53 mutations were detected in 6/23 PGL samples. Of these, one was a
non-coding sequence change, whilst a second mutation was deletion of a single 'G'
residue in codon 361 causing a frame-shift of-1 and termination in codon 369. The
remaining 4 were point mutations, all occurring in exon 7 and each resulting in
amino acid substitutions (Table 28, page 138). Searching of the International Agency
for Research on Cancer (IARC) TP53 mutation database revealed that each of the
missense mutations detected in this study has been previously described
(http://www.iarc.fr/p53/Index.html). Moreover, each mutation affects conserved
amino acids important to p53 function, suggesting that wild-type p53 function will be
compromised as a result of the mutation. Taken together, these considerations
support the hypothesis that mutation in p53 may be an early molecular genetic
change in HIV-associated lymphomagenesis, at least in a subset of cases.
It is interesting and instructive to consider the selective advantage imparted to cells
containing p53 mutations in the context ofHIV infection. One possibility is that loss
ofwild-type p53 function confers a replicative advantage to HIV, and that this, rather
than selective pressure for growth advantage to the host cell is the mechanism for the
outgrowth of clones containing p53 mutations. This hypothesis is supported by the
ability of p53 mutants to transactivate the LTR of HIV-1 (Subler et al., 1994).
Furthermore, wild-type p53 is a potent suppressor of Tat-dependent HIV LTR
transcription, whereas, in turn, Tat can inhibit p53-mediated transactivation (Li et al.,
1995). In this model, it is proposed that mutations in p53 would abrogate the
repressive effects of the protein on HIV replication, resulting in increased levels of
Tat. A second model envisages that mutations are selected as a result of the growth
advantage, due to loss of one or more of the wild-type functions of p53, conferred to
the host cell, rather than HIV. Such a hypothesis has been proposed in many models
of multi-step carcinogenesis (Fearon and Vogelstein, 1990). The properties of the
p53 mutants detected in the PGL samples have not been formally investigated in the
present study. However, based on previous studies, it is highly likely that such
mutants will be functionally compromised (Raycroft et al., 1990; Rowan et al.,
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1996). A third possibility which merits consideration is suggested by the observation
that apoptosis of HIV-infected B and T cells may occur through a p53-dependent
pathway (Genini et al., 2001). In this study, it was demonstrated that HIV activates a
p53-dependent apoptotic program in CD4+ T cells, through the release of cytochrome
c and subsequent caspase induction. It is possible therefore, that HIV may induce a
similar p53-regulated death program in B cells and that functional inactivation of the
gene by mutation would inhibit such a pathway. Whichever of these possibilities is
the underlying mechanism, it is likely that cells expressing mutant p53 will possess a
selective growth advantage over those with wild-type p53.
It is intriguing that p53 mutations are detectable in PGL, at a stage significantly
preceding clinical presentation of lymphoma. As such, it is clearly of interest to
question (i) whether such mutations function as initiating genetic events in
lymphomagenesis, and /or (ii) whether the detection of such mutations is predictive
of future development of lymphoma. When considering the possibility that p53
mutation may initiate lymphomagenesis, it is pertinent to note that mutations are
consistently absent in most AIDS-DLCLs and AIDS-PELs, although present in 60%
of AIDS-SNCCL (Ballerini et al., 1993; Carbone et al., 1996b). This clearly
demonstrates that mutation in p53 is not an obligatory genetic change during AIDS-
associated lymphomagenesis. However, it is particularly attractive to hypothesise
that the cases of PGL with detectable p53 mutations are those which may
subsequently progress to p53 mutant lymphomas. This hypothesis is certainly viable
in the context of AIDS-SNCCL sub-type in which p53 mutation occurs commonly
(see above, Ballerini et al., 1993; Gaidano et al., 1997b). It is therefore entirely
possible that p53 mutation may represent an initiating or at least early molecular
event in this subset of lymphomas. Such lymphomas typically harbour chromosomal
translocations involving the c-myc gene. Analysis of PGL for such translocations,
was however, uniformly negative (see later). A study of additional samples will be
required to further define the role of p53 mutation in AIDS-associated
lymphomagenesis.
The presence of p53 mutations in PGL also raises the possibility that they may have
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use as molecular markers predictive of future lymphoma development. This can only
be definitively tested in cases where both PGL and lymphoma are available from the
same individual(s) for p53 analysis. Unfortunately, it is unknown which individuals
with PGL in the present series subsequently developed lymphoma and therefore this
issue cannot be addressed, but would clearly merit such an approach when suitable
tissue becomes available.
An interesting finding in the present study was the detection of a silent p53 mutation
in genomic DNA from the tonsil of an HIV-uninfected, healthy individual. It was
first important to exclude the possibility that this is due to experimental artefact. This
is unlikely to be the case since SSCP analysis of this DNA revealed a distinct
mobility shift consistent with the presence of a mutation (figure 34, page 132).
Moreover, the DNA was re-amplified using a thermostable DNA polymerase, Pfx,
which has an extremely high degree of replication fidelity (see Table 27, page 130),
before subsequent cloning and sequencing. The presence of the same mutation in
multiple independent plasmid clones further argues strongly against the possibility
that errors arising in cloning or amplification account for the presence of this
mutation. Experimental studies of p53 mutations in healthy individuals are limited
(Mao et al., 1996; Lazarus et al., 1995). However, in a recent analysis of base
substitution mutations, Wilson and co-workers reported that p53 mutations in codon
248 were detectable in the circulating peripheral blood lymphocytes of 22% of
normal individuals. This remarkably high frequency of mutations was thought to be
due to the presence of a highly mutable CpG site (Wilson et al., 2000). In the present
study, such a high frequency of mutations was not observed, although this may be
attributable to the different methodologies employed. The SSCP technique used here
is able to detect mutations at a frequency of 5% mutant alleles (T. Crook, personal
communication), whereas the Needle-in-a-haystack mutation assay employed by
Wilson et al had a detection sensitivity of one cell in a million. Silent mutations have
been reported at variable frequencies in several tumour types. Such mutations play
no role in tumour development, but, according to some authorities are sensitive
indicators of genomic instability and hence of random mutation within a tissue or cell
type (Strauss, 2000).
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4.2 Exon 2 deleted isoforms of p73 (a2 p73) are over-expressed in PGL
The discovery of 2 novel members of the p53 family, p63 and p73, during the course
of this study, prompted an investigation into their possible role(s) in PGL and
predictive value, if any, in the development of AIDS-NHL. The extreme infrequency
of somatic mutations in p63 and p73 in human cancer (Osada et al., 1998; Ichimiya
et al., 1999) has raised doubts as to the tumour suppressor function of the two
proteins. However, it is now clear that mechanisms of inactivation independent of
mutation occur in human cancer. For example, specific p53 mutants are able to
abrogate p63 and p73 function via formation of heterotypic protein-protein
complexes (Di Como et al., 1999; Marin et al., 2000). Furthermore, p73 has been
shown to be subject to methylation-dependent transcriptional silencing in some
haematological malignancies (Corn et al., 1999).
Alternative splicing of both p63 and p73 generates multiple isoforms, differing at
both N- and C-termini (Yang et al., 1998; De Laurenzi et al., 1998, 1999 and see
section 1.4.1). The N-terminal variants of p73 (a2 p73) and p63 (an p63) can behave
in a dominant negative manner with respect to their full-length counterparts and
wild-type p53. The a2 form of p73 inhibits full-length p73 and p53, whereas an p63
inhibits wild-type p53 (Pozniak et al., 2000; Yang et al., 1998).
Little is known, however, of the patterns of expression of p63 and p73 in normal and
neoplastic lymphoid tissues. Neither is it known by which mechanism (if any) p63
and p73 are inactivated in AIDS-NHL. These questions were addressed in the present
study by RT-PCR expression analysis of full-length and deleted variants of p63 and
p73 and also by analysis of CpG methylation in the p73 promoter by methylation-
specific PCR (MSP).
In initial work, expression of C-terminal splice variants of p73 was investigated and
these analyses revealed that p73 mRNA was expressed in all cases of PGL. In
contrast, p73 expression was detected in approximately 50% of control, reactive
tonsil and lymph node tissues. Importantly, the steady-state level of p73 mRNA was
markedly higher in the majority of cases of PGL than in controls (figures 43A and B,
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page 143). These observations reveal that p73 over-expression is common in PGL. A
further significant finding was afforded by the observation of qualitative differences
in expression of p73 isoforms between PGL and controls. Whereas only 3 variants
(a, p and y) were identified in the HIV-uninfected tissue, at least 5 isoforms (a, p, y, e
and Q were detected in PGL. The predominance of the p73 a and p variants in both
PGL and control tissues is consistent with previous analyses of other tissues (Yang et
al., 1998; Ozaki et al., 1999). Although the y isoform was expressed to a similar
extent as the a and p variants in PGL tissue, this isoform was detected in only 3/16
(18%) HIV-uninfected normal tissue. Two recently described splice variants, e and C,,
were weakly expressed in the PGL tissue but were consistently absent in the
uninfected tissue. Taken together, these experiments clearly indicate both
quantitative and qualitative differences in expression of p73 between HIV-infected
and uninfected lymphoid tissue. Interestingly, the expression pattern of p73 isoforms
in control vulval (epithelial) tissue was different to that observed in lymphoid tissue,
with expression of the a, y, C, and 5 but not the p isoforms in normal vulval
epithelium. In contrast, whereas the p form was readily detectable in lymphoid tissue
in the present study, the 8 form could not be detected. These results suggest that
different C-terminal variants have distinct roles in different tissues in vivo.
Over-expression of p73 relative to surrounding normal tissue has been observed in
several cancers, including prostate, breast, lung, colorectal and bladder carcinomas
(reviewed in Ikawa et al., 1999). The high frequency of p73 over-expression in PGL
is, therefore an intriguing observation as it reveals clear similarity between PGL and
common carcinomas. Having demonstrated over-expression of p73 mRNA in PGL, it
was important to determine whether this was the full-length form or the more
recently described A2 variant which lacks exon 2. RT-PCR analysis revealed that a2
variant was the only form expressed in both PGL and in p73-expressing control
lymphoid tissue. Interestingly, expression of the a2 form of p73 was accompanied by
the absence of full-length p73 in all the samples tested. Previous studies of A2 p73
have been limited, but expression has been described in malignant but not normal
ovarian epithelium (Ng et al., 2000), in breast cancer cell lines (Fillippovich et al.,
2001) and also in the developing neurons ofmice (Pozniak et al., 2000).
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What then are the mechanistic and biological implications of the over-expression of
various forms of p73 in PGL? One possibility is that over-expressed full-length p73
competitively inhibits p53-dependent transactivation of p53-responsive promoters
(Ueda et al., 1999). If this mechanism operates in PGL, attenuation of p53-dependent
transactivation would result from over-expression of p73. In view of the predominant
detection of A2 forms of p73, the most likely effect of p73 over-expression is trans-
dominant inhibition of wild-type p53 and of full-length p73, since both activities
have been clearly attributed to a2 p73 (Fillippovich et al., 2001; Pozniak et al.,
2000).
4.3 Aberrant hypermethylation of p73 is not a feature of PGL
Hypermethylation of the promoter region of p73 was examined by methylation-
specific PCR (MSP), given that silencing of p73 by this mechanism is operative in
specific haematological malignancies, but not in normal lymphocytes (Kawano et al.,
1999; Corn et al., 1999). The absence of aberrant hypermethylation of p73 in this
study was well supported by the observation of mRNA expression in all the PGL
samples analysed, indicating that epigenetic silencing of p73 is not a feature ofHIV-
infected PGL. The detection of 1/1000 methylated alleles, established in preliminary
studies of the sensitivity of MSP, in a background of unmethylated DNA, excluded
possible lack of sensitivity of the MSP analysis used in this study as the reason. A
point to note is that p73 may be functionally compromised by mechanisms other than
epigenetic silencing of the promoter region. This hypothesis is supported by the
observation that a subset of p53 mutants can bind and inhibit the transcriptional
activity of various isoforms of p73 (Marin et al., 2000; (Gaiddon et al., 2001).
Although yet to be formally demonstrated, it is conceivable that the p53 mutants
detected in this study have similar trans-dominant properties with regards p73.
4.4 Over-expression of the TA, but not the AN isoform of p63 occurs in PGL
RT-PCR analysis of PGL and control lymphoid tissues revealed a difference in
patterns of expression. The TA isoform was predominantly expressed in HIV-
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infected and uninfected lymph nodes and in one tonsil. In contrast, expression of the
AN isoform was strictly limited to the HIV-uninfected tonsils, with expression of this
isoform being undetectable in the PGL cases. The most likely explanation for the
expression of the AN isoform in non-PGL lymphoid tissue is that this expression is in
the epithelial tissue within the tonsils. This hypothesis is favoured by data from other
studies which indicate an epithelial-specific expression of AN p63 in both normal and
malignant tissue (Yang et al., 1998; Crook et al., 2000), but clearly requires
immunocytochemical analysis for verification. It is unclear, however, why the AN
isoform is expressed in reactive nodes and tonsils, but not, apparently, in PGL.
Again, immunocytochemistry might provide insight as to whether this is a reflection
of the absence of epithelial tissue in PGL nodes or whether isoform switching has
occurred. In any case, the biological significance of expression of TA p63 in PGL
and in other lymphoid tissues awaits clarification.
The absence of somatic mutations in p63 has led some authors to question the
putative tumour suppressor role of this gene. Similar to p73, there is now evidence
that specific mutant forms of p53 can exert trans-dominant inhibitory effects on the
function of p63 (Gaiddon et al., 2001), suggesting that alternative mechanisms of
inactivation may occur in some cancers. The presence of p53 mutations within some
PGL cases expressing TA p63, suggests that inhibition of p63 function by these
mutants might be operative at least in these cases.
Over-expression of AN p63 occurs in some squamous carcinomas. For example,
Yamaguchi et al (2000) reported amplification and over-expression of AN p63 in
head and neck cancer, consistent with a potential oncogenic function (Yamaguchi et
al., 2000). Similarly, over-expression of AN p63 was observed invariably in
undifferentiated NPC, wherein it was proposed that over-expression of AN p63 might
function via trans-dominant inhibition to counteract the negative growth regulatory
effects of over-expressed wild-type p53 protein, which characterises this cancer
(Crook et al., 2000). In any case, data from this study do not support a role, either
tumour suppressor or oncogenic, for this gene in the pathogenesis of PGL.
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4.5 Lack of involvement of the INK4 locus in the pathogenesis of PGL
The INK4 locus contains 3 genes, pl6INK4a, pl51NK4b and pl4ARF that function in pRb-
and p53-dependent pathways of tumour suppression (see section 1.5). In cases of
PGL which lack mutations in p53, it was of interest to determine whether alterations
occur in pl4ARF which might functionally substitute for such mutations. In the case
of RB, no mutations have been reported in AIDS-NHL. As such, it was important to
determine whether the pl6INK4a and pl5INK4b genes are subject to genetic or
epigenetic changes, which might themselves compromise pRb function.
A bona fide tumour suppressor role for pl6INK4a has been firmly established (Kamb
et al., 1994; Hussussian et al., 1994). Inactivation of the gene by homozygous
deletion, mutation, and/or methylation has been observed in a diverse range of
human cancers (reviewed in Ruas and Peters, 1998 and see section 1.5).
Abnormalities in pl5INK4b and pl6INK4a occur commonly in B cell lymphomas, with
aberrant hypermethylation being the most common mechanism of inactivation
(Klangby et al., 1998; Baur et al., 1999). The status of the gene in lymphomas
affecting HIV-infected individuals is, however, unknown. Therefore, a detailed
analysis of the mutation status, methylation and expression pattern of the INK4 locus
was performed in HIV-PGL.
4.5.1 No evidence for mutation or hypermethylation in INK4a
SSCP analysis of exon la and 2 of INK4a did not reveal any abnormally migrating
bands indicative of mutations. This result is consistent with studies of B cell
lymphomas in which inactivation of the gene by point mutation was shown to be a
relatively uncommon event (Ruas and Peters, 1998; Uchida et al., 1995). No attempt
was made to examine the INK4 locus for genomic deletion in the present study. Not
all germinal centre (GC) B cells in PGL lymph nodes are maintained in an equivalent
hyperproliferative state, and as such the proportion of "normal" B cells in each
sample cannot be assessed, making interpretation of deletion analysis unreliable. In
the absence of point mutations in the coding sequence of the gene, a study of gene
deletion would be of obvious value and interest, but would require the availability of
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micro-dissected malignant and matched normal tissue for each case.
Aberrant hypermethylation is a common mechanism of inactivation of pl6INK4a in
NHL occurring in immunocompetent individuals (Baur et al., 1999; Klangby et al.,
1998). MSP was therefore utilised to seek evidence of aberrant CpG
hypermethylation in the pl6INK4a gene in the series of PGL. However, no evidence of
CpG methylation in exon la was observed in this study. It should be noted that the
sensitivity of the MSP technique to detect hypermethylated alleles of pl6INK4a had
been carefully titrated in initial experiments using genomic DNA from the Raji cell
line, in which both pl6INK4a alleles are methylated. Methylated pl6iNK4a DNA was
readily detectable at a dilution of 1:1000, suggesting that the inability to detect CpG
methylation in the PGL samples is unlikely to be attributable to sensitivity
limitations. Moreover, RT-PCR analysis revealed that pl6INK4a mRNA was
detectable in all samples analysed. Although the presence of some normal tissue in
the PGL samples is a potential complicating factor in interpretation of these RT-PCR
studies, expression of pl6INK4a RNA is, nonetheless, consistent with the absence of
gene methylation. Immunocytochemical analysis would provide definitive evidence
of pl6INK4a expression in PGL, but suitable tissue sections were not available in the
present study.
4.5.2 No evidence for abnormalities of pl5,NK4b in PGL
pl5'NK4b is a tumour suppressor gene located adjacent to the pl6INK4a gene on
chromosome 9p21. Inactivation of pl5INK4b in human cancers may occur by deletion,
which is often, but not invariably, accompanied by simultaneous loss of pl6INK4a
(Drexler, 1998). Mutations in pl5INK4b are extremely rare in human cancers in
general and are virtually absent in NHLs (Gombart et al., 1995; Koduru et al., 1995).
The gene is, however, frequently inactivated (>70%) by methylation in acute
leukaemias of the myeloid and lymphoblastic subtypes, and to a lesser extent in B-
NHL (11%). A distinct role for this gene has been indicated in murine T-cell
lymphomas, wherein gene inactivation was found to be independent of pl6INK4a
alterations (Malumbres et al., 1997). Again, because of the lack of micro-dissected
PGL biopsy material available for analysis, examination of gene deletion was not
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attempted and work in the present study was focused on examination of the
methyiation status and mRNA expression pattern of the gene. No evidence was
obtained for methyiation of pl51NK4b in any of the PGL samples analysed, despite
preliminary studies showing the adequate sensitivity of the MSP conditions
employed. Consistent with the lack of methyiation, RT-PCR analysis revealed
abundant expression of pl5IN1C4b mRNA in all the PGL lymph nodes analysed,
although expression was absent in 8/16 uninfected controls (7 lymph nodes and one
tonsil). It is likely therefore, that pl5INK4b is expressed in the hyperproliferating GC
B cells of PGL tissue, although definitive conclusions can be drawn only after
immunocytochemical examination of tissue sections or genetic analysis of micro-
dissected material.
In conclusion, no evidence was obtained in the present study to support genetic or
epigenetic inactivation of the pl61NK4a and pl51NK4b genes in PGL and the results, as
such, do not support a contributory role for these genes in the pathogenesis of PGL.
Structural and epigenetic alterations affecting the INK4 locus have previously been
reported to correlate with aggressive high-grade tumours and with the histological
transformation/progression of indolent lymphomas (Garcia-Sanz et al., 1997; Pinyol
et al., 1998; Villuendas et al., 1998). With regards to the findings in this study, it is
hypothesised that the absence of detectable mutations and aberrant hypermethylation
in the INK4 genes analysed may reflect the fact that such abnormalities occur late in
HIV-associated lymphomagenesis, probably as secondary genetic events contributing
to the more aggressive biological nature of lymphomas.
4.5.3 Analysis of pl4ARF in PGL
Inactivation of the p53 pathway can occur by a number of mechanisms in cancer.
These include, loss of function of p53, alteration of ARF, or alternatively over-
expression of hMDM2 (Eischen et al., 1999; Sanchez-Cespedes et al., 1999).
Functional inactivation of/lRFby deletion and less frequently by mutation, often but
not always, occurs concurrently with alterations in INK4a (Ruas and Peters, 1998).
Their concomitant disruption has been associated with progression and a poor
prognosis in up to 40% of aggressive NHLs (Pinyol et al., 2000; Gronbaek et al.,
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2000). These observations suggested the possibility of pl4ARF abnormalities in PGL.
SSCP analysis of exon ip however, revealed no abnormally migrating conformers
suggestive ofmutation in any of the PGL cases. This is consistent with reports from
previous studies (Pinyol et al., 2000; Tanaka et al., 1997).
Deletions targeting the INK4a/ARF locus commonly inactivate both pl6INK4a and
ARF, whereas cancer-associated mutations within exon 2 of the mouse INK4a gene
have been shown to specifically target pl6INK4a, and not pl9ARF, for inactivation
(Quelle et al., 1997). Conversely, mutations in human ARF exon 2 have been shown
to disrupt its nucleolar localisation and impair its ability to block nuclear export of
hMDM2 and p53 and subsequent p53 stabilisation (Zhang and Xiong, 1999).
Furthermore, Rizos et al have shown that in the human ARF gene the carboxy-
terminal nucleolar localisation domain lies within the shared INK4a/ARF exon 2 and
is mutated in some melanoma-prone kindreds (Rizos et al., 2000). However,
mutations in exon 2 were not observed in the present study, and therefore it is
reasonable to conclude that ARF inactivation by point mutations is not a
characteristic feature ofHIV-associated PGL.
An inverse correlation between p53 and ARF expression/inactivation in human
tumours has been suggested by some investigators, consistent with the theory that
they are functionally linked in the same pathway (Stott et al., 1998; Vonlanthen et
al., 1998). The expression of pl4ARF was, therefore, examined by RT-PCR using
cycling conditions determined in preliminary experiments to be in the exponential
phase of amplification. Despite the evidence that p53 negatively regulates the
expression of ARF and generally increased levels of endogenous ARF mRNA and
protein are observed in cells that lack functional p53 (Stott et al., 1998), such
findings were not validated in this study. Of note, pl4ARF protein expression was not
examined in this study, due to lack of suitable tissue sections for
immunocytochemical analysis. Expression of ARF mRNA was observed in both the
HIV-infected and uninfected samples investigated, independent of their p53
mutational status. There are several explanations that may account for the apparent
lack of reciprocity between expression of ARF and p53. One is that the p53
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mutations documented in this study do not abrogate its function and hence ARF
expression would be under the normal regulatory control of p53. Although unlikely,
without formal testing of each mutant, this hypothesis cannot be disproved.
Secondly, in cases in which p53 is functionally compromised by such mutations, it is
possible that ARF expression is regulated by a p53-independent mechanism.
Recently, ARF has been shown to act independently of the hMDM2-p53 pathway, by
arresting cell growth in mice that were lacking in p53 alone or both p53 and hMDM2
(Weber et al., 2000). Finally, contrary to evidence that p53 and ARF are inversely
correlated, in lung cancer it has been demonstrated that inactivation of ARF and
mutation of p53 are not mutually exclusive events (Gazzeri et al., 1998; Sanchez-
Cespedes et al., 1999). Additionally, post-transcriptional modification was suggested
to account for the discrepancy observed between ARF mRNA and protein expression
(absence of protein in tumours with detectable mRNA) in these tumours (Gazzeri et
al., 1998). A plausible theory in the present context would be that in cells with
mutant p53, post-transcriptional modification of ARF mRNA occurs, despite
apparently normal levels of the P transcript. However, this hypothesis can be
confirmed only by immunocytochemical staining of the lymph node tissue for ARF
protein expression. It should be re-emphasised here that the complicating effects of
"normal" B cells in PGL nodes on the analysis ofmRNA levels are not known, and
again micro-dissected tissue would prove invaluable in validating the above findings.
Epigenetic silencing of ARF by promoter hypermethylation has been demonstrated
in gastric and colorectal cancer (Iida et al., 2000; Esteller et al., 2000), and
infrequently in murine lymphomas. Future studies of methylation of pl4ARF,
combined with immunocytochemical analysis of protein expression would be of
obvious interest in NHL and PGL.
Analysis of oncogenes
Given the importance of deregulated oncogene expression in the pathogenesis of
certain B cell lymphomas in both the immune-competent and -compromised host,
alterations including chromosomal translocations and mutations in relevant genes
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such as c-myc, bcl-2 and bcl-6 were investigated in the present study.
4.6 Absence of c-myc/IgH translocations in PGL
Chromosomal translocations juxtaposing the c-myc and immunoglobulin genes are
an invariant feature of Burkitt's lymphoma (BL) in the immunocompetent host
(Dalla-Favera et al., 1982b). Although, this translocation is also invariably present in
AIDS-BL, it is detected in only 20-50% of AIDS large-cell lymphomas (Ballerini et
al., 1993; Delecluse et al., 1993b). Recombination in AIDS-BL, commonly involves
the first exon or first intron of the c-myc gene and the switch regions of the IgH
locus, similar to sBL (Pelicci et al., 1986a; Ballerini et al., 1993). Taken together,
these observations suggested that c-myc translocation might occur in HIV-PGL. This
was addressed in the present study by use of a LD-PCR assay to amplify the t(8:14)
translocation breakpoint.
The translocation was however, not detected in any of the PGL samples. One
possibility is that the LD-PCR assay used is insufficiently sensitive to detect a low
frequency of translocations occurring in a background of normal lymphocytes.
However, the assay used in this study is able to detect 1 translocation-positive cell in
a background of 10 normal lymphoblastoid cells and this sensitivity is comparable
to that used in previous studies to detect c-myc translocations in BL (Akasaka et al.,
1996; Basso et al., 1999). Nevertheless it is worth considering the possibility that a
minor population of translocation-bearing cells characteristic of an initiating event in
a single clone of cells will escape detection, whereas the greater number of
translocations present in BL tumours will be readily detected. Arguing against this
was the surprising discovery of a translocation event in an HIV-uninfected lymph
node (case no. 2435). It is highly likely that this translocation is present in only a
minority of cells within the normal lymph node. For this reason it is highly
improbable that the failure to detect similar translocations in PGL is attributable to
lack of sensitivity.
The second possibility is that PGL is not per se a precursor of HIV-associated BL. A
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third interpretation is that such translocations occur as later events in
lymphomagenesis. Polack et al (1996) made the intriguing observation that
activation of c-myc in EBV-immortalised, B lymphocytes rendered growth of the
cells independent of EBV-encoded proteins. These studies suggested a model of
lymphomagenesis in which c-myc activation occurs subsequent to an initial
immortalisation step effected by EBV (Polack et al., 1996). This model is
particularly interesting in the light of the observation that EBV was present at a high
copy-number in 23/23 lymph nodes of HIV-infected individuals with PGL (see
later).
Cloning and sequencing of the PCR product from case 2435, identified a reciprocal
exchange of chromosomal segments involving the 5' flanking region, 424bp
upstream of the ATG in the first exon of c-myc, and the switch gamma 4 (Sy) region
of the Ig locus. Surprisingly, the breakpoint was detected in 5/5 translocation-bearing
clones, indicating possible clonal outgrowth of a cell that may have a distinct
survival advantage as a result of the translocation event. This hypothesis is currently
under investigation. Of further interest, was the identification of a run of 5
nucleotides, mapping to neither the c-myc gene nor the Sy region at the inter-
chromosomal junction of the breakpoint. In a study of c-myc translocations in murine
plasmacytomas, Gerondakis and colleagues have observed deletions, duplications
and/or small insertions at most of the breakpoint junctions sequenced (Gerondakis et
al., 1984). The authors believe that the insertion of residues is a result of competing
polymerase (repair) and exonuclease activities following single-stranded breaks in
either chromosome.
The observation of a c-myc translocation in an apparently healthy individual is not
unique. In a study of t(8:14) recombinations in the blood lymphocytes of HIV-
infected and uninfected homosexual men, c-myc translocation-bearing clones have
been detected at a frequency of 10.5% and 2% respectively (Muller et al., 1995). In
addition, c-myc deregulation by chromosomal recombination is believed to be
associated with the normal physiological process of B cell differentiation, increasing
in frequency with antigenic stimulation (Roschke et al., 1997). It may be pertinent in
this respect that the lymph node in which the translocation was identified was
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"reactive", implying that an active immune response was in progress at the time of
biopsy. The clinical history and follow-up of the individual in whom the
translocation was detected is not available. Nevertheless, it is known that the
individual had no evidence of a lymphoma at the time of biopsy. The presence of a c-
myc translocation event in the absence of detectable lymphoma in case 2435 can
readily be explained by the fact that secondary "hits" by co-operating oncogenes are
required for tumourigenesis to occur (Land et al., 1983). This hypothesis is supported
by the fact that, in this individual, no abnormalities were detected in any of the genes
analysed in this study. Furthermore, EBV, which is believed to have a contributory
role in the development of BL, was below the detectable level (sensitivity of PCR
assay was <10 genomes). Therefore, it is possible that in this case subsequent
aberrant alterations in oncogenes and/or tumour suppressor genes, not analysed in
this study, maybe required for malignant transformation to occur.
Although the finding of a c-myc translocation in a healthy individual is of interest,
the most important conclusion to be drawn from the above observations is that such
translocations were not detectable in PGL. It will be of interest to determine whether
the deregulation or stability of c-myc in PGL is affected by mechanisms other than
translocation. This would involve mutations, which have been shown to occur in the
exonl/intronl regions (Cesarman et al., 1987; Bhatia et al., 1994) or within the
transactivation domains of c-myc (Salghetti et al., 1999; Gu et al., 1994).
4.7 bcl-2/IgH translocations are not detected in PGL
Another translocation involving the Ig loci, and observed in more than 70% of
follicular lymphomas and 20% of diffuse B cell lymphomas in the immunocompetent
host, is the t( 14:18), which involves the bcl-2 gene on chromosome 18 resulting in its
deregulated expression (Yunis et al., 1987; Weiss et al., 1987). The relatively few
studies that have looked for bcl-2 alterations in AIDS-associated lymphomas have
found no evidence of bcl-2HgH rearrangements (Subar et al., 1988; Gaidano et al.,
1997b; Davi et al., 1998). Furthermore, t( 14:18) rearrangements have also been
detected in the peripheral blood B cells of up to 60% of healthy individuals (Limpens
et al., 1991, 1995; Aster et al., 1992; Liu et al., 1997). These studies, however, have
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only examined breakpoints within defined regions, the MBR and mcr, which harbour
roughly 70% of translocations. In the present study, utilisation of the primers
designed by Akasaka et al (1998), allowed for the detection of breakpoints 5' of the
mcr and 3' of the MBR, including >20kb of intervening sequence (Akasaka et al.,
1998). This region has been shown to harbour approximately 30% of translocations
(Akasaka et al., 1998). Despite the comprehensive methodology employed, no
rearrangements were detected in the present study in either the HIV-infected or
uninfected population. The most likely explanation for the lack of detection of
translocation events in PGL is that the sensitivity of the LD-PCR assay used in this
study is one translocation-positive cell in a background of 104 normal
lymphoblastoid cells (see section 3.4.1.4). The prevalence of translocation-bearing
clones in "normal" individuals, however, as assessed by previous studies, is 10-fold
lower (Limpens et al., 1991; Aster et al., 1992). In conclusion, there was no evidence
from the present studies that constitutive expression of bcl-2, secondary to
deregulation due to chromosomal translocation, has a role in PGL.
4.8 Mutations in bcl-6 are frequently detected in PGL
The bcl-6 gene is characteristically altered by translocations and mutations in B cell
NHL (Lo Coco et al., 1994; Migliazza et al., 1995). Greater than 90% of the
mutations cluster within the 5' non-coding region of the gene, are often multiple in
the same allele, frequently bi-allelic and have been reported in lymphomas
displaying both normal and rearranged bcl-6 genes (Migliazza et al., 1995).
Importantly, mutations in bcl-6 are observed at a similar frequency (70%) throughout
the clinico-pathologic spectrum of AIDS-NHL and they represent the most
commonly observed genetic alteration in these lymphomas (Gaidano et al., 1997d).
Interestingly, the gene is mutated both in lymphoma tissue and in normal B cells
(Migliazza et al., 1995; Shen et al., 1998). The frequency of mutation in bcl-6 is
estimated to be 1.4xl0"3 to 1.6xl0"2 per bp in B-NHL and 6.8xl0"4 to 1.9xl0"3 per bp
in normal memory B cells (Pasqualucci et al., 1998; Shen et al., 1998). Consistent
with this marked difference in mutation frequency, bcl-6 mutations in the present
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study were observed at an increased incidence, by SSCP and sequencing analysis of
a 735bp region within the first intron that represents a mutational hot-spot (Migliazza
et al., 1995). The frequency ofmutations was found to be 5-10 times higher (9.8xl0~4
to 1.3xl0"3 per bp) in the HIV-PGL samples than in the healthy controls (8.2xl0~5 to
5xl0"4 per bp). Intriguingly, this observation lends indirect support to the hypothesis
that PGL lesions may serve as precursors of A1DS-NHL, as the mutation rate is
similar in the two pathological entities and is significantly higher than that observed
in normal B cells. Identifying identical mutations in the corresponding tumour tissue
would help clarify whether these mutations are enriched and selected for in the GC,
and highlight their usefulness as possible predictive markers of lymphoma
outgrowth. These results should however be interpreted with caution, as one cannot
definitively exclude the fact that contamination with normal B cells in the PGL tissue
accounts for this difference.
It is currently unclear why bcl-6 is mutated more frequently in tumour cells than in
normal B cells, bcl-6 mutations are regarded as a marker of a transition of a given B
cell through the GC. Mutations arise only in tumours and normal B cells of GC or
post-GC origin, whereas they are absent in precursor and virgin B cells (Gaidano et
al., 1997d; Pasqualucci et al., 1998; Shen et al., 1998). One possible explanation to
account for the increased frequency of mutations observed in the HIV-infected tissue
in this study, is that the "explosive" nature of follicular hyperplasia seen in PGL
maybe characterised by a greater number of follicular germinal centres than reactive
lymph nodes and tonsils (Metroka et al., 1983). However, this hypothesis can be
ascertained unequivocally only through histopathological examination of the tissues,
but no such material was available during the period of study. Further substantiation
of the origin of the mutations in this study would require micro-dissection of the
PGL and control tissue, to verify whether these mutations, do in fact, arise from the
GC B cells of these nodes.
So why then do mutations occur both in tumour and normal B cells? Some
researchers postulate that such mutations are a consequence of the same
hypermutation mechanism that generates antibody diversity in germinal centre (GC)
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B cells, during the process of affinity maturation (Chang and Casali, 1994; Capello et
al., 1997; Migliazza et al., 1995). The characteristics of the bcl-6 mutations observed
in this study lend further credibility to this hypothesis, and are consistent with reports
from other studies (Migliazza et al., 1995; Gaidano et al., 1997d; Betz et al., 1993).
Observed mutations were single nucleotide substitutions, with absence of deletions
and insertions, somatic in nature, bi-allelic and multiple within the same allele.
Transitions were favoured over transversions, with the 'T* residue being more
frequently targeted than the 'A' residue. Although consistent with previous studies
(Capello et al., 2000; Sahota et al., 2000), the T>A bias was at variance with that
associated with somatic Ig hypermutation, which preferentially targets A' over 'T'.
Studies of the cis-acting regulatory sequences on bcl-6 and Ig gene mutations might
aid in the understanding ofwhy this gene is targeted.
In contrast to mutations in p53, bcl-6 mutations target the non-coding region of the
gene. The high frequency of mutation and the clustering of breakpoints in the 5' non-
coding region of bcl-6 may reflect the importance of this region in the normal
regulation of the gene (Ye et al., 1993; Lo Coco et al., 1994). Recently, Kikuchi and
co-workers have provided provocative evidence of 2 cA-acting regulatory elements
within the first exon (ES) and intron (IS) of bcl-6, which negatively regulate Bcl-6
expression. Interestingly, the IS region is entirely included within the 735bp region
analysed in this study (Kikuchi et al., 2000). Thus, a functional consequence of the
mutations that occur within these regions, as seen in this study, might be the de¬
repression of negative inhibitory effects on Bcl-6 expression, leading to inappropriate
expression and subsequent lymphomagenesis. However, the presence of mutations
outside this region, and also within healthy individuals, questions the "oncogenicity"
of all bcl-6 mutations, and suggests that these might simply reflect a GC-associated
physiological process (see above).
Of further interest, 2 nucleotide substitutions likely to represent polymorphic variants
were detected in this study. These variants, a G to C transversion at position +753,
and a single base deletion (AT) at position +875, have been previously described
(Migliazza et al., 1995; Sahota et al., 2000) and permitted the identification of bi-
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allelic mutations in bcl-6. Interestingly, of all the mutations found to be associated
with the individual polymorphic variants in both the study and control groups, 6/8
(75%) were found on the allele that had the 'C' residue at position +753, and 5/7
(71%) on the allele that had the T residue at position +875, (see Tables 30 B and C,
page 179). Of great interest is the fact that such an association of bcl-6 mutations
with polymorphic variants has not been previously reported. These results however,
need to be interpreted with caution due to the relatively limited number of samples
analysed. Furthermore, it remains to be determined whether polymorphic association
with bcl-6 mutant alleles has any biological relevance in the context of deregulation
of bcl-6. Both questions represent issues that warrant further research.
To establish functional significance for the observed bcl-6 mutations it needs to be
determined whether mutated alleles in HIV-PGL have altered transcriptional activity
and consequently deregulate Bcl-6 expression. It would then be interesting to
observe whether those mutants with altered transcriptional activity cluster with
specific polymorphic alleles. In addition, analysis of bcl-6 translocations would also
help ascertain whether this gene has any role in the pathogenesis of PGL.
The predictive value of bcl-6 mutations has been demonstrated in post-transplant
lymphoproliferative disorders, arising in organ transplant recipients. Cesarman et al
(1998) have shown that the presence of bcl-6 mutations predicted shorter survival
and the need for aggressive therapeutic intervention (Cesarman et al., 1998).
Therefore, the analyses of bcl-6 mutations in this study may be clinically relevant in
the context of predictiveness of lymphoma outgrowth, although further investigations
are clearly required to verify such a possibility.
Virological analysis of PGL
On account of their association with lymphoid malignancies in the
immunocompromised host, the presence of DNA viruses, EBV and KSHV was
analysed in the current study.
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4.9 EBV is uniformly detectable in PGL
EBV is associated with approximately 30-90% of AIDS-NHL, unlike its invariable
association with other malignancies of immunosuppressed hosts (Hamilton-Dutoit et
al., 1991). However, the presence of EBV genomes in the lymph nodes of HIV-
infected individuals has been considered as a predictive marker of subsequent
lymphoma outgrowth (Shibata et al., 1991). Therefore, to address the presence of
EBV in the lymph nodes ofHIV-infected individuals, the BamHl W fragment of the
EBV genome was amplified in a semi-quantitative PCR. EBV was detectable in
23/23 (100%) cases in the HIV-infected group and in 12/14 (86%) tissues in the
control group. In comparison to the HIV-uninfected group (median viral load: <10
genomes/106 EBV negative cells), a greatly increased viral load (median viral load:
104 genomes/106 EBV negative cells) was observed in the HIV-infected individuals
(p<0.005, Mann-Whitney test). These findings are in agreement with previous
studies carried out in HIV-infected (Birx et al., 1986) and healthy individuals
(Miyashita et al., 1995), and can be explained as a loss of immune control of EBV
consequent to the immunodeficiency induced by HIV. However, whether the
increased levels of virus detected contributes directly to the pathogenesis of PGL or
indirectly contributes to the polyclonal activation of B cells is not known.
Interestingly, one HIV-uninfected individual (2478) was found to harbour 105 EBV
copies/106 cells. The significance of this high viral load is unknown, as the case
histories of these individuals were not available.
4.10 Analysis of the presence of KSHV
Apart from its etiological association with KS and primary effusion lymphoma
(PEL), KSHV has also been found to be present in lymphoproliferative disorders
such as multicentric Castleman's disease (MCD) (Cesarman and Knowles, 1999).
Hence, the extent of its involvement in HIV-PGL was considered a relevant
investigation. In a recent study by O'Leary et al KSHV was detected by PCR in
14.2% of AIDS-related lymphadenopathy cases, and all the positive cases either
subsequently developed KS or had KS at the time of diagnosis (O'Leary et al., 2000).
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Similarly, in the present study, 2/23 (8.7%) HIV-PGL cases was found to be positive
by PCR amplification of KSHV-LNA. Since the presence of KSHV in AIDS related
lymphadenopathy is predictive of KS development (O'Leary et al., 2000), it will be
interesting to determine the clinical outcome of those individuals with detectable
virus.
KSHV is also known to target non-neoplastic and reactive lymph nodes in
immunocompetent individuals, albeit rarely (Chadburn et al., 1997, Trovato et al.,
1999). The absence of KSHV in the HIV-uninfected lymph nodes and tonsils
investigated in this study is thus not remarkable. Moreover, the PCR conditions used
were sensitive enough to detect between 30 and 50 viral copies. Serological analysis
using antibodies to KSHV LNA would help verify the absence of KSHV DNA,
provided stored serum from these individuals is available for analysis.
4.11 Conclusions
The studies described in this thesis are an initial attempt to identify virological,
genetic and epigenetic characteristics of HIV-associated PGL. The starting point of
the work was to examine in PGL genes and viruses known from previous work to be
implicated in lymphomagenesis in either the immunocompetent or the
immunocompromised host. The principal results from the work are: i) the finding of
p53 missense mutations in 5/23 cases studied; ii) a potentially interesting spectrum of
polymorphisms and mutations in bcl-6; iii) over-expression of the trans-dominant
p73 isoform, a2 p73, in a majority of cases; iv) the absence of genetic or epigenetic
changes in any other tumour suppressor genes studied; v) the lack of detectable
chromosomal translocations implicated in non-Hodgkin's lymphomas. A
comprehensive overview of the results of this study is presented in Appendices 1 and
2.
The results suggest that loss of p53 function, mediated by mutation within the gene
or perhaps by over-expression of trans-dominant members of the p53 family, may be
an early event in the pathogenesis of PGL and perhaps in HIV-associated
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lymphomagenesis. In contrast, inactivation of the INK4 gene locus, which occurs
commonly in NHL, predominantly by methylation of CpG sequences in the gene
promoters, does not appear to occur in PGL, implying that such changes are later
events. Whereas the identification of p53 mutation can be regarded with confidence
as a bona fide result, other findings need to be interpreted within the limitations
imposed by the lack of immunocytochemical analysis and micro-dissected tissue,
enriched for hyperproliferating germinal centre B cells, for direct comparison with
matched normal (see later). For example, it was not possible to definitely analyse
plgiNK4a eXpressjon jn presence of unknown amounts of normal tissue.
Nevertheless, the sensitivity of the methylation analyses established in preliminary
experiments does suggest that sensitivity was adequate to exclude methylation-
dependent transcriptional silencing of the INK4 locus and the p73 genes in PGL.
Whether such changes occur later in the natural history of the disease awaits further
study, ideally by in situ methylation analysis.
Throughout the course of this work, a major limiting factor was the unavailability of
tissue sections from the lymph nodes analysed. It is highly likely that many of the
candidate genetic and epigenetic changes sought are restricted to sub-populations of
cells within the lymph node and therefore in a minority of cells within the population
analysed. As a result, detection of these changes in nucleic acid preparations from
whole lymph nodes will suffer from reduced sensitivity due to the dilutional effect of
the normal tissue within the biopsy material. Future studies would undoubtedly
benefit from the availability of tissue sections. For example, it would be of interest to
determine what proportion of cells have detectable p53 protein, since the mutants
detected in the present work would be predicted to be readily detectable by
immunocytochemistry. The question could then be addressed of whether discrete
clones ofmutant p53 cells are present within the node.
Immunocytochemistry would also enable a more accurate assessment of the
expression of other tumour suppressor genes such as pl6INK4a and pl5INK4b. Analysis
of expression by RT-PCR of whole lymph node RNA preparations is clearly
significantly affected by the presence of normal tissue and immunocytochemical
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analysis would provide a definitive answer to the question of whether loss of
expression occurs during HIV-associated lymphomagenesis. Furthermore, the
availability of paraffin sections would enable micro-dissection of abnormal and
normal tissue from the same node, allowing analysis of LOH and gene sequence in
the PGL tissue and tumour, free from the masking effects of normal tissue
contamination. Moreover, it would also permit conclusive analysis of the cell of
origin of the bcl-6 mutations.
It would also have been extremely informative to have obtained clinico-pathological
follow up data from the individual patients in this series of PGL. Since it was known
that some of the individuals subsequently developed lymphoma, such data would
have allowed several pertinent questions to be addressed. Primarily, whether p53 and
bcl-6 mutations predict future lymphoma outgrowth, and also whether genetic and
epigenetic changes not observed in PGL truly occur as later events in AIDS-
lymphomagenesis.
4.12 A speculative model for AIDS-lymphomagenesis
AIDS-NHL is a strikingly heterogeneous disease. Based on the data summarised
from several studies 3 major pathogenetic pathways can be identified. The first of
these pathways associates with AIDS-SNCCL, which is characterised by relatively
mild immunosuppression (Beral et al., 1991; Boyle et al., 1990) and more frequently
than other AIDS-NHL, is preceded by a PGL phase (Kalter et al., 1985). These
tumours harbour multiple genetic lesions including deregulation of c-myc (100%),
deletions of 6q (15%), mutations in p53, bcl-6 and ras in 60, 70 and 15% of cases
respectively and less frequently infection with EBV (30-60%) (Ballerini et al., 1993;
Gaidano et al., 1993, 1994).
A second major pathway generally characterised by a marked disruption of immune
function is associated with variants of AIDS-DLCL- AIDS-LNCCL and AIDS-IBL,
as well as AIDS-PCNSL (Beral et al., 1991). These tumours are thought to be EBV-
driven lymphoproliferations, a view supported by the presence of EBV in >90% of
AIDS-IBL and 40% of AIDS-LNCCL, and the lack of molecular lesions in the
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majority of these cases (Hamilton-Dutoit et al., 1993). Genetic lesions when present,
include bcl-6 rearrangement and mutations (20% and 70%) and c-myc translocations
(20%) (Ballerini et al., 1993; Gaidano et al., 1994).
A third and final pathway associates with AIDS-PEL. This rare lymphoma type
consistently harbors KSHV and frequently also EBV (Nador et al., 1996). Apart
from mutations in bcl-6 in 20% of cases, all other genetic lesions commonly detected
among AIDS-NHL are consistently absent in AIDS-PEL (Nador et al., 1996;
Carbone et al., 1996a).
Taken together the genetic and virological findings of this study permit construction
of a speculative model for the evolution of AIDS-NHL in the context of the
heterogeneous and multi-factorial nature of this disease (see above and figure 72). It
is proposed that AIDS-lymphomagenesis begins with a complex interplay of one or
more factors (outlined below) leading to the florid B cell hyperplasia within
enlarged, reactive PGL lymph nodes. These factors include:
a) Chronic antigenic stimulation (Riboldi et al., 1994).
b) Viral infection: direct or indirect role for EBV and/or HIV (Kundu et al., 1999;
Birx et al., 1986; Pelicci et al., 1986b).
c) Disturbance of cytokine (IL-6 and IL-10) and co-stimulatory (CD40/CD40L)
networks that are critical to the growth and differentiation of B cells (Kundu et al.,
1999; Moses et al., 1997).
Identification of EBV DNA in the lymph nodes of PGL patients in this study, does
not solely justify a role for this virus in the pathogenesis of PGL. However, the virus
may perhaps indirectly contribute to and maintain the characteristic B cell
hyperproliferation by inducing IL-6 secretion (Liebowitz 1998) and/or inhibiting
EBV-specific memory CTL response via upregulation of viral and cellular IL-10
(Bejarano and Masucci, 1998). In addition, the HIV-Tat gene product may similarly
induce cellular IL-6 and IL-10 expression (Kundu et al., 1999) and possibly
contribute to the B cell hyperplasia in PGL.
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Lymphomagenesis in AIDS is believed to begin with the florid B cell hyperplasia that is
characteristic of PGL. PGL results from the complex interplay of several factors of which the
role of viruses such as HIV and EBV (either directly or through the disturbance of cytokine
networks) and mutations in bcl-6 are indicated. Inactivation of tumour suppressor genes
such as p53, either through mutation or trans-dominant inhibition by A2 p73 is the second
step. Deregulation of c-myc would then be an obligatory event in the case of AIDS-SNCCL,
whereas this genetic event might not be required for the progression of all DLCLs. A third
and possible questionable step perhaps involves inactivation of the INK4 genes.
HIV, human immunodeficiency virus; EBV, Epstein-Barr virus; SNCCL, small non-cleaved
cell lymphoma; DLCL, diffuse large cell lymphoma.
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Apart from the known effects of viruses on B cell proliferation, a contributory role
for bcl-6 is also proposed in this model. Deregulation of bcl-6 via alterations
observed within the cA-acting negative regulatory elements present within the first
intron, might relieve the inhibitory effects on Bcl-6 expression. Such constitutive or
inappropriate expression ofBcl-6 within the germinal centre (GC) B cells would then
impede B cell differentiation within the GC by repression of target genes (Shaffer et
al., 2000) and consequently sustain these cells in a permanent proliferative state.
Although a role for EBV and HIV in the pathogenesis of PGL cannot entirely be
discounted, it is clearly apparent that other factors are required before a cell acquires
a growth/clonal advantage. Inactivation of tumour suppressor genes and/or
deregulation of oncogenes might provide a second crucial step in the cascade of
events to lymphomagenesis. Mutation in the tumour suppressor, p53, as observed in
the panel of PGL tissue examined, is one genetic event that would be predicted to
have such a role. It is known that only a subset of AIDS-NHL harbour p53
mutations, in particular 60% of AIDS-BL, whereas such alterations are only
occasionally observed in the other subtypes (Gaidano et al., 1997b; Ballerini et al.,
1993). Therefore, one can predict that the p53 mutations observed in this study
predispose to the development of AIDS-BL. However, although c-myc translocations
are a consistent feature of BL, such findings were not validated in this study, leading
to the premise that deregulation of c-myc, secondary to translocation might occur as a
later event in lymphomagenesis. Such a scenario is certainly viable in light of the
studies by Polack and co-workers wherein activation of c-myc, secondary to EBV-
induced B cell immortalisation, is sufficient to maintain the immortalised state that is
initially effected by EBV (Polack et al., 1996).
It is interesting to speculate that in those tumours with absence of p53 mutations,
other mechanisms of inactivation of p53 may exist. It is known that the N-terminal
deleted variants of p63 and p73, an p63 and a2 p73 respectively, can trans-
dominantly inhibit wild-type p53 (Pozniak et al., 2000; Crook et al., 2000).
Predominant high level expression of a2 p73 in the current series of HIV-PGL
suggests that this mechanism of inactivation of wild-type p53 function might be
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operative, at least in a subset of AIDS-NHL. Furthermore, inactivation of ARF and
hMDM2, in tumours with wild type p53, could be proposed as an alternative to p53
mutation. Inactivation of the p53-ARF-hMDM2 pathway, by deletion and/or
overexpression of ARF and hMDM2 respectively, in tumours that retain wild-type
p53 function, has recently been shown to be an essential step in Burkitt's
lymphomagenesis (Lindstrom et al., 2001; Eischen et ah, 1999).
Lastly, the absence of genetic and epigenetic lesions in members of the INK4 locus,
either predicts that these genes have no role in the pathogenesis of AIDS-NHL, or
that they are altered late in lymphomagenesis.
An important consideration in the proposed speculative model is that it must be
viewed in the light of the absence of micro-dissected PGL and lymphoma tissue. The
availability and analysis of such tissue would help definitively to conclude whether
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